The triad of Type 2 diabetes, obesity and cardiovascular disease : investigating optimal dietetic treatment strategies by Barratt, Rachel
The triad of Type 2 diabetes, 
obesity and cardiovascular 
disease: investigating optimal 
dietetic treatment strategies 
A thesis submitted in accordance with the 
requirements of the University of Surrey for the 
degree of Doctor of Philosophy 
Rachel Barratt 
--
2005 
School of Biomedical and l\lolecular Sciences 
Univcrsit~r of Surrey 
Abstract 
Obesity and type 2 diabetes (T2DM) are increasing in prevalence at an alarming rate. T2DM 
is a multifactorial disease that requires careful medical management of all its elements, often 
involving vast polypharmacy. Treatment options are under constant review to ensure that the 
morbidity and mortality associated with this chronic disease are reduced. Since the discovery 
that tighter control over glycaemia reduced the risk of developing microvascular 
complications, the use of insulin therapy in T2DM has expanded. However, insulin therapy 
has been associated with significant gain in body weight which potentially exacerbates the 
risk of cardiovascular disease. Dietetic clinics are often full of people with T2DM and 
obesity who tend to be resistant to current treatment strategies. This thesis contains a series of 
investigations that collectively contribute to the evidence base as to best practice in the 
dietetic management of T2DM. 
The first study uses a novel sensor that monitors interstitial glucose continuously over a 24 
hour period. This study demonstrated that insulin treatment for people with T2DM did not 
improve glycaemic control compared to patients with T2DM treated with oral hypoglycaemic 
agents. Patients treated with insulin had wider daily variations of glucose, experiencing on 
average more than one hypoglycaemic event per day and spending over 9 hours 
hyperglycaemic. This study questioned whether insulin therapy actually achieves improved 
glycaemic control. 
Chapter 2 describes a randomised control trial which was designed to compare clinical 
outcomes in patients with T2DM who were newly starting insulin therapy. Subjects were 
randomised to follow either standard care or an intensive dietetic lifestyle intervention. 
Significant weight gain was associated with the introduction of insulin in the control group 
(5.6% body weight gain in 6 months), but weight gain was prevented in the intervention 
group (p<O.OO 1). The control group required more medications to counteract cardiovascular 
risk factors and reported poorer quality of life than those in the intervention group. 
In chapter 3, changes in postprandial metabolism were investigated in the first 6 months of 
insulin therapy. The sample size for this study was very small but in 3 out of 4 subjects there 
were trends towards improved postprandial glucose and lipid metabolism, in spite of weight 
gain. During the first six months of insulin treatment all patients became more insulin 
resistant. 
In the final study, with a case controlled retrospective design, a new dietetic led clinic with 
the ability to prescribe Sibutramine was compared to the outcomes achieved using diet and 
lifestyle advice only in overweight women with and without T2DM. This showed that people 
with T2DM have more difficulty in losing weight than people without T2DM when following 
Lifestyle intervention. In patients who were unable to lose weight following Lifestyle 
intervention alone, the addition of Sibutramine to Lifestyle advice enabled similar or greater 
amounts of weight 1m"> as pair matched patients who successfully lost weight in the Lifestyle 
clinic. 
These studies demonstrate that effective dietetic management for patients with T2DM result 
in positive outcomes, such as weight loss. However, changes to standard care would be 
required towards more intensive and longer term dietetic interventions as well as the use of 
pharmacotherapy. The treatment of obesity in T2DM needs to be more aggressive to enable 
people to manage their weight, and different weight loss strategies should be attempted until 
success prevails. Dietitians provide an excellent foundation on which new skills for obesity 
management can be built, which then urgently need to be implemented nationwide to help 
turn the tide on the obesity epidemic. 
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1 Introduction 
1.1 Background 
This project developed from the very real need for more effective nutritional management 
strategies for people with Type 2 diabetes. In clinical dietetic practice, the numbers of people 
referred for dietary advice with diabetes and, in particular, for weight management has grown 
exponentially. 
To date the largest study involving people with type 2 diabetes was the United Kingdom 
Prospective Diabetes Study (UKPDS Study Group, 1998a). The UKPDS was a 20-year trial, 
from 1976 to 1997, which recruited 5,102 patients with type 2 diabetes in 23 clinical centres 
based in England, Northern Ireland and Scotland. The UKPDS investigated the clinical 
management strategies and the risk of developing diabetic complications. The major results 
were first presented at the European Association for the Study of Diabetes meeting in 1998. 
alongside the publication of 5 papers in the Lancet and the British Medical Journal. Since 
then numerous papers have been published under the collaborative project name of the 
UKPDS. The study proved that tight glycaemic control reduced the incidence of 
microvascular complications which contribute to the morbidity of this chronic disease. 
Following the publication of the results, clinic practice changed to focus more greatly on the 
use of exogenous insulin to improve glycaemic control in those who previously were regarded 
as having 'non-insulin dependant diabetes'. The role of exogenous insulin was further 
acknowledged with a change in name of this condition from non-insulin dependent diabetes 
(NIDDM) to type 2 diabetes mellitus (T2DM). The implications of using insulin are 
profound, particularly in those who are overweight, as insulin tends to lead to further weight 
gain. Therefore the gains in achieving better glycaemic control with insulin therapy must be 
balanced against the increased risk of obesity related co-morbidities. There is no research to 
date that explores whether the weight gain experienced as a consequence of initiating insulin 
therapy can be attenuated by different dietetic management strategies. 
As medical research dri ves the evidence base for practice, dietetic practice needs also to move 
forward. This project examines the interrelationships between obesity. cardiovascular disease 
risk and the use of insulin in people with T2DM and assesses the impact of dietetic led 
interventions on clinical outcomes. 
The idea for the research developed from two previous investigations. the United Kingdom 
Prospective Diabetes Study (UKPDS Study Group 1995) and a retrospective case-control 
study carried out by Dickinson et al (Dickinson et al.. 2(02). The UKPDS inve~tigated 
whether intensive glycaemic control. using either Oral Hypoglycaemic Agent~ (OHAs) or 
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insulin, in people with newly diagnosed T2DM improved long term morbidity and mortality 
rates as compared to conventional treatment, which was dietary modification. The UKPDS 
found that "Intensive blood-glucose control by either sulphonylureas or insulin substantially 
decreases the risk of microvascular complications, but not macrovascular disease, in patients 
with type 2 diabetes." (UKPDS Study Group. 1998a). The finding that tight glycaemic 
control did not significantly reduce the incidence of macrovascular disease is vital in a 
population at much higher risk of all coronary artery disease (Hurst and Lee, 2(03). A 
significant finding of the UKPDS was that those individuals who followed the intensive 
regimens, in particular those treated with insulin, gained a significant amount of body weight. 
The impact of this weight gain in terms of confounding the potential benefit of improved 
glycaemic control on cardiovascular outcome is unknown. Dickinsons' retrospective case-
control study assessed the impact of initiating insulin therapy in 148 people with T2DM 
(Dickinson et aI., 2(02). Dickinson found that glycaemic control significantly improved in 
patients starting insulin therapy, but despite the improvement, glycaemic control in patients 
on insulin remained worse than the pair-matched subjects on oral hypoglycaemic agents. The 
initiation of insulin therapy was associated with a 6% increase in body weight, no 
improvement in fasting lipids and only 26% of patients saw a dietitian prior to starting insulin 
therapy. The implications of these findings and their relationship with the work described in 
this thesis needs to be considered in the context of current understanding of the obesity 
epidemic and its relationship with diabetes. 
1.2 Definitions of obesity 
The World Health Organisation (WHO) defines obesity as "a disease state in which excess fat 
has accumulated to an extent that health may be adversely affected" (WHO, 1997). The most 
widely used clinical measure of obesity is the Body Mass Index (BM!), calculated by dividing 
weight in kilograms by the height (m) squared (kglm2) (Keys et aI.. 1972). BM! is used as a 
surrogate marker for degree of adiposity and as a predictor of developing co-morbidities. The 
'healthy' range of BM! is considered to be 20-24.9 kglm2 as it is associated with the lowest 
morbidity and mortality risk (de Onis and Habicht, 1996). A BM! below 19.9 kglm2 is 
underweight. 25-29.9 kglm2 as overweight, 30-39.9 kglm2 as obese and >40 kglm2 as 
morbidly obese. 
1.3 The obesity epidemic 
The incidence of overweight and obesity as defined by the BMI. has been increasing not only 
in the United Kingdom. but virtually throughout the entire Western world and more recently 
in economically less developed countries. which has propelled the condition to pandemic 
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proportion (WHO, 1997). In 1980, the WHO tarted the MONICA project (Multinational 
MO NItoring of trends and determinants in CArdiovascular di ease) and found that 6* of 
British adult men and 8% of British women were obese (Rennie and Jebb, 2005). The mo t 
recent BMI data available for England are shown in Figure 1-1 and Figure 1-2 (Department of 
Health, 2005). This indicates that between 1980 and 1993, the prevalence of obe it had 
more than doubled in both men and women to 13.4% and 17.8% re pectively. In 1993. half 
of all women and 57.8% of all men in the UK had a BMI greater than that deemed to be 
healthy (>25kg/m2). 
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Figure 1-1 Trends in body mass index for men aged 16 years and above from 
1993 to 2003 (from the Health Survey for England, Department of Health 2002b) 
Th mo t r c nt HaIth Survey for England (Department of Health 2002b) reported the 
prevalence of obe ity had increa ed by 10.5% in men and 8.5% in women to 23 .9 *' and 
26.3% re. p cti Iy. m aning that appro imat ly one in four people in England are n \\' 
bes . B 200., th majorit of the UK populati n (68.3 % f men and 5 .7% of w m n) had 
) 
a 8MI greater than 25kg/m-. Ith ugh th incid nee of being \' rweight did n t chan e 
much between 1993 and 2003, in r a_ed by approximat I l o/c a ar. indicating 'in 
upward !->hift in 8MI range~. a~ th numb rs m \ lng LIt f the healthy range lnt tht.: 
oven eight ran~c w re !->imilar t th . e m \'ing lit fthe o\erw i~ht range and into tilt.: ohe e 
range. 
~ I 
c 
o 
.~ 
100% 
90% 
80% 
70% 
5. 60% 
o 
Q. 
'0 50% 
Q) 
01 
f! 40% 
c Q) 
(J 
Q; 30% 
C1. 
20% 
10% 
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 
Year 
I_ BMI >40 
_ BMI >30 
_ BM125-30 
_ BM120-25 
10 BMI <20 
Figure 1-2 Trends in body mass index for women aged 16 years and above 
from 1993 to 2003 (from the Health Survey for England, Department of Health 2002b) 
From 1993 to 2003 there wa also an increa e in morbid obe ity (>40kg/m2). from 0.2% to 
I % of men and from 1.4% to 2.9% of women. However, the e are likely to b an 
under timation of the true incidence, a the e data do not take into account other influential 
factor uch a ethnicity and/or fat di tribution, which alter the level at which the BMI ha 
comparable co-morbidity risk. 
1.3.1 Obesity related co-morbidities 
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Table 1-1 The estimated increased risk for an obese person of developing 
disease from International studies. (Table taken from the National Audit Office, Tackling 
Obesity in England report 2000-2001) 
Disease 
Type 2 diabetes 
Hypertension 
Myocardial infarction 
Cancer of the colon 
Angina 
Gall bladder disease 
Ovarian cancer 
Osteoarthritis 
Stroke 
Relative risk - women 
12.4 
4.2 
3.2 
2.7 
1.8 
1.8 
1.7 
1.4 
1.3 
Relative risk men 
5.2 
2.6 
1.5 
3.0 
1.8 
1.8 
nla 
1.9 
1.3 
Obesity increases the risk of developing a number of diseases, with highest increase in risk 
attributed to the development of T2DM as well as other cardiovascular risk factors. The 
Framingham Heart Study commenced in 1948 was designed to 'identify the common factors 
or characteristics that contribute to CVD by following its development over a long period of 
time in a large group of participants who had not yet developed overt symptoms of CVD or 
suffered a heart attack or stroke' (National Heart Lung and Blood Institute 2002). For the 
past 50 years this study has continued to follow over 5,000 men and women in order to 
identify causes of CVD. It found that the lowest risk of CVD and mortality was associated 
with a BMI of 22.6kg/m2 for men and 21.1 kglm2 for women and with each standard deviation 
increment of weight there was a 15% and 22% increase in CVD respectively (Kannel et al., 
1996). In overweight men and women there was a reduction in life expectancy of 3.1 years 
and 3.3 years compared to those with a BMI within the healthy range. As BMI increases to 
the level of obesity, life expectancy is shortened by 7.1 years in men and 5.8 years in women, 
which is supported across all age groups (Bender et al., 1999). 
In the USA, the Framingham Heart Study also reported that obesity caused a clustering of 
CHD risk factors such as, increases in blood pressure, total cholesterol and heart rate, as well 
as low HDL-cholesterol, the presence of T2DM and left ventricular hypertrophy. All of these 
findings led to the identified need to correct risk factors, and one strategy was to aim for long 
term sustained weight loss (Kannel et al., 2002). 
Through large multicentre trials it is possible to measure the majority of morbidity and 
mortality risks associated with obesity, but it is more difficult to evaluate the psychosocial 
factors linked to obesity, such as stigmatisation and discrimination which reduce quality of 
life. Obesity is an issue of vital importance with regards to health and well being hut the 
economic implications need also to be considered. 
1.3.2 The economic impact of obesity 
The cost of treating obesity and its consequences is astronomical and will continue to rise 
alongside the obesity epidemic (Quesenberry et al., 1998). There are direct costs, which are 
the amount that it costs to treat obesity and the consequences of obesity and indirect costs 
which are the estimated loss of economic output due to sick days and death. Table 1-2 
provides the estimated direct cost of obesity in England in 2000-200 I. 
Table 1-2 The estimated direct annual costs of treating obesity and its 
consequences. (Table taken from the National Audit Office, Tackling Obesity in England report by 
the Controller and Auditor General 2000-2001) 
Cost Component 
Treating Obesity 
General practitioners consultations 
Ordinary admissions 
Prescriptions 
Outpatient attendances 
Day cases 
Total cost of treating obesity 
Treating the consequences of obesity 
General practitioners consultations 
Ordinary admissions 
Prescriptions 
Outpatient attendances 
Day cases 
Total cost of treating the consequences of obesity 
Total Direct costs 
Annual Cost (£million) 
6.8 
1.3 
0.8 
0.5 
0.1 
9.5 
247.2 
120.7 
51.9 
44.9 
5.2 
469.9 
479.4 
The conservative estimate of the direct costs of obesity in England during 2000 to 2001 was 
approaching half a billion pounds. This is probably an underestimate of the actual cost 
because the cost of treating related conditions such as dyslipidaemias and depression are not 
included due to the absence of clear evidence of relative risk. Treating the consequences of 
obesity. rather than treating obesity itself, constitutes the largest proportion of costs. It can be 
speculated that if there was an increased spending on the treatment and prevention of obesity, 
there would be a reduction in complications and overall long term financial costs. 
1.3.3 The aetiology of obesity 
The single cause for becoming overweight is an imbalance between energy input and energy 
output. In positive energy balance. more energy is consumed through the diet than is 
expended by the maintenance of metabolic functions and physical activity. If the state of 
positive energy balance is sustained, fat deposition occurs, which accumulates and leads to 
overweight and obesity. 
Although over time being in positive energy balance is the single cause of obesity, there are 
numerous reasons for energy imbalance. These include; genetic and physiological pathologies 
(i.e. Prader-Willi syndrome, hypothyroidism), psychological factors (i.e. binge eating 
disorders, comfort eating), social factors (limited nutritional knowledge, limited finances), 
iatrogenic causes (antipsychotic medications) and physical factors (osteoarthritis or having 
restricted mobility). There are a few single gene defects that cause obesity but these are very 
rare. The majority of overweight and obesity results from the interplay between genes and 
the environment. In recent years obesity has become much more widespread, which has been 
attributed to a changing environment. Thousands of years ago, humans were "hunter 
gatherers", feasting in times of plenty and fasting during times of food shortage. Survival 
favoured those who were genetically able to store and use energy efficiently; those with 
"thrifty genes" (Chakravarthy and Booth, 2004). The human genome has been highly 
conserved over the past 10,000 years and is unlikely to have changed in the past 100 years. 
However, the environment has changed radically, flooding the thrifty genes and resulting in 
obesity. The term 'obesogenic', literately meaning obese causing, is widely used to describe 
the present day environment (Poston and Foreyt, 1999). The obesogenic environment has 
occurred due to technological advances (Finkelstein et aI., 2005), social trends towards a busy 
lifestyle leading to use of convenience and labour saving strategies, resulting in a marked 
decrease in voluntary energy expenditure (Banwell et aI., 2005). 
A small proportion of obesity can be directly attributed to a physiological cause, however the 
majority results from genes responding naturally to the present day environment. When the 
environment started to change, those with the most thrifty genes became overweight or obese. 
As time progresses and the environment becomes more obesogenic it forces those with 
weaker genetic susceptibilities to become overweight and obese, until only those most 
resistant to obesity manage to maintain a healthy weight. 
1.4 Type 2 diabetes 
1.4.1 Definition 
Diabetes is a condition characterised by raised blood glucose concentrations, caused by an 
absolute or relative lack of the hormone. insulin. There are several types of diabetes. the main 
ones are type I diabetes mellitus (T 10M) and type 2 diabetes mellitus (T2DM). People with 
TIDM have an absolute lack of insulin resulting from autoimmune destruction of beta cells 
within the pancreas. which generally occurs in younger people and always requires exogenous 
25 
insulin. T2DM is a progressive complicated disorder resulting from a relative lack of insulin 
due to a decrease in insulin production and an increase in insulin resistance. The full extent 
of the reduced insulin production usually occurs later in course of the disorder, but insulin 
resistance is apparent much earlier and is largely the consequence of obesity and in particular 
central obesity (Greenfield and Campbell, 2004). The relative lack of insulin results in raised 
blood glucose levels, the common element of all types of diabetes, which in turn instigates 
diabetic symptoms and enables diagnosis. 
The World Health Organisation has set the following diagnostic criteria for diabetes (WHO, 
2000): 
I. Diabetes symptoms (ie polyuria, polydipsia and unexplained weight loss) plus 
• a random venous plasma glucose concentration ~ 11.1 mmolll or 
• a fasting plasma glucose concentration ~ 7.0 mmolll (whole blood ~ 
6.1 mmolll) or 
• two hour plasma glucose concentration ~ 11.1 mmolll two hours after 
75g anhydrous glucose in an oral glucose tolerance test (OGTT). 
2. With no symptoms present, diagnosis should not be based on a single glucose 
determination but requires a confirmatory plasma venous determination. At least one 
additional glucose test result on another day with a value in the diabetic range is 
essential, either fasting, from a random sample or from the two hour post glucose 
load. If the fasting or random values are not diagnostic the two hour value should be 
used. 
Elevated blood glucose is only one element of T2DM; in reality it is a complicated metabolic 
disorder that requires careful management of all its interconnected elements. 
1.4.2 Obesity and Diabetes 
The precise origins of T2DM are unknown. However, there is a strong genetic component. 
demonstrated by the high concordance rate seen in identical twins and in different generations 
of the same family. If a parent has T2DM, their children have a lifetime risk of developing 
T2DM in the region of 40%; doubling if both parents are affected (Betteridge, 2(00). 
However, T2DM is not caused by a single gene defect. but is a heterogeneous disorder. 
Despite the associated predisposing genetic components there is considerable interplay 
between genes and external factors particularly with body weight and degree of physical 
activity (Ostenson, 2001). Overweight and obesity has been identified as the primary 
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aetiological factor of T2DM. Astrup and Finer (2000) have suggested that T2DM should be 
renamed diabesity "since T2DM is obesity dependent, and obesity is the main aetiogical 
cause ofT2DM." It is the endocrine properties of adipose tissue that causes insulin resistance 
which drives the relationship between obesity and T2DM. 
1.4.2.1 Insulin resistance 
Insulin resistance was first described by Reaven (1988) and is defined as "a state (of a cell, 
tissue, system or body) in which greater than normal amounts of insulin are required to elicit 
a quantitatively normal response". The molecular processes linking obesity, insulin 
resistance and T2DM are complex and have been intensely researched in recent years. 
Traditionally it was thought that adipose tissue was metabolically inactive, providing a dense 
storage facility for energy; however adipose tissue has recently been described as 'a highly 
active closely-regulated metabolic tissue' (Frayn, 2001). Adipose tissue has an important role 
in buffering the fluxes of fatty acids in the circulation which vary with dietary intake. When 
there is a consistently high intake of dietary fat, fat cells become overloaded with 
triacylglyceride, preventing the protective buffering role. If consumption of dietary fat 
remains at a level higher than the rate of oxidation, triacylglycerides accumulate in skeletal 
muscle, liver and pancreatic ~-cells resulting in insulin resistance and impaired insulin 
secretion (Frayn, 2001). Mechanistically, insulin resistance occurs as a result of adipose 
tissue secreting free fatty acids (FFA) and a range of mediators (adipokines) that adversely 
affect insulin signalling, such as tumour necrosis factor (TNF-a) and interleukin-6 (IL-6) 
(Schinner et aI., 2005). 
Under normal physiological conditions, FFA are an important energy source for most body 
tissue and are the primary oxidative fuel for the liver, resting skeletal muscle, the renal cortex 
and the myocardium. Free fatty acids are a particularly important energy source during 
starvation, exercise and pregnancy, as they allow the preservation of glucose for cerebral 
requirements (Boden and Shulman, 2002). However, overproduction of FFA, which occurs 
in obesity, is the cause of a number of pathological processes, one of which is insulin 
resistance. Free fatty acids are secreted from adipose tissue in concentrations controlled by 
insulin. In obesity high FFA concentrations inhibit insulin stimulated peripheral glucose 
uptake through the inhibition of glucose transport and decreased muscle glycogen synthase 
activity resulting in hyperglycaemia (Roden et aI., 1996; Boden, 1997; Boden and Shulman. 
2002). Over time. hyperinsulinaemia occurs to suppress FFA release, which downregulates 
the process. reducing tissue sensitivity to insulin. thus causing insulin resistance (Campbell et 
al.. 1994). Meanwhile the high FFA concentration has an additional direct influence on 
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pancreatic ~-cel1s, reducing insulin secretion. The processes of insulin resistance and ~-cell 
damage results in hyperglycaemia and eventually T20M. 
The strongest evidence for the cause of insulin resistance involves the effects of increased 
FFA release in obesity, however a number of other factors have also been implicated. 
particularly the role of cytokines such as TNF-a and ll....-6. Adipose tissue has diver~e 
functions depending upon its location. Visceral fat releases 2 to 3 times more IL-6 and T\ F-
a than subcutaneous fat (Fried et aI., 1998) and tends to drain directly into the portal vein and 
~traight to the liver where the cytokines inhibit gluconeogenesis and stimulate FFA synthe .... is 
(Lang et aI., 1992). This process further increases FF A concentrations exacerbating their 
effect on insulin sensitivity and release (Bergman et aI., 2002). 
The relationship between insulin resistance and ~-cell dysfunction has been described as 
either an open or a closed loop. The open loop theory proposes that a common factor .... uch as 
a high fat diet and limited physical activity contribute equally to both facets. The closed loop 
theory proposes that as a result of causati ve factors such as FF A release from vi .... ceral fat 
there is an internal feedback mechanism, so that when there is a decrea~e in insulin 
sensitivity, there is compensatory upregulation of ~-cell function to normalise glucose levels 
(Bergman et aI., 2002). The closed loop theory has strongest scientific support, but both 
theories encompass lifestyle factors and obesity as the primary trigger, for which weight loss 
has the most benefit (Kern et aI., 1995). 
1.4.3 The incidence and prevalence of T2DM 
Five percent of the worldwide population has diabete~ (Marso. 2004) and the prevalence i~ 
doubling every generation (Gerdes, 2003). There are nearly 2 million people with diabetes in 
thL' UK, (Ylc, of the population) and for everyone person with T 10M there are ~ix people 
with T2DM (Watkins, 2003a). What is more worrying is that it has been estimated that there 
arl' up to I million people with undiagnosed T20M in the UK (Watkins, 2003b). 
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Figure 1-3 The UK prevalence rate for Type 2 Diabetes (Diabetes UK, 2004a) 
The prevalence ofT2DM ha been increa ing exponentially for the pa t 50 year (Figure 1-3). 
By the end of the decade it is e timated that 3 million people in the UK will ha e diabete 
(Diabete UK,2004a). 
1.4.4 Complications of Type 2 diabetes 
Type 2 diabete 
(WHO, 2000) . 
a ociated with a number of co-morbiditie and higher mortality rat 
omplication can be eparated into micro a cular and macrova cular 
disea e (Tab le 1-3). 
Table 1-3 The major macrovascular and microvascular complications 
associated with Type 2 diabetes 
Macrovascular complications Microvascular complication 
• • Retinopathy 
• • Neuropathy 
• • Nephropathy 
The III I r a~ ular mpli ati n t nd to au e morbidit \Vh lhe llld r \ a .... cul.lJ 
c mpli ati n~ au~e b th m rtalit and m rbidit '. Th treatm nt r T2 1 <lIn,., l rt:Julc 
thl' incidl.::!1 e of b th mi r \ a cular and ma r \tl .... ular mpli all n . and optimal lrel ltl1lcnt 
ar'L1nder n. tant .... rutin . 
1.4.5 Cardiovascular disease 
Cardiovascular disease (CVD) is the most common complication of T2DM. People with 
T2DM have a 2 to 3 times higher risk of developing CVD than those without diabetes 
(Abraham, 2004) and a staggering 80% of people with T2DM die from CVD (Barnett, 2003). 
Recent medical advancements allow the optimal management of individual cardiovascular 
risk factors which have reduced the incidence of CVD in diabetes at the population level. but 
the incidence remains higher than the general population (Fox et aI., 2004). 
The link between T2DM and CVD is complex, but the two conditions appear to have similar 
pathophysiological routes which stem from insulin resistance (Rennert and Charney. 2003). 
It is known that insulin resistance is the primary cause of T2DM and the processes by which 
this occurs has implications for CVD. The high FFA release which causes insulin resistance 
is also associated with a clustering of cardiovascular risk factors including hypertension. 
dyslipidaemia and abnormal fibrinolysis (Fagot-Campagna et al.. 1998). There are additional 
diabetes specific factors such as metabolic abnormalities. glycoxidative stress, 
hyperglycaemia, insulin resistance and hyperinsulinaemia (Candido et al.. 2003), which 
increase CVD risk further. The treatment of each cardiovascular risk factor individually has 
been shown to be successful, but does not tackle the primary cause of the problem. which is 
the obesity and insulin resistance. 
1.4.6 Treatment options for type 2 diabetes 
The overall aim of treatment for T2DM is to normalise glycaemic control to reduce the risk of 
complications and there are a number of treatment strategies available to achieve this aim. 
1.4.6.1 Dietary manipulation 
The cornerstone of treatment at all stages of T2DM is dietary modification (Campbell and 
Rossner. 2001). Dietary management for T2DM aims to maintain or improve health. 
optimise metabolic and physiological outcomes, reduce risk of microvascular complications 
by achieving near normal glycaemia without undue risk of hypoglycaemia and reduce the risk 
of macrovascular disease by managing body weight, dyslipidaemia and hypertension (Frost et 
al.. 2003). The dietary composition as recommended by diabetes UK is provided in Table 
1-4. 
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Table 1-4 Summary of nutrient recommendations for people with Type 2 
diabetes (Frost et aI., 2003) 
Nutrient 
Protein 
Fat 
Carbohydrate 
Vitamins and 
antioxidants 
Salt 
Recommendation 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Not to exceed 1 g per kg body weight 
Total fat <35% of energy intake 
Saturated and transunsaturated fat <10% of energy intake 
n - 6 polyunsaturated fat <10% if energy intake 
n - 3 polyunsaturated fat - eat fish, especially oily fish. once or twice 
weekly 
cis - monounsaturated fat 10 - 20% total energy 
Total carbohydrate 45 - 60% energy intake (combined intake from 
carbohydrate and monounsaturated fat to equal 60 - 70% total energy) 
Sucrose - Up to 10% of daily intake, provided it is eaten in the context 
of a healthy diet. Those who are overweight or who have 
hypertriglyceridaemia should consider using non-nutritive sweeteners 
where appropriate. 
Fibre - No quantitative recommendations. 
Soluble fibre - has beneficial effects on glycaemic and lipid 
metabolism 
Insoluble fibre - no direct effects on glycaemic and lipid metabolism 
but its high satiety content may benefit those trying to lose weight and 
it is advantageous to gastrointestinal health. 
Encourage foods naturally rich in vitamins and antioxidants. With the 
exception of some patients in 'special groups or situations' there is no 
evidence for the use of supplements and some evidence that some are 
harmful 
Salt - <6g sodium chloride per day 
1.4.6.2 Oral hypoglycaemic agents (OHA) 
Dietary intervention is rarely used in isolation for the treatment of T2DM. Oral 
hypoglycaemic agents are almost always introduced at the time of diagnosis and given in 
conjunction with dietary change. There is a range of OHA currently available (Royal 
Pharmaceutical Society of Great Britain 2005): 
Biguanides 
Metformin is the only Biguanide available. which is only used in patients with some residual 
insulin. Metformin has a dual action; it decreases liver gluconeogenesis and increases 
peripheral utilisation of glucose. resulting in reduced glycaemia. It has a very low 
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hypoglycaemic risk and is the preferred pharmacological choice for obese patients as it aids 
weight loss (UKPDS Study Group 1995). Metformin helps slow the progression of T2DM by 
reducing hyperinsulinaemia and insulin resistance by lowering plasma insulin concentrations. 
ii Sulphonylureas 
Sulphonylureas require residual beta-cell activity as they stimulate the pancreas to release 
endogenous insulin. Glycaemia is reduced due to hyperinsulinaernia, but this can cause 
severe hypoglycaemic events and is associated with weight gain. The most common 
sulphonylureas used in the UK are Gliclazide, Glibenclarnide and Glipizide. 
iii Other antidiabetic agents 
New OHA are in constant development. In recent years these have included the 
thiazolidinediones, acarbose, guar gum and neteglinide and repaglinide. 
The thiazolidinediones, namely pioglitazone and rosiglitazone, enhance insulin action by 
reducing peripheral insulin resistance and increasing muscle glucose uptake. 
Thiazolidinediones are licensed in the UK only for combination therapy. 
Acarbose inhibits intestinal alpha glucosidases causing a delay in the digestion and absorption 
of starch and glucose. Acarbose has a small but significant effect on lowering blood glucose, 
however is not frequently used. 
Nateglinide and repaglinide are insulin secretagogues, with a rapid onset and short duration of 
action. As a result of their action profile nateglinide and repaglinide reduce postprandial 
glucose. 
1.4.7 Secondary failure 
Secondary failure is the term used when oral medications fail to adequately regulate blood 
glucose levels. T2DM is a progressive disease, over time the p-cells of the pancreas diminish 
in number and function until inadequate amounts of insulin are produced in relation to need, 
even with the assistance of polypharmacy. It is at this time that insulin therapy is considered 
and, with the patient's agreement, implemented. 
1.S Insulin therapy 
The need for insulin therapy in the treatment of T2DM is unequivocal, especially when OHA 
fail to control blood glucose levels. However, the decision to initiate insulin remains difficult. 
even when the physician decides that insulin is necessary. patients can often be resistant to the 
decision. The following table iIlustrates the majority of the reasons as to why insulin therapy 
is started. 
Table 1-5 Reasons for initiating insulin therapy 
Main reasons 
Improved glycaemic control for: 
• Reduction of symptoms 
• Reduced microvascular disease risk 
Other reasons 
• Intercurrent event (eg stress, infection. 
acute injury) that will cause 
decompensation. 
• Preparation for surgery 
• Allergy or other serious reaction to oral 
hypoglycaemic agents 
• A preference for insulin therapy by the 
patient or the physician 
• Post myocardial infarction 
In clinical practice, primarily due to patients' understandable reluctance, insulin therapy is 
frequently initiated quite some time after it is firstly recommended by the physician. 
1.5.1 The costs associated with treating type 2 diabetes 
Along with the rising prevalence, the cost to the NHS of managing T2DM in the UK is 
increasing annually. As with obesity there are direct costs which include health care 
resources, indirect costs such as reduced economic activity due to lost working days and early 
death and intangible costs which are the immeasurable social and personal losses. At least 
5% of the total NHS budget and 10% of hospital budgets is spent on treating T2DM and its 
complications each year, equating to more than £3.5 billion annually (Department of Health, 
2001). It is predicted that NHS spending on the management of diabetes will grow to 10% by 
20 II and unless drastic measures are put in place both financial and personal costs will 
continue to escalate. 
1.5.2 The benefits of weight loss in T2DM 
Medical treatment strategies for T2DM concentrate on the management of associated risk 
factors; however lifestyle modification has additional benefit. The Diabetes Prevention 
Programme (DPP) (Diabetes Prevention Programme Research Group 2002) showed that it 
was possible to prevent T2DM with an intensive programme of diet and lifestyle advice. The 
DPP managed to reduce the incidence of T2DM by 58% in a population at high risk of 
developing the disorder. (identified due to impaired glucose tolerance), by lifestyle 
intervention which aimed to achieve 7% body weight loss and increased physical activity. 
The DPP showed that it is possible to prevent or slow down the progression of the metabolic 
disarrangements associated with T2DM and the metabolic syndrome through appropriate 
lifestyle intervention in a free living population. The DPP demonstrated that T2DM can be 
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prevented through adoption of lifestyle changes, but the benefit of similar lifestyle change~ 
during the life course of T2DM are not as clear. 
Overweight and obesity are not only the major causes of T2DM, but make the management of 
the disorder more difficult. Weight los~ improves glycaemic control and reduces the risk of 
cardiovascular disease outcomes, whereas weight gain has detrimental effects. Williamson et 
aI., (2000) performed a prospective study tracking intentional and unintentional weight lo~~ in 
those with T2DM (n=4,970) over 12 years, without any particular intervention. A third of 
subjects reported intentional weight loss, which was associated with a 289c reduction in 
cardiovascular disease and diabetes mortality. The best outcome was a 331/( reduction in 
these mortalities which was achieved after a weight loss of 20-291b (approximately 9-13kg). 
Similar beneficial effects of weight loss on mortality have been reported in retrospecti \'e 
studies. Lean et aI., (1990) examined medical notes of deceased patients \\'ho had T20;"'1 and 
found that on average each I kg weight loss was associated with a 3 to -+ month gain in 
survival. 
Overweight and obesity not only cause T2DM, but contribute to the metabolic deterioration 
of the disorder and make effective management more difficult. The interactions between 
obesity, T2DM and CYD are under constant investigation and are particularly important due 
to the increasi ng prevalence and demand on medical and social resources. Strategies to treat 
obesity in T2DM need greater investigation to understand their full implication and enable 
optimal treatment provision. 
1.6 The Overall Aims 
This thesis aims to: 
1. understand how insulin therapy affects glycaemic control over a 2-1 hour period 
Following the results of the UKPOS, insulin therapy is now used extensively in the 
treatment of T2DM. Insulin is used to improve glycaemic control with ~uccess measured 
in the clinical setting by HbA I c. HbA I c provides an average measure of glucose o\'er 3 
months. but does not provide visibility of the fluctuating range of glucose lew\-". The 
first ~tudy aim~ to elicit how insulin therapy affects the daily fluctuation in plasma 
glucose in those with T201\1. 
., dctcrmine whether an increased access to dietctic support can prcycnt the 
iatrogenic wdght gain associated with initiation of insulin therap~' in those with 
T2DM 
3. discover the effects of weight gain on cardiovascular disease risk factors 
following the initiation of insulin therapy 
The UKPDS found that insulin therapy does not significantly reduce the risk of 
cardiovascular disease in T2DM (UKPDS Study Group 1998a). The UKPDS and 
Dickinson et aI., (2002) found that insulin therapy is associated with a significant increa.;;e 
in body weight however, neither study analysed the cardiovascular risks associated with 
the weight gain. This study, designed as a randomised control trial, will compare the 
cardiovascular risk outcome of patients with T2DM who received an intensive dietetic 
intervention to those who received standard care. The intensive dietetic intervention 
aimed to prevent iatrogenic weight gain associated with the initiation of insulin therapy. 
4. investigate how insulin therapy affects postprandial lipid and glucose 
metabolism 
Impaired postprandial lipid and glucose metabolism is an emergIng independent risk 
factor for cardiovascular disease (Karpe. 1999). but it is unknown how postprandial 
metabolism changes for people with T2DM directly following insulin therapy. This pilot 
study was designed to elucidate whether there were changes in postprandial lipid and 
glucose metabolism in the first six months following the initiation of insulin therapy. 
5. assess the efficacy of two dietetic weight loss interventions in people with, and 
without, T2DM 
Obesity is an independent risk factor for cardiovascular disease (Hubert et aI., 1983) and 
the large Framingham Heart Study found that weight loss has great potential to prevent 
and lessen cardiovascular disease at a population level (Kannel et aI., 1996). It has been 
suggested that people with T2DM have greater difficulty in losing weight than their non-
diabetic counterparts (Wing et aI., 1987; Guare et aI., 1995; Hensrud, 2001). Intensive 
Li festyle intervention is proven to be more effectiw for weight loss than standard dietetic 
care. but does not work for ewryone (Frost et aI., 2002). This study compares the weight 
loss in people with and without T20M whilst following the Lifestyle intenention. For 
patients where Lifestyle intenention was ineffective in achic\ing weight los .... , the .... tudy 
wi 11 abo namine whether there is any added benefit of adding pharmacotherapy 
(Sibutramine) to I .ife .... tyle ad\icc. 
2 A comparison of 24 hour habitual glucose levels in people 
with type 2 diabetes treated with insulin therapy or 
maximum oral hypoglycaemic agents 
2.1 Introduction 
The primary aim of insulin therapy is to improve glycaemic control. as this reduces the risk of 
developing microvascular complications (UKPDS Study Group 1998c; Stratton et al.. 2000a). 
Conventional tests used to monitor glycaemic control include the patient carryi ng out home 
blood glucose monitoring using capillary blood. and in the clinical setting. measurement of 
both fasting blood glucose and glycated haemoglobin (HbAlc) from a venous blood sample. 
However, these conventional tests for glycaemic control do not give a full picture as to how 
insulin therapy actually affects daily patterns of blood glucose. 
2.1.1 Standard monitoring of glycaemic control 
2.1.1.1 Home blood glucose monitoring 
Home blood glucose monitoring (HBGM) is achieved using one of a large number of blood 
glucose meters. A lancet is used to prick the finger so that a drop of blood can be applied to a 
testing strip which is inserted into the meter: the calibrated meter has a digital display which 
after a few seconds. shows the blood glucose level. Ideally patients should monitor their 
blood glucose levels and respond appropriately to the reading. such as taking more exercise if 
rcadings are high or eating a carbohydrate based snack if readings are low. 
Patients with fairly well controlled diabetes are advised to test their blood glucose once per 
day and to \'ary the testing times. Clinical experience indicates that of those patients who 
carry out HBGM, most test early morning. therefore generating readings representative of 
fasting samples. For a better understanding of blood glucose profiles throughout the day, 
Il1L'aSurements need to be taken on a rotational basis (Table 2-1). Testing still occurs just onCL' 
a day, but u\er a period of a couple of weeks daily fluctuations in blood glucose become more 
apparent. hO\\L'\er in reality rotational blood glucose testing rarely happens. 
Table 2-1 Recommended times of carrying out HBGM 
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2.1.1.2 Clinical measures of glycaemic control 
linically fa ting venou blood gluco e and the percentage of glycated haemoglobin (Hb I ) 
are mea ured to a e glycaemic control over a period of 3 month . A with the morning 
HBGM ample taken by the patient, the fa ting venou ample i of limited u e a it provides 
ju t a snap hot picture of glycaemic control; therefore the HbA I c i the preferred mea ure. 
Th HbAlc repre ent the average blood gluco e for the pa t three month bye ploiting th 
fa t that gluco e attache it elf to the haemoglobin component of the red blood cell matri , 
proportionally Lo circulating concentration. The half-life of the red blood cell i 90-120 day 
and it i a umed that the HbA 1 c i an indication of the average blood gluco e for the pa. t 
thre m nths. Du th continuou proce of red blood cell death, the HbA lei the m t 
repres ntati of glu 0 e I v I 0 er th pa t 4 week and in particular, the previou 2 \\e b. 
rather than the complete a rage of th pa t 3 month . De pite thi min r limirali n the 
JIb I c is the mo t idel used m a ur of m dium to long term blood glu 
clinical practi . It is th IlbA I c hi h d n te h n a pati nt rna ne d in ulin th rap) and 
for pe pi \ irh diabetes is ft n th III a ur f tr atment ffica . The tar t JIbi\ 1 f r a 
person \ ith 2 M is 7 r. and repr enrati\ e r p r t,1) <lemil 
lontr)\. s a mpdri.., n th n n-diab tic p pula!1 n \\ uld ha\e a IIb\\ bet" l!11 _.0 
When the available methods of mea uring glycaemic control are combined. it i po ible to 
have an indication of general daily glucose fluctuation (HBGM) fasting blood gluco e le\'e1 
and average blood glucose levels (HbAlc), however the full variation of glycaemic ontrol 
remains unknown. Recent advances in technology have enabled the de elopment of 
Continuous Glucose Monitoring Systems (CGMS). 
2.1.2 Background to continuous glucose monitoring systems and the 
Minimed 
There are a small number of continuous gluco e monitoring ystem (CGMS) available, ne 
of the earliest developed is the Minimed, manufactured by Medtronic (Figure 2-1) . 
Figure 2-1 The Medtronic Minimed, a continuous glucose monitoring system 
used to measure daily glucose variations 
The Minimed device i of a imilar ize to a pager which tore information received b a 
sensor. The sensor is placed subcutaneously in the abdominal area by a trained profe ional. 
A mea urement of interstitial glucose i taken every 10 econd and pro ide average alue 
every 5 minute (288 time a day) which are tored by the Minimed device, The Minimed i 
calibrated again t home blood gluco e monitor reading at lea t 4 time a day by the pari nL 
fter 3-7 day th en, or i remo ed and the data collected by the Minimed are downloaded 
nto a computer. Th download d data produce graph and tati tic which can banal ed 
in a numb r of way to how 24 hour bl od glueo e ontrol. 
U~ing the Minim d ha, di tinct advantage ov r ther linical m a<;ure 
a" it enabl s th id ntifi ation of hypogl Cil mic and hyp rgly a mi 
f gl aeml nlr I 
vent~ in ludlng (he 
amount f time ~pcnt lit id n rmal rano , and th tim at \\ hi h the 
inf rmati n an n t be d ri\cd fr m ther 111 a"ure . 
ceur. lhi 
2.1.3 Previous uses of the Minimed 
The initial outlay and disposable component costs of CGMS are high; therefore currently they 
are mostly used for research purposes. Their use in clinical practice is rare and occurs only 
where there is a specific need such as pregnancy in someone with type 1 diabetes. recurrent 
hypoglycaemic events. metabolic disorders and 'brittle' diabetes. Most research using CGMS 
have involved patients with type 1 diabetes (TIDM), particularly children. In the TIDM 
popUlation CGMS have been used in conjunction with insulin pumps (Guerci et al.. 2(03). as 
a comparison to HBGM (Boland et aI., 2(01), as a comparison to HbAlc results (Salardi et 
aI., 2002), to identify unrecognised hypoglycaemic events (Chico et al.. 2003) and to measure 
the variations glycaemic control (Sachedina and Pickup, 2003). The effects of peritoneal 
dialysis on blood glucose patterns have also been assessed using a CGMS (Schwing et al.. 
2004). The CGMS's are a fairly novel technology therefore research involving their use is in 
its infancy, especially in the area ofT2DM. 
2.1.3.1 Research involving patients with type 2 diabetes 
Clinical research and the testing of the functionality of CGMS technology has involved 
people with T2DM (Nyback-Nakell et aI., 2004). CGMS have been used to test the efficacy 
of new oral hypoglycaemic agents (OHA) for the treatment of T2DM (Abrahamian et al.. 
2004). In testing new OHA, the CGMS is considered superior to other markers of glycaemic 
control over 24 hours, as it demonstrates the effect of the medication on postprandial as well 
as fasting glucose levels. The ability of the CGMS in providing information about the 
patterns of glucose control has been exploited to discover the effects of dietary change 
(Colette et aI., 2005). The investigations that have used CGMS before and after treatment 
demonstrate its use as a comparative tool. 
Two investigations have used CGMS to explore variations in glycaemic control in people 
with T2DM. The first of these found that 47% of patients with adequately controlled T2DM 
as measured by HbAlc (HbAlc 7.4 ± 1.6%) had hypoglycaemic events (Chico et al.. 2(03) 
and concluded that standard measurements of glycaemic control underestimate 
hypoglycaemic frequency. The second study. investigated patients with tightly controlled 
T2DM (HbA 1 c 6.2 ± 0.8%) found that 80% of patients experienced hypoglycaemia (glucose 
<2.7mmolll) and 96% of patients had borderline hypoglycaemia (glucose <3.6mmolll) (Hay 
et al.. 2003). with an average of 7% of the time spent with blood glucose below the desired 
level. These two studies indicate that standard measures of glycaemic control such as HbA I c 
and HBGM are inadequate in revealing the full extent of the variations and patterns of 
glucose control. Worryingly and more importantly it appears that lower HbAle's, which are 
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indicative of better glycaemic control, are in part, a result of time spent below glycaemic 
norms. 
2.1.4 Reliability and validity of the Minimed 
Continuous glucose monitoring systems measure the glucose of interstitial fluid as opposed to 
plasma glucose from venous blood which is used in normal clinical practice. The variation 
between interstitial fluid and plasma has been found to be less than 6% (Rebrin and Steil, 
2000), which is similar to the variation between arterial and venous blood glucose. The 
variance between blood glucose and interstitial fluid is minimised as the Minimed is 
calibrated against a capillary blood glucose sample, as measured by the patient, at least four 
times each day. 
In children with T 10M HbA 1 c has been shown to correlate with the glucose results obtained 
with the Minimed (r=O.53, p=O.002), however the correlation was lost with low glucose 
readings «5mmolll) (Salardi et aI., 2002). It was concluded that HbA I c provides a good 
general marker of overall glycaemic control, but does not adequately account for low blood 
glucose levels in children. 
Minimed's have been shown to give both reliable and valid results. The reliability was tested 
by using two Minimed's simultaneously with the results showing a high degree of correlation 
(r=O.84) (Metzger et al., 2002). Within the same study the Minimed was also shown to 
correlate with random capillary blood samples which were not used for calibration (r=O.93), 
indicating good validity. Another study used a euglycaemic clamp and showed that the 
Minimed could accurately track hypoglycaemia when correctly calibrated, but significantly 
overestimated hypoglycaemia when calibration was incomplete (Monsod et aI., 2002). The 
Minimed has the highest degree of accuracy during the first 48 hour of use, which then 
diminishes with time (Nyback-Nakell et aI., 2004). 
The reliability of the Minimed has been extensively researched and the measurements appear 
to correlate well with blood glucose, but care has to be taken to ensure that the Minimed is 
calibrated successfully by the patient to ensure the correct interpretation. 
2.1.5 Gaps in knowledge 
Few investigations have used CGMS to investigate clinical uncertainties In people with 
T20M. No previous investigation has compared the 24 hour blood glucose control of people 
with T20M on maximum OHA to those treated with insulin therapy. 
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2.1.6 Aim and Objectives 
The first study aim was to compare the results of clinical markers of glycaemic control 
(HbAlc) with the results of the Minimed and the HBGM, to see if clinical markers accurately 
represent daily glycaemic patterns. Following this the study aimed to discover how insulin 
therapy affects 24 hour glycaemic control for patients with T2DM by comparing the 
glycaemic control of patients on established insulin therapy with patients who are reaching a 
point when insulin therapy was being considered (i.e. those treated with maximal oral 
hypoglycaemic agents). 
2.1.7 Hypothesis 
Insulin is used to improve glycaemic control; therefore it is hypothesised that patients with 
T2DM treated with insulin therapy will have better 24 hour blood glucose control than those 
with T2DM on maximal oral medication. Better glycaemic control for insulin treated patients 
will constitute: 
• Lower HbAlc's 
• Lower average glucose readings as measured by the Minimed 
• A smaller range of glucose readings and with fewer excursions above and below 
normal ranges 
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2.2 Method 
2.2.1 Study design 
The study was designed as a pair-matched case-control trial. The cases were those patients 
with T2DM being treated with insulin therapy (n=8) and the controls were patients with 
T2DM on maximal oral hypoglycaemic agents (n=8). 
2.2.2 Ethics 
Ethical approval was received from the following centre: 
• Hammersmith, Queen Charlotte's and Chelsea and Acton Hospitals research 
ethics committee, Hammersmith Hospital, London 
Approval was required at this hospital as patients of these NHS Trusts were involved in the 
study. Participation in the study required signed informed consent which was obtained from 
all patients. 
2.2.3 Sample size 
The hospital protocol for CGMS analysis is that 10 patients per group should be recruited for 
comparative investigations, due to a balance between data quality and cost. Ten case subjects 
were recruited and had Minimed's placed. The results obtained from two case patients were 
insufficient (1 due to incorrect usage and 1 due to equipment failure); therefore the results of 
eight patients in each group were available for this analysis. 
2.2.4 Recruitment 
Patients were recruited from the diabetes clinic at Hammersmith Hospital. Medical records 
were examined during the general diabetes outpatient clinic, with the author approaching 
those patients who were suitable. All patients had T2DM and were either well established on 
insulin therapy or were on maximal doses of oral hypoglycaemic agents and were being 
considered for insulin therapy. If the patient was interested in participating in the study. two 
appointments were made. one to place the Minimed and one to remove it and discuss the 
results. Control patients were pair matched to the cases in terms of age. sex and ethnicity. 
Table 2-2 Inclusion and exclusion criteria for eligibility for study 
Inclusion criteria 
• Presence of T2DM. 
• Either one of the following: 
• On maximal doses of an OHA 
(highest recommended or tolerated 
dose) and being considered for 
insulin therapy. 
or 
• Well established on insulin therapy-
treatment time> 1 year. 
Exclusion criteria 
• Existence of other major morbidities 
which either effect nutritional intake or 
metabolism, e.g. diagnosed renal 
disease, liver disease, cancer. 
The maximal dose of Metformin recommended by the British National Formulary (BNF) 
(Royal Pharmaceutical Society of Great Britain, 2005) is 3g1d, although it states that most 
physicians limit the dose to 2g1d. The maximum dose of Gliclazide is 320mg/d spread over 
the day. The true maximal doses of OHA on an individual basis were a clinical decision, 
depending upon individual tolerance levels and overall medical condition. 
2.2.5 Methodology 
When a patient had been recruited, the Minimed was placed by the author according to the 
manufacturers instructions. Habitual glucose patterns were being analysed so patients were 
asked to continue with their normal diet and lifestyle patterns. To help ensure this, strong 
emphasis was placed on the benefits of continuing normal patterns of behaviour to the patient, 
so that they personally would obtain the most useful information from this unique 
opportunity. The Minimed was placed for a minimum of 72 hours, primarily during the 
week, rather than at the weekend. Patients returned after the agreed period of time, results 
were downloaded and explained in full to the patient who was provided with a copy. In 
accordance with the Minimed instructions patients were required to measure their blood 
glucose using home blood glucose monitoring at least four times a day and enter the value 
into the Minimed for calibration. 
2.2.6 Data analysis 
One day for each patient was used in the analysis. The day was selected by the optimal 
accuracy criteria provided by the downloaded information; in the order of (with ideals), 
number of sensor readings (288), correlation coefficient between the Minimed sensor and 
home blood glucose meter (r= 1.00) and mean absolute error (lowest percentage). Examplc,> 
of the downloaded data can be found in Appendix A. 
The data were entered into an SPSS spreadsheet which included the results of the optimal 
accuracy criteria used for the day selected, average readings (with SD) and range of reading.., 
for both the sensor and home meter, number of excursions above IOmmolll and below 
3.9mmol/l and the percentage time spent within and outside blood glucose norms. Patient 
demographics, details regarding diabetic treatments and the HbAlc (±2 wcck'> of using the 
Minimed) were recorded and used in the analysis. The number of hours per day spent above. 
below or within glycaemic norms was calculated for each patient from the percentage time. 
The data shown are means (with SD). All data were normally distributed and analysed using 
parametric tests. Comparisons between the groups were made using independent T-Tcsts and 
paired T -Tests were used for within group analysis. Correlations between markers were 
analysed using Pearsons correlation coefficients. 
2.3 Results 
2.3.1 Baseline characteristics 
Baseline characteristics are shown in Table 2-3. The case and control patients were well 
matched for age, sex and ethnicity. There were no significant differences in any baseline 
characteristics between the groups, although the insulin treated group had a tendency towards 
a higher body weight and BMI than the group treated with oral hypoglycaemic agents (NS). 
Table 2-3 Baseline characteristics of patients with T2DM treated with either 
insulin therapy or OHA 
Characteristic 
Sex (n) 
Ethnicity 
Male 
Female 
White 
Non-white 
Age (years ± SD) 
Weight (kg ± SD) 
BMI (kglm2 ± SD) 
Duration of T2DM (years ± SD) 
Duration of treatment (years ± SD) 
Insulin treated (n=8) 
3 
5 
5 
3 
56±9 
100.9 ± 28.7 
37.0 ± 10.6 
10.2 ± 3.6 
2.7 ± 1.6 
MaximumOHA 
(n=8) 
3 
5 
5 
3 
55.9 ± 10.4 
89.7 ± 13.8 
32.3 ± 4.5 
7.8 ± 3.2 
1.4 ± 0.8 
p 
NS 
NS 
NS 
NS 
0.98 
0.34 
0.27 
0.72 
0.63 
The insulin treated group used an average of 84.1 ± 31.4 units of insulin a day, seven patients 
using a 30170 premix twice daily and one patient using a 20/80 mix. In the insulin treated 
group, 3 patients were also taking an average of 2.4 ± 0.7g of Metformin per day. In the 
maximum OHA group all eight patients took Metformin (mean 2.3 ± 0.7g1d) (max 
recommended dose in BNF is 2-3g/d) and seven patients were prescribed Gliclazide (mean 
247 ± 1 33mg/d) (max recommended dose in BNF is 320mg/d). 
The insulin treated group had been diagnosed with T2DM for 2.4 years longer than those on 
maximum OHA (NS) and had on average been on insulin for nearly 3 years. The group 
treated with OHA had been on maximal doses for longer than one year and all were being 
considered for insulin therapy. 
2.3.2 Baseline glucose measurements 
Patients with T2DM treated with insulin had slightly lower mean HbAlc's than those treated 
with maximum OHA (8.2 ± 1.4% vs. 8.5 ± 1.0%). but the difference was not significant 
(t=0.53. 95% CI -0.98 to 1.63. p=O.60). 
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The insulin treated group al 0 had a larger range in HbAl c's, both at the lower and upper 
ranges (Figure 2-2) . 
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Figure 2-2 Average HbA1 c for patients with T20M treated with insulin or oral 
hypoglycaemic agents. Boxes represent the 2S-7Sth percentile; whiskers are 
the S_9Sth percentile 
Patient treated with insulin had higher mean reading for the Minimed en or; 9.2 ± 2.8 v . 
9.0 ± 2.2 (t=0.20, CI -2.46 to 2.96, p=0.85) and the HBGM meter 9.2 ± 3.2 v . 8.8 ± 2.0 
Ct=0.33, I -2.44 to 3.31, p=0.75) than those treated with maximal OHA' . 
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Figure 2-3 Average glucose readings measured by the Minimed (Sensor) and 
readings from the home blood glucose meter (Meter) for patients with T2DM 
treated with insulin or oral hypoglycaemic agents. Boxes represent the 2S-7Sth 
percentile ; whiskers are the S_9Sth percentile 
There were no significant differences in HbAlc, the Minimed a erage and the HBGM meter 
av rage between the group, nor were there any ignificant difference in any mea ur of 
glycaemic control, although the range for the Minimed and HBGM were much larger than 
th HbA lc. 
2.3.3 Glucose ranges and extremes 
Table 2-4 how th m an lowe t and highe t reading recorded by the Minimed en rand 
th home blo d gluco e meter in both group. The table aJ 0 how the numb r of tim ~ 
( . ursi n ) that r ading went beyond the normal range, including the numb r r hour and 
th percent gc tim trem . 
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Table 2-4 Average highest and lowest readings of the Minimed Sensor and the 
HBGM meter for each group and number of excursions and amount of time 
spent outside of normal glucose ranges per 24 hours 
Insulin MaxOHA 
(mean+SEM) (mean+SEM) 
Minimed sensor Lowest (mmol/l) 4.3 ± 0.8 5.6 ± 1.0 
glucose readings Highest (mmol/l) 17.0 ± 1.2 14.6 ± 1.4 
Home blood glucose Lowest (mmol/l) 5.1±0.9 6.8 ± 1.0 
meter readi ngs Highest (mmolll) 13.9 ± 1.7 ILl ± 0.8 
Minimed readings Excursions (n) 2.5 ±0.4 2.6±0.6 
>IOmmol/l Time (hours) 9.2 ±2.7 7.7 ± 2.6 Proportion of time (%) 38.1 ± 11.2 31.8 ± 10.8 
Minimed readings Excursions (n) 1.25 ± 0.5 0.38 ± 0.3 
<3.9mmolll Time (hours) 1.9 ± 1.3 1.3 ± 1.0 Proportion of time (%) 7.9 ± 5.3 5.4 ± 4.1 
Minimed readings Time (hours) 13.0±2.8 15.1±2.7 
4.0 - 9.9mmolll Proportion of time (%) 54.0 ± 11.7 62.8 + 11.4 
The insulin treated group experienced a wider range of glucose readings as recorded by the 
Minimed and through HBGM than those treated with maximal OHA. Both groups exceeded 
10mmolll on average 2Y2 times each day, but those treated with insulin spent I Y2 hours longer 
above this level. Conversely, the insulin group had on average more than I episode of 
hypoglycaemia each day, spending nearly 2 hours below 3.9mmolll, whereas those treated 
with maximal OHA's had fewer episodes and spent less time below this level. As a result 
patients treated with insulin spent just over 50% of time with glucose in the normal range, 
while those treated with maximal OHA's spent over 60% of time with good glucose control. 
All results between and within groups were not significantly different. 
2.3.4 Correlations 
The average Minimed readings strongly correlated with HbAlc for all patients (r=O.887. 
p<0.OO5) (Figure 2-4) and for the individual groups (r=0.925 p=O.OOI for the insulin treated 
groups and r=0.869 p=0.OO5 for the OHA group). The strong correlation indicates that a 
snapshot assessment of 24 hour glucose control (Minimed) relates well to methods of 
assessing longer term control (HbA I c). 
48 
16r---------------------------------------~ 
Q) 
OJ 
ro 
14 
12 
Q; 10 
> ro 
.... 
o (/) 
c 
~ 8 
"0 Q) 
E 
c 
a 
a 
a 
a a a a 
a 
a 
a 
a 
a 
a 
a 
a ~ 6+-______ ~------~~D ----_.------~,_----~ 
6 7 8 9 10 11 
HBA1C 
Figure 2-4 Correlation between HbA1 c and average Minimed sensor readings 
for all patients (r=O.887 p<O.005) 
In the j n ulin treated group the HbA I c correlated with the time gJ uco e wa above 10mmolll 
(1'=0.76 p=0.03), however the HbAlc wa negatively but non- ignificantly correlated with 
time both in the normal range and in the hypoglycaemic range (r=-0.595 p=0.12 and r=-0.286 
p=0.492). In the maximum OHA group, the HbAlc had imilar po itive correlation with 
time pent with readings greater than 10mmoll1 (r=0.904 p=0.002). In thi group there wa a 
ignificant negative correlation with HbA I c and time pent in the normal range (r=-0.822 
p=O.O 12) and a negative but non- ignificant relation hip with time pent below 3.9mmoJ/J 
(r=-0.112 p=0.791). The e results indicate that the HbAlc i a good marker of high gJuco e 
r ading , but i. inadequate in representing hypog\ycaemia. 
l) 
2.4 Discussion 
The first aim of the investigation was to ascertain if currently used clinical markers of 
glycaernic control were representative of daily fluctuations in glucose levels. In clinical 
practice, glycaernic control is monitored primarily by glycated haemoglobin (HbAlc); which 
correlates well with average glucose readings but this study shows that it does not adequately 
represent hypoglycaemia. HbAlc was positively correlated with high glucose readings and 
negatively correlated with low glucose readings. This is relevant as the HbA 1 c is an average 
of the blood glucose for the past few months and if a proportion of time is spent below the 
normal glucose range the HbAlc would fall correspondingly. The reciprocal relationship 
between HbAlc and hypoglycaernia is substantiated by previous investigations (Chico et al., 
2003; Hay et al., 2003). 
The second aim of the study was to discover how insulin therapy changes glycaemic control 
for patients with T2DM in comparison to those patients on maximal doses of OHA's. The 
HbA 1 c for those established on insulin therapy was essentially the same as for those on 
maximal OHA's for whom insulin therapy was being considered. Therefore patients with 
T2DM on maximum OHA's and on insulin therapy had poor glycaemic control. The 
Minimed revealed that patients treated with insulin therapy had wider glucose ranges than 
those on maximal OHA's. Patients treated with insulin spent nearly half the time with either 
worryingly high or low glucose levels (> 1 Ommolll and <3.9mmol/l) and experienced on 
average more than one hypoglycaemic event each day. Patients treated with maximal OHA's 
however had tighter glucose ranges and experienced far fewer hypoglycaemic events than 
those treated with insulin. The reduction in HbA 1 c achieved with insulin therapy can in part 
be attributed to the amount of time spent with low glucose levels. The results indicate that 
there is a worsening in the quality of glycaemic control in patients treated with insulin therapy 
compared to OHA. The hypothesis to be tested was that insulin therapy would improve 
glycaemic control by reducing HbAlc, having lower average 24 hour glucose levels and 
allowing greater maintenance of glycaemia within normal ranges; however this study has 
consistently opposed the hypotheses. This demonstrates that the null hypothesis has to be 
accepted due to the absence of differences in all measures of glycaemic control between the 
insulin treated group and the maximal oral hypoglycaemic treated group. However there are 
some limitations of this study which should be taken into account when interpreting these 
results. 
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2.4.1 Limitations 
Patients were requested to continue with normal patterns of behaviour whilst wearing the 
Minimed to best represent habitual glucose control; however compliance to this request was 
not measured. It is possible that patients could have altered their diet and lifestyle patterns 
during the investigation period to optimise their personal results and although this could occur 
equally in each group, it can be argued that it would have occurred more in the group on oral 
medication. Patients on maximal doses of OHA's and being considered for insulin therapy 
often delay the change in treatment on the premise that efforts will be made to improve 
glycaemic control through weight loss, dietary modification and increased physical activity. 
The opportunity to prove these efforts, for some people, may have been provided during the 
investigation in an attempt to avoid insulin. However the impact of this on the overall results 
is unlikely to be significant and does not detract from the results achieved from those patients 
already on insulin therapy. 
The insulin treated group were heavier than the OHA treated group, a difference which did 
not reach significance due to the small sample size (a type I error). Increased body weight 
and possibly increased insulin resistance could be an influential factor for patients on insulin 
therapy preventing the achievement of good glycaemic control. To reduce the effect of body 
weight on the results, the BMI of patients in both groups should be pair matched, so that the 
only difference between the groups would be the treatment received. The interactions 
between insulin therapy, glycaemic control, body weight and cardiovascular disease are 
investigated in the next chapter. 
The sample size was relatively small, but deemed large enough to have been able to detect 
differences between the groups. None of the comparisons in glycaemic control between the 
groups approached the level of significance, which is likely to be attributable to an absence of 
a true difference; however this could be confirmed in a larger study. 
2.4.2 Further work 
There were only relatively few patients involved in the study; therefore findings would need 
confirmation in larger cohorts. Of particular interest is the relationship between HbA I c and 
the period of time spent in hypoglycaemic ranges. It is widely accepted that tight glycaemic 
control as measured by HbA I c results in more frequent hypoglycaemic events (UKPDS 
Study Group 1993), however it could be that an increase in time spent hypoglycaemic. in 
particular sub-clinical or unrecognised hypoglycaemia. could account for low HbA Ic·s. In 
the long term the fluctuations in daily glucose levels could be investigated to determine how 
these relate to clinical outcomes. however this would require large cohorts. 
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Continuous glucose monitoring systems (CGMS) could be used to investigate the best way in 
which insulin therapy should be initiated for people with T2DM. As a greater variety of 
insulin's become available, investigation of their full impact on glycaemic control would 
enable optimal treatment. The effect of different levels of patient education could be assessed 
through use of CGMS. People with type 1 diabetes have the opportunity to follow 
programmes such as DAFNE (Dose Adjustment for Normal Eating) which allows greater 
freedom to change insulin doses in response to dietary intake (DAFNE Study Group 2(03). 
Similar programmes to DAFNE and their efficacy could be investigated for those with 
T2DM; however consideration would need to be given to the difference in patient 
demographics and risk of CVD between those with TI DM and those with T2DM. 
Finally the influence that insulin resistance has upon the efficacy of insulin therapy could be 
assessed using CGMS. The weight of patients on insulin therapy in this study was higher 
than those on maximal OHA, which may mean they were more insulin resistant. Further 
investigation could elicit how insulin resistance affects glycaemic control during treatment 
with insulin. 
2.4.3 Conclusion 
These preliminary findings surprisingly show that the HbAlc does not improve with the 
addition of insulin therapy to the treatment of T2DM. It appears that the introduction of 
insulin may cause wider variations in glucose, including an amount of time spent in the 
hypoglycaemic range. The HbAlc is an approximate representation of the average blood 
glucose which decreases slightly with insulin therapy as result of the proportion of time spent 
hypoglycaemic. Therefore, although the HbA 1 c decreases a little it has been shown that 
insulin treatment does not necessarily result in optimal glycaemic control. 
The Minimed reveals trends in glycaemic control that can not be obtained from current 
clinical measures. The use of Minimeds in clinical practice is limited due to their high 
expense, but research involving Minimeds can show the effect of treatments on glycaemic 
control, which can ultimately help improve the management of diabetes. 
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3 A randomised control trial investigating the effect of an 
intensive lifestyle intervention versus standard care in 
adults with type 2 diabetes initiating insulin therapy 
3.1 Introduction 
The previous chapter demonstrated that for people with T2DM 24 hour glycaemic control was 
not significantly improved for patients on established insulin therapy compared to those 
treated with oral hypoglycaemic agents. This study will investigate in greater depth the wider 
impact of insulin therapy in T2DM with respect to changes in body weight. risk of 
cardiovascular disease risk and quality of life. 
3.1.1 Arguments against insulin therapy 
Insulin therapy plays an integral role in the treatment of T2DM, however uncertainty remains 
as to the true impact that insulin has upon body weight and consequentially the cardiovascular 
risk. The following provides background as to the negative effects of insulin and why this 
particular area of T2DM requires further investigation. 
3.1.1.1 Weight gain 
The average weight gain experienced by individuals with T2DM commencing insulin therapy 
has been reported to be 3 to 5kg in the first 6 to 12 months (Henry et aI., 1993; Sinha et aI., 
1996; Yki-Jarvinen et aI., 1997; 1998a; Dickinson et al.. 2002; Wright et aI., 2002). Although 
weight gain as a result of insulin therapy has been mentioned in numerous studies, it had not 
been the focus of a study itself. The weight gain however has the potential to impact 
negatively upon a disorder in which the metabolism, especially that of lipid metabolism, is 
already disturbed (Williams, 1999). 
The large majority of patients with T2DM are overweight or obese at diagnosis. It has been 
suggested that T2DM should be renamed "diabesity" as it is largely obesity dependent 
(Astrup and Finer, 2000). It is widely accepted that weight management should be the 
cornerstone of the diabetes treatment (Campbell and Rossner. 2001). With this in mind it 
seems ironic that the final remedy used to optimise glycaemic control of T2DM exacerbates 
these weight problems. The iatrogenic weight gain following insulin therapy has a negative 
impact upon metabolic processes. not only because of the added strain of extra adiposity. but 
also because of the process of weight gain per se. To gain weight an individual must be in 
positive energy balance. which results in higher circulating glucose and lipid levels. 
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increasing metabolic stress and abnormalities (British Nutrition Foundation. 1999). In 
addition the increasing adiposity exacerbates insulin resistance which leads to larger doses of 
insulin necessary to control glycaemia, causing a self perpetuating negative cycle. The costs 
of insulin treatment must therefore be weighed up against the benefits of treatment prior to 
starting insulin therapy. 
Aside from the metabolic consequence of weight gain and the effect it has on diabetes. weight 
gain will increase the likelihood of other obesity related conditions, such as osteoarthritis, 
cancer, sleep apnoea, reproductive difficulties, and gallstones to name a few. In addition 
weight gain may have a large impact upon an individual's psychological well being and 
quality of life, particularly at a stressful time such as that when insulin therapy is initiated. 
3.1.1.2 Cardiovascular disease 
Cardiovascular disease (CVD) is thought to precede the development of T2DM (Rett, 1999). 
T2DM develops gradually over a number of years, therefore at the time of diagnosis 
considerable detrimental changes to the cardiovascular system may have already occurred. 
The development of CVD is multifactorial, there are internal factors which are genetic and 
largely predetermined, but there are also external (environmental) events that influence the 
homeostasis of the body, resulting in reversible and irreversible changes. The external 
influences include smoking, diet. body weight and exercise which can all be manipulated to 
alter overall cardiovascular disease risk. 
A number of studies have questioned the use of insulin therapy in T2DM due to the potential 
increased risk of CVD. Barranco, (1998) highlighted that the T2DM population are at high 
risk of CVD, but that an integrated approach to management of the metabolic disorder was 
preferable, including management of lipids and weight as well as that of blood glucose. As 
T2DM is a multifactorial disease consisting of hypertension, dyslipidaemia, obesity, 
prothrombotic states, endothelial dysfunction and high blood sugars, it would appear that 
controlling blood glucose is only a small part of optimising cardiovascular health. 
Worryingly the incidence of coronary artery disease (CAD) is four times higher in those with 
T2DM than that of the general population (Ali Raza and Movahed, 2(03). In recent years 
there has been a reduction in death from CAD in the general population due to improved 
treatments, a trend that is not replicated in those with T2DM. Therefore in a population at 
high risk of CVD, ideal treatments would aim to reduce this risk, rather than increase it 
further and it is questionable as to whether insulin achieved this aim. particularly due to the 
intermediate effect of hyperinsulinaemia. 
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3.1.1.3 Hyperinsulinaemia 
One of the main arguments against use of insulin therapy in T2DM is the pronounced effect 
of insulin resistance and the consequences of hyperinsulinaemia. Insulin resistance is 
characteristic of T2DM and means more insulin is required to that to elicit the same response 
to glucose as the non-diabetic population. This results in higher circulating levels of insulin 
and hence the individual being in a state of hyperinsulinaemia. The major factor of insulin 
resistance is being overweight or obese, particularly central obesity (Greenfield and 
Campbell, 2004). Early on in the progression of T2DM it is the hyperinsulinaemia that masks 
the disorder, delaying its diagnosis. As an individual becomes more insulin resistant the body 
compensates by producing more insulin to control blood sugar. Eventually the p-cells of the 
pancreas can not keep producing the amount of insulin that the body demands, insulin level 
then falls and blood glucose level rises, resulting in the symptoms and diagnosis of T2DM. It 
has been proposed that insulin resistance and hyperinsulinaemia are the cause of a number of 
the detrimental characteristics of diabetes such as dyslipidaemia and hypertension and are the 
consequence of central obesity (Balkau and Eschwege, 1999). Even in normal weight 
subjects hyperinsulinaemia has been positively correlated with coronary artery disease (CAD) 
(r=0.480, p<0.05) suggesting that hyperinsulinaemia is an independent risk factor for CHD 
(Bressler et al., 1996). The intertwined relationship between insulin resistance and 
hyperinsulinaemia, which are the foundation components of the insulin resistance syndrome. 
have consistently been associated with CHD (Walton et al., 1995; Rett, 1999; Reaven. 2002; 
Parker et aI., 2003), however the full mechanisms of the association are not as yet fully 
understood. 
If, as the evidence to date suggests, hyperinsulinaemia is an independent risk factor for CHD, 
then the use of exogenous insulin in T2DM should be questioned, as this would potentially 
introduce unacceptably high levels of circulating insulin. Therefore, the full implications of 
insulin therapy need to be known so that a thorough risk-benefit analysis can be executed 
prior to a patient starting insulin; however further research is required into this area so that a 
more informed choice can be made. 
3.1.1.4 Quality of life 
Quality of life for patients with T2DM with regards to insulin therapy has focussed on the 
psychological barriers to treatment with insulin and comparison of intensive and standard 
strategies for glycaemic control. There are many barriers to initiating insulin therapy and 
change in quality of life is one of the major concerns. Technical concerns and experimental 
concerns have been highlighted as barriers to starting insulin (Hunt et al.. 1997). Technical 
concerns include anxiety over the processes of injection and the potential of hypoglycaemic 
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events (Zambanini et al., 1999), whereas experimental concerns are the feelings of failure and 
guilt when insulin therapy is considered and apprehension over disease progression 
(Korytkowski, 2(02). Additional patient anxiety surrounds the fear of weight gain following 
the initiation of insulin therapy (Korytkowski, 2(02). It appears therefore that there are high 
levels of concern and anxiety regarding the initiation of insulin therapy, but this does not 
indicate how quality of life actually changes once insulin therapy has commenced. 
Once the barriers to insulin therapy are overcome and treatment is initiated, research indicates 
that the actual change, rather than the perceived change, in quality of life, is minimal. When 
comparing intensive and standard therapies for glycaemic control, where the intensive therapy 
involves treatment with insulin, it is suggested that the change in quality of life for those in 
the intensive group did not change due to a reciprocal balance between improved health 
related quality of life and the increase demands of insulin therapy (Pitale et al., 2(05). This 
suggests that the negative demands of insulin therapy are outweighed by the positive health 
benefit derived from its administration. This finding has been substantiated by another study 
which showed that insulin therapy resulted in significant improvements in glycaemic control 
and significantly fewer hyperglycaemic complaints, but no change in quality of life (de 
Grauw et al., 2001). The microvascular and macrovascular complications associated with 
diabetes have been shown to significantly reduce quality of life, although the strategies used 
to reduce the risk of these complications, such as insulin therapy, have neither a positive nor 
negative effect on the quality of life (UKPDS Study Group 1999). Just one study mentions 
the influence that weight gain has upon quality of life and found there was no relationship 
between these two factors (Wilson et al., 2004). 
Patients' quality of life is an important factor that needs to be considered prior to and during 
treatment with insulin therapy. The impact that insulin therapy has on quality of life, in 
particular, as a result of the iatrogenic weight gain following insulin therapy requires further 
investigation. 
3.1.2 Gaps in knowledge 
There are many gaps in knowledge with regards to insulin induced iatrogenic weight gain in 
diabetes. Although it is widely accepted that weight gain does occur when insulin is 
introduced into the treatment of T2DM. the full effects of this are largely unknown. Weight 
gain is often mentioned as a side effect of the treatment used. but to date no studies have 
focused directly upon the weight gain and its effects. There are little data on the changes in 
quality of life. blood lipid profile. postprandial lipids. body composition and the consequences 
of these on CHD risk in patients with T2DM as a result of weight gain following initiation of 
insulin therapy. The present investigation aims to answer some of these questions. 
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It has been suggested that the cornerstone of T2DM management should focus on reducing 
levels of obesity with lifestyle, exercise and behaviour modification (Campbell and Rossner, 
2(01), one way that this may be achieved is through a dietetic led weight management 
programme. Intensive dietetic strategies have only recently been developed as a treatment 
option for people who are overweight and are not extensively implemented. The marked 
success however of the intensive diet and lifestyle programmes has been shown in the 
overweight population (Frost et aI., 2002) and in populations at risk of developing T2DM 
(DPP Research Group 2002). It is hoped that the success of the intensive weight management 
programme may be transferred to the specific population group in this study, being those 
patients with T2DM who are starting insulin therapy and that the success will be the 
prevention of weight gain that occurs at this time. 
One study that particularly highlighted a gap in knowledge and acted as an impetus to the 
present investigation was a retrospective case-control study that compared diabetic. lipid and 
weight parameters of people with T2DM starting insulin to matched controls without insulin 
therapy (Dickinson et aI., 2002). It was found that over a year the insulin treated group 
gained 4.2kg (SD 4.0) more weight than the control subjects. There were some improvement 
in diabetic control, as measured by fasting glucose and HbA 1 c, in those treated with insulin. 
but their results after a year remained higher than those not on insulin therapy. in addition 
there were no beneficial changes in fasting lipids. A worrying finding of this study was that 
only 26% of those patients who started insulin therapy had access to a dietitian. This 
stimulated the suggestion that prospective studies should be implemented to determine 
whether increased access to specialised dietetic programmes could offset the negative effects 
of weight gain caused by initiating insulin therapy. In achieving weight maintenance or 
weight loss after initiation of insulin through intensive diet and lifestyle advice it is hoped that 
it would be possible to distinguish between the outcomes caused by the direct effects of 
insulin and the indirect effects as consequence of iatrogenic weight gain. 
3.2 Aim and Objectives 
This study aimed to discover the wider implications of the weight gain that is experienced by 
patients with T2DM as they start insulin therapy. Specific risk indicators were measured and 
compared and the UKPDS risk score was tested in this population. Comparisons were made 
within each group at the start (baseline) and at the end of the study (baseline + six months). 
To measure the impact of the weight gain on its own. comparisons were also made between a 
control group (whose weight is expected to increase) and an intervention group (whose 
weight is expected to be maintained). The study aimed to investigate the use of an intensive 
dietetic strategy. originally developed as an intensive weight management service. within the 
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diabetes framework. It tested and evaluated this treatment strategy as compared to standard 
care. 
This study aimed to investigate the effect that starting insulin therapy has on body weight in 
T2DM. The two main aims of the study are summarised as follows. 
• The first aim of this study was to investigate the effects of the increase in weight that 
is experienced immediately after insulin therapy is initiated. The metabolic effects of 
weight gain in patients with T2DM commencing insulin therapy were examined. The 
study will show what changes occur with regards to lipid parameters, blood pressure, 
body composition, postprandial lipid handling and change in cardiovascular risk. 
• The second aim of the study was to investigate whether an intensive programme of 
lifestyle and weight management advice is effective in reducing weight gain or 
promoting weight loss over the first six months of insulin treatment. If weight 
maintenance or weight loss is achieved this will indicate whether the negative 
consequences of insulin therapy can be offset by appropriate lifestyle changes. The effect 
of a dietetic intervention will also be evaluated, with regards to achieving weight 
maintenance or weight loss and managing CHD risk. 
3.3 Hypotheses 
The main hypotheses to be tested are that: 
1. Patients with T2DM who start insulin therapy and have access to standard dietetic 
care will experience significant weight gain in the first 6 months compared to those 
who undertake an intensive lifestyle i1l1en'ention. 
2. During the first six months of insulin therapy there will be significant improvemeIl1s 
in glycaemic control ill all patients. 
3. Those patients who receive standard care and gain the most weight are more likely to 
experience more Ilegative changes ill cardiovascular risk markers than those who 
receive intensive dietetic intervention. The difference between the groups will be 
apparent in cardiovascular risk markers such as: 
• All increase in percentage body fat. particularl.'v in the central region (increasing 
central adiposity) 
• All increase ill both systolic alld diastolic blood pressure 
• A lowerillg offasting HDL-cholesterol and elemtioll offastillg WL-cllOleslaol 
• A worsening of the calculated UKPDS cardiol'Oscltlar disease risk score 
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4. Change in the quality of life will be related to the difference shifts in body weight 
between the two groups. 
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3.4 Method 
3.4.1 Study design 
The study was designed as a randomised control trial (RCT). Each patient was randomly 
assigned to either the control or intervention group. The control group received standard care 
and the intervention group received a programme of intensive dietetic advice. 
3.4.2 Ethical approval 
Ethical approval was received from the following centres: 
• 
• 
• 
• 
University of Surrey Advisory Committee on Ethics, Guildford. Surrey 
Hammersmith, Queen Charlotte's and Chelsea and Acton Hospitals Research 
Ethics Committee, Hammersmith Hospital, London 
South West Surrey Local Research Ethics Committee, Royal Surrey County 
Hospital, Guildford, Surrey 
St Mary's Clinical Ethics Committee, St Mary's Hospital, Paddington, London 
Although ethical approval was obtained at St Mary's Hospital, Paddington, this recruitment 
centre was not used in the investigation. Patients were recruited from the Hammersmith 
Hospital, Charing Cross Hospital in London and the Royal Surrey County Hospital in 
Guildford. Full informed consent was obtained from each subject prior to inclusion into the 
study. 
3.4.3 Primary outcome measure 
The primary outcome measure was change in weight following initiation of insulin therapy. 
The power calculation that was done for the number of subjects has been based on a weight 
change difference of 2kg, with a standard deviation of 2, between the control and intervention 
groups after 6 months treatment. All other measures are secondary to change in weight. 
3.4.4 Sample size 
Power calculations were used to estimate the required sample size for the primary outcome 
measure which was difference in weight change of 2kg between those receiving standard care 
and those following intensive dietetic intervention. The online calculations were based on 
information provided by Rosner. (1995). Initially the calculation was conducted using the 
best available data from other studies, but was repeated when six patients from each group 
completed the study. at which point there was a 3.5kg weight difference and standard 
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deviation of 4. The power calculation indicated that 21 subjects in each group were required 
for a statistical strength of 80% and a significance of 0.05. Allowing for a drop out rate of 
20%, the target number to recruit was 24 subjects in each group. 
The power calculation use is expressed as 
Where: 
• 
• 
• 
• 
Where: 
Power = Pr(tv, ncp < tv, al2) + Pr(tv, ncp > tv, l-al2) 
Pr = probability of a given number 
tv. ncp follows a non-central t-distribution with v degrees of freedom and a non-
centrality parameter of ncp 
tv. a/2 is the a/2 quantile of a central t-distribution with v degrees of freedom 
and v = 2n - 2 
ncp is the non-centrality parameter of non-central t-distribution, estimated by: 
d 
ncp= uJ!. 
• 5 is a large enough sample to detect a difference with a significance level test with 
I-p power 
Patients were randomly assigned to the control and intervention groups. Randomisation was 
achieved following randomisation tables. There were two levels of stratification for sex; male 
and female and three levels of stratification for ethnicity; White, Black, and Asian resulting in 
six groups from which each recruited subject was randomised. Subjects were randomised 
according to the order in which they were recruited and the sequential order of the 
randomisation table (See Appendix B for randomisation tables). The study could not be 
blinded to either the subject or the investigator due to the nature of the intervention. as those 
in the intervention group were required to attend frequent dietetic appointments and make 
lifestyle changes, which were not required by those in the control group. 
3.4.5 Participant recruitment 
The diabetes specialist nurses (DSNs) referred patients to the author who assessed their 
eligibility for the study against the entry criteria. The DSNs were the optimal referral source 
as they carried out the patient training for insulin and therefore had contact with all patients 
commencing insulin therapy. The diabetes. endocrinology and cardiac physicians were 
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informed of the study, but were not involved in the recruitment process, due to time 
con"traint~ and frequent rotation of staff. A different recruitment process occurred at each 
hospital to best suit the individual needs of each location. At Charing Cros" Hospital referrab 
were received verbally at the weekly multi-disciplinary team (MDT) meeting .... while at the 
Hammersmith Hospital verbal referrals were received by meeting the DSN'" individually on a 
weekly basis. At the Royal Surrey County Hospital (RSCH) referrals were written at the time 
the patient was seen and these were collected weekly. Of the 189 patient" referred to the 
study 72% were excluded, either for not meeting the criteria or the patients not \\ishing or 
unable to participate (see Figure 3-1). Patients had to commence the study within -+ weeks of 
starting insulin therapy. 
Once the patient had been referred the author attempted to contact them by telephone. If 
telephone contact was unsuccessful after one or two weeks, a letter was sent to the patient 
informing them of the study and requesting that they should contact the department if 
interested in participating. Responses to the letters were very poor. If telephone contact was 
successful, patients were briefly informed about the study and if they were interested an 
appointment was made. At the first appointment patients were screened for <.,uitability as 
denoted by the inclusion and exclusion criteria. 
Table 3-1 The inclusion and exclusion criteria patients were required to meet 
prior to participation in the study 
Inclusion criteria 
• Presence of T2DM and at a time in 
their treatment when insulin 
therapy is being introduced (± 4 
weeks ). 
1 
• BMI >27kg/m-
• Aged between 18 and 75 years 
• Able to understand written English 
• Able to make and give informed 
con<.,el1t to participate in the study 
Exclusion criteria 
• Co-existing morbiditie<., that may affect 
nutritional intake. such as Crohns disease, renal 
impairment, liver disease, cancer and HIV+. 
• Indi vi duals whose treatment may be affected 
detrimentally through participation in the study, 
including those who would ordinarily receive 
greater dietetic input than that of which the 
control group will receive, for example those 
who were morbidly obese (Body Mas<., Index 
>50kg/m\ 
• Females who were pregnant, planning to 
become pregnant or breastfeeding. 
• Individuals who, as part of their treatment. u<.,e 
medication that ha<., been <.,hown to promote 
weight loss (Reductil and Orli"tat) 
3.4.6 Participant flow 
Figure 3-1 documents the flow of patients through the tudy. 
c 
(j) 
E 
o 
... 
c: 
W 
"tl (j) 
~ 
a. 
E 
o () 
Assessed for eligibility (n= 189) 
(HH and CXH=166, RSCH=23) 
~ 
Excluded 
(n=136) 
I Randomised (n=53) I .... 
~ 
Allocated to control Allocated to intervention 
group (n=27) group (n=26) 
Lost to follow up (n=2) : 
. Unable to contact Lost to follow up (n=l) : 
(n=l) 
. Patient unwi ll ing to . Concurrent unrelated 
attend follow up illness (n=l) 
appointment (n=l) 
, 1 
Completed (n = 25) Completed (n = 25) 
Patient not meeting criteria (n:60) 
BMI too low (n=18) 
Age (n=7) 
Did not start insulin (n=17) 
Other medical condition (n=6) 
Did not speak English (n=7) 
Trying to get Pregnant (n=5) 
Patient unable to participate (n: 76) 
Not interested (n=43) 
Work commitments (n=13) 
Too many hospital appt (n=5) 
Unable to contact (n=15) 
Figure 3-1 Flow of patients through trial investigating the effect of initiating 
insulin therapy in type 2 diabetes for patients following standard care or 
intensive lifestyle intervention 
3.4.7 Study procedure 
The f II 1I1g flowchart (Figur 3-2) ummari ed the tudy procedure. nc patient had 
be n r ruit d into th tudy the were randoml a igned into th control or inl f\ nti n 
group and ba~ lin III a · ur m nL were tak n. Th patient ontinued f r the ~ 110\\ ing i\ 
l11onth~ a~ det rmin d b th ir rand mi d gr up and at th nd f the i m nth~ the ba..,el1n 
mca..,urel11 III " re r peat d. Th time peri d b tw 
commencing th ~tud \'va~ a maximum f -+ \v b. 
m nt r r lioibilllY and 
Initial Contact: Patient referred : Patient contacted by • Introduction of P.I. 
• MDT meeting 
• Verbally ~ Principle Investigator ~ . Brief Introduction to study (PI) • Answering queries 
• Written 
• Arrange appointment 
Patient wishes not to participate ~ I . 
Patient excluded Inclusion and Patient information 
from the study , !+- No - exclusion criteria .... sheet for general H First Appointment I further treatment sheet completed '" study provided and 
unaffected. and cleared explained fully 
If patient wishes to Patients randomly Data sheets take part CONSENT assigned into control .. ~ 
completed FORM signed or intervention group 
Form 2 Social Form 3 History Form 1 I+- and Medical f+-of Diabetes History Personal details 
.. 
Form 4: Baseline and endpoint 
(baseline + 6 months) Measurements 
j 
+ + + + 
Anthropometry ~ I Blood Pressure I I Quality of Life I Haematological 
~ + 1 ~ 
Weight (kg) I I Average of 3 ~ ~ EuroQol J Fasting sample : .. I BMI (kg/m2) ~ readings Questionnaire Glucose, HbA 1 c, Cholesterol , 
.. Height (m) I 
--* 
HDL, LDL, TAG 
~ 1 Baseline data collected, Waist continuation of study 
circumference dependant on randomly 
~ 
(cm) assigned group 
~ '- ~ -I Body fat (%) BIA I Control group l lntervention J group Intensive weight 
I Continue with Enter Lifestyle management clinic - consisting 
standard care for Clinic for 6 of6 
6 months L months .J appointments '--
-
over 6 months 
End point 
measurements -
repeat of baseline 
measurements 
Figure 3-2 Flowchart of study procedure 
3.4.8 Measurements 
The following tests and measurements were taken at baseline. when the patient entered the 
study and repeated after 6 months, when the patient completed the study. These 
measurements formed the basis of the data collection and included the parameters used to 
calculate cardiovascular risk. Due to the different locations at which the patients were seen. 
some equipment varied slightly; however for each individual patient the equipment used 
remained consistent. 
3.4.8.1 Height 
The height was measured using a wall-mounted stadiometer and was taken when the patient 
was not wearing shoes. The patient was asked to stand facing away from the height meter 
with their feet flat on the floor. The patient was positioned so that their back was straight, 
shoulders relaxed and level, and looking straight ahead, so that their line of vision was 
parallel to the floor. The headrest was bought down slowly to rest on the top of the head and 
the reading taken to the nearest 0.5cm. The patient was only measured at their first 
appointment and this measurement was used for subsequent calculations of Body Mass Index 
(BMI) and percentage body fat. 
3.4.8.2 Weight 
Patients recruited from Charing Cross and Hammersmith Hospitals were weighed on the same 
equipment that measured percentage body fat, the Bioelectric Impedance Analyser (BIA) 
(detailed in Section 3.4.8.5). Shoes were removed and patients were weighed in light indoor 
clothes. The weight was recorded to the nearest 0.1 kg. 
Patients recruited from the Royal Surrey County Hospital were weighed on portable scales. 
The scales that were used were the SECA 770 high capacity floor scales. which are used by 
the World Health Organisation (WHO) and designed to be highly accurate and portable. 
Patients were again weighed without shoes and in light clothing. Weight was measured and 
recorded to the nearest 0.1 kg. 
3.4.8.3 Body mass index (BMI) 
The body mass index (BMI) is a ratio between weight in kilograms over the height in metres 
squared (kg/m2) and was calculated for each patient, using the following formula. 
BMI = Weight (kg) 
Height (m)~ 
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BMI was used in the present investigation as part of the inclusion criteria (>27 kg/m2) and 
exclusion criteria (>50 kg/m2), but also enables analysis of the degree of weight loss between 
patients, regardless of differences in height. 
3.4.8.4 Waist circumference 
Waist circumference was measured using a standard flexible tape measure accurate to 0.2cm. 
produced by Xenical®. The waist circumference measurement was recorded to the nearest 
0.5cm at navel level. 
3.4.8.5 Estimation of percentage body fat 
The percentage body fat was estimated by a Bioelectric Impedance Analyser (BIA). Two 
models were used dependent upon the location from which the patient was recruited. A BIA 
sends a small electrical charge through the body and calculates the percentage body fat from 
the resistance, exploiting the fact that an electrical charge cannot pass through fat, but can 
through muscle and other water containing tissues. 
The BIA used at Hammersmith Hospital for the London patients was the eight point Biospace 
In Body 3.0 body composition analyzer. The individual patient data were entered into the 
machine according to the manufacturers guidelines. Care was taken to ensure that the patient 
held their arms away from their body so that the electrical charge could not take a shorter 
route between the upper arms and the body, as this which would have affected the result. 
The BIA used for patients recruited from the RSCH was the four point Bodystat® 1500MDD, 
which required the author to position the electrodes in the desired position, 2 on each right 
limb. Information entered into the equipment included the patients age, sex, height, waist and 
hip circumference and activity level. The patients percentage and actual body fat was then 
calculated, along with lean mass and estimated energy requirements. The influence of 
activity on the results of the Bodystat® 1500MDD was notable, therefore the same level of 
activity for each individual patient was used at the end of the study as it was at the beginning. 
despite any change in activity there may have been in the six month period. 
Intrapersonal variation was measured to compare the methods which were less than 5llc 
different (Appendix C), therefore no adjustment for variation between the different 
bioelectrical impedance analysers was required. 
3.4.8.6 Blood pressure 
Subjects' blood pressure was measured using an electronic sphygmomanometer (Omron M4). 
The blood pressure was measured when the patient was at rest. at least 20 minutes after 
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arriving for the appointment. The patient was seated, with their right arm at right angles 
turned upwards and relaxed. The blood pressure was taken 3 times, recording the systolic and 
diastolic pressures, the mean of the three readings was calculated and used in analysis. 
3.4.8.7 Quality of life questionnaire 
Subjects were asked to complete a quality of life questionnaire. The questionnaire that was 
used was the EuroQol ED-50 (See Appendix D), which has been available since 1990 
(Brooks, 1996). The ED-50 is a simple standardised questionnaire, which is non-disease 
specific and has been extensively used for a number of health related conditions such as sleep 
apnoea (Moyer et aI., 200 I), kidney dialysis (Wasserfallen et aI., 2004), rheumatoid arthritis 
(Wolfe and Michaud, 2004) and diabetes (Hart et aI., 2003). It consists of a series of 5 
questions, each with 3 potential answers (Table 3-2). 
Table 3-2 Dimensions of health status and response options for the E~-50 
questionnaire 
Health status questions Response options 
• Mobility 
• Self-care • No problem 
• Usual activity • Some problem 
• Pain / discomfort • Extreme problem 
• Anxiety / depression 
The questionnaire identifies 243 different health states, determined by all the combinations of 
answers. A numerical score (ED-50 Tariff) ranging from -0.59 to I has been assigned to 
each health state by Dolan, (1995). A score of I represents a full health state, 0 is dead and 
minus scores indicate a state which is considered worse than death (See Appendix E for tariff 
assigned to each health state). 
The second part of the ED-50 is a visual analogue scale. The patients were asked to rate their 
own health and mark this on the scale. The scale ranged from 0 to 100, with 100 representing 
the best health imaginable and 0 representing the worst health imaginable. The scale was 
marked by the patient drawing a line from the box on the right hand side saying "your health 
state today" to the point on the scale that they think best represented this. 
The results of the ED-50 were analysed in terms of the answers for the individual elements, 
the health state score and the patient self-rated health state. 
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Validity and reliability of the E~-50 
A comparison of results from the EO-50 with data from the Office for Population Censuses 
and Surveys (OPCS) and General Household national survey showed that the EO-50 gave a 
20-40% higher rate of disability than these other measures (Kind et al., 1998). This was 
attributed to the fact that the EO-50 uses fewer and broader ranges of measurement than the 
other surveys. However the EO-50 has been found to be valid, responsive to change and 
sufficiently reliable for group comparisons with condition specific instruments, with 
reliability coefficients reported to be 0.70 (Hurst et al., 1997). In this study the Cronbach 
alpha was 0.81, demonstrating the robust nature of the study. 
3.4.8.8 Cardiovascular risk score 
Estimated cardiovascular risk was calculated for each patient at the start and end of the study 
with use of the UKPOS 'Risk Engine' (Stevens et aI., 2001). The UKPOS study followed 
5102 patients for a median of 10.7 years and enabled, among many other findings, an analysis 
of the natural history of T20M. From this, a model was composed which provides estimates 
of probability for cardiovascular disease risk determined by multiple risk factors. The risk 
factors found to have significant (p<O.OOI, except smoking where p=O.0013) and independent 
influence on cardiovascular outcome and therefore data required for the program are as 
follows; age at diagnosis, duration of diabetes, sex, ethnicity (White, Afro-Caribbean or 
Asian-Indian), smoking (current, past or never), systolic blood pressure, HbA 1 c, total 
cholesterol and HOL cholesterol. Presence of atrial fibrillation was an additional factor that if 
known could be accounted for in the equation, for the purpose of the present investigation 
however the answer for this was kept as 'No'. Regression dilutions were available for the 
number of HbA 1 c, systolic blood pressure and cholesterol measurements; in this investigation 
there was one measurement for the HbA 1 c and cholesterol and three for blood pressure. 
Once the information had been entered into the programme ten year risk was calculated. Four 
estimated risk scores were provided (including lower and upper confidence intervals) for; 
coronary heart disease (CHO), fatal CHO, stroke and fatal stroke. These estimated risk scores 
were used in the analysis. 
Validity and reliability of the UKPOS risk engine 
The reliability and validity of the UKPDS risk engine for people with diabetes supersedes any 
other models as it is disease specific and taken directly from the largest long term study 
involving patients with T20M. Other models, such as the cardiac risk assessor developed 
jointly by the British Cardiac Society, the British Hyperlipidaemia Association, the British 
Hypertension Society and endorsed by the British Diabetic Association (collectively known 
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as the Joint British Societies (JBS» (Joint British Societies, 1998, British Diabetic 
Association 1998) were based mainly on data from the Framingham study (Anderson et al., 
1991). The Framingham study contained relatively few people with T2DM (-6%), despite 
this JBS cardiac risk assessor has been used for both people and populations with T2DM, 
however uncertainty remains regarding the accuracy of this tool in people with T2DM (Yeo 
and Yeo, 2(01). 
The validity and reliability of the UKPDS risk engine within the T2DM population has been 
tested against the JBS cardiac risk assessor (Song and Brown, 2004; Guzder et aI., 2(05). 
These studies show that the UKPDS risk engine calculated significantly higher 10 year CHD 
risk than the JBS cardiac risk assessor. This was to be expected as the JBS cardiac risk 
assessor was designed for use in the general population and therefore includes just one 
dichotomous question regarding diabetes; either its presence or not. The UKPDS risk engine 
on the other hand was disease specific and includes questions regarding age at which T2DM 
was diagnosed, duration of T2DM and a measure of glycaemic control, all been shown to 
have an effect on overall CHD risk. Both models were effective in discriminating between 
low and high-risk patients, but quantifying absolute risk on an individual basis was poor. The 
UKPDS risk engine calculated more patients at high risk and was considered more accurate 
than the JBS calculations as other studies have shown that people with T2DM are 2 to 4 times 
more likely to develop CHD than the non-T2DM population (Haffner et aI., 1998). It is 
difficult to accurately measure risk compared to outcome as the calculated risk determines 
treatment strategies which aim to lower outcome events. 
As the UKPDS Risk Engine is the best measure to estimate risk in people with diabetes, it 
was used for this study. The aim was to assess the direction of change in risk over the first 6 
months after the initiation of insulin and compare the difference in change between those 
following standard care to those receiving intensive diet and lifestyle advice. The results 
obtained by this study were not used to predict outcome on an individual basis or direct 
medical treatment. 
3.4.9 Fasting blood sample 
A fasting venous blood sample was taken from each patient at baseline and at the end of the 
study (baseline + six months). The fasting sample was required as levels of some 
components, in particular triacylglycerides, change in response to recent food intake. The 
patient was requested in writing to fast for 12 hours prior to the sample being taken, 
compliance with this was then verbally checked at the appointment. The patient was also 
instructed not to take their morning insulin until after their appointment and until they were 
going to have something to eat. to minimise risk of hypoglycaemia and standardise the 
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results. The author was trained in venepuncture and took all samples. The samples taken for 
analysis are shown Table 3-3 and details ofthe procedures follow. 
Table 3-3 Fasting blood sample taken at baseline and at the end of the study 
Test 
All patients 
Glycaemic control 
Blood lipids 
Subgroup analysis 
Lipid subfractions 
Components 
• Glucose 
• HbAlc 
• Total Cholesterol 
• HDL-Cholesterol 
• LDL-Cholesterol 
• Triacylglycerides 
• Calculated Total-Cholesterol: HDL-Cholesterol ratio 
• 
• 
LDL-cholesterol subfractions 
Non-esterified fatty acids (NEF A) 
3.4.9.1 Analysis methods and equations 
Blood samples were collected in EDT A vacutainers, except for glucose which was collected 
in Fluoride Oxalate. All blood samples from the patients recruited at Hammersmith Hospital 
(HH) and Charing Cross Hospital (CXH) were analysed by the hospital laboratories by 
standard automated spectrophotometric methods (reagent kits from Randox, Country Antrim, 
Northern Ireland, UK). HbAlc samples were analysed by the corresponding hospital 
laboratory for all patients, including those recruited from the Royal Surrey County Hospital 
(RSCH). All other blood samples for patients recruited from the RSCH (glucose, cholesterol, 
HDL-cholesterol, LDL-cholesterol triacylglycerides and NEFA) were measured at 
Southampton University by laboratory technicians using standard automated 
spectrophotometric methods with reagent kits from Konelab, Thermo Electron Corporation. 
Vantaa, Finland. For the patients recruited from the RSCH once the sample had been taken 
the plasma was separated from the red blood cells by centrifuge (3000rpm for 15 minutes) 
then split into individual aliquots and stored at -80°C until required for analysis. 
A spectrophotometer measures the amount of light that a sample absorbs. The 
spectrophotometer has a light source that emits a given number of photons per second. these 
pass through the sample. which absorbs a proportional number of photons to its concentration 
and the remaining photons are detected. The concentration of the sample can then be 
calculated using calibration curves depending upon the number of photons detected 
subsequent to passing through the sample. For the analysis of plasma glucose and lipids a 
number a chemical reactions have to take place to prepare the sample. so that the sample itself 
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or an equimolar derivative of the sample is a suitable analyte molecule for the 
spectrophotometer. The analyte molecule coloured (i.e. dyes) as these absorb photons. The 
following equations summarise the chemical reactions for each analysis, indicating the 
analyte in bold. Quality controls were repeated for each analysis, giving rise to Interassay 
coefficients of variation (CV), which were all <5% and are stated after the equation for each 
analysis. 
i HbA1c 
The HbAlc was measured in the hospital laboratories using procedures standardised to that of 
the Diabetes Control and Complications Trial (DCCT aligned) (1993). The HbAlc's were 
analysed using automated High-Performance Liquid Chromatography (HPLC), with CV<5%. 
Following lyses of the red blood cell, the glycated haemoglobin was separated from the non-
glycated haemoglobin by reverse phase ion exchange chromatography. A spectrophotometer 
was used to quantify the amount of glycated haemoglobin (HbAlc), which was then 
expressed as a percentage of non-glycated haemoglobin. 
ii Glucose 
Glucose and lipids were analysed using spectrophotometry as described above (Section 
4.4.9.1). The follow provides details of the chemical reactions for each analyte required prior 
to analysis to give rise to a coloured substance (in bold) which could be read by the 
spectrophotometer. 
Glucose + ATP Hexokinase) Glucose - 6 - phosphate + ADP 
Glucose - 6 - phosphate + NAD+ G-6-PDH) 6 - phosphogluconate + NADH + H+ 
CV=0.60% 
iii Cholesterol 
Cholesterol esters Cholesterol Esterase) Choleserol + Fatty Acids 
Cholestero I + O
2 
Cholesterol Oxidase) Cholest - 4 - en - 3 - one + H 202 
2 d b . 'd 4 . t" Peroxidase) QUl'nonemine DYe + 4H_,0 H 202 + Hy ro enzOiC aCI + - ammoan lpyrme J 
CV =0.44% 
iv HDL-cholesterol 
HDL - cholesterol esters + H 20 Pf.(j ClwleM .. ,.,.,1 ('>lao-\<' ) HDL - Cholesterol + RCOOH 
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HDL - cholesterol + 02 
2H20 2 + 4 aminotipyrine 
+HSDA+H20+H+ 
CV = 1.30% 
v LDL-cholesterol 
PEG Cholesterol oxidase ) A4 Ch I H 
LJ - 0 estenone + ~02 
Peroxidase) Purple blue pigment + 5H 202 
LDL - cholesterol esters + H 20 Cholesterol esterase) LDL - Cholesterol + RCOOH 
LDL - cholesterol + O2 Cholesterol oxidase A4 Ch I H 0 ) LJ - 0 esteno ne + 2 2 
2H 20 2 + 4 aminotipyrine Peroxidase P I bl . 
+ HSDA + H
2
0 + H+ ----'~=~) Urp e ue pIgment + 5H 202 
CV = 0.32% 
vi Triacylglycerides 
Triacylglycerides lipase) Glycerol + Fatty acids 
Glycerol + AT'P Glvcerolkinase Gl I 3 h h ADP . ) ycero - - p osp ate + 
Dihydroxyaceton phosphate Glycerol- 3 - phosphate + 02 _G.;;.;·I::..:.yc.:.;.er.:.;.ol--.:;-3;....-.!:.:.ph-=-os:!:.p=ha-=-It!(:;.;.;)x:.::;idas::.e~) 
+H20 2 
2H 202 + Aminoantipyrine Peroxidase Quinonemine + HCI 
-;:":';":=:':'::"'-4) 
+ 4 - Chlorophenol + 4H 20 
CV = 1.79% 
3.4.9.2 Subgroup analysis 
Patients recruited from the RSCH had additional analysis carried out on their blood samples. 
These were analysis of LDL-subfractions and NEFA. 
Low Density Lipoprotein Subfractions 
The LDL-subfractions were analysed at the University of Surrey, by Iodixanol Gradient 
Ultracentrifugation. The method has been explained in full by Davies et a!.. (2003). The 
present investigation deviated slightly from the method that is described by Davies as a 16 
place rota was used instead of an eight place rota; however Rf calculations were adjusted 
accordingly. The samples were centrifuged for 2 hours 30 minutes at 65,OOOrpm at 16°C, 
using the acceleration and deceleration programme 5. The LDL peak density. percentage of 
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the large buoyant LDL subclasses I and II and the percentage of the small dense LDL 
subclass ITI were used in the analysis. Depending upon the percentage of each LDL subclass 
patients were defined as lipoprotein phenotype A, B or I. Patients were A if LDL III <4Olk. 
B ifLDL ill >SO% and I (or intermediate) ifLDL ill was between 4O-S0%. 
The subgroup of patients who had LDL-subfractions measured, did so at the start and end of 
the investigation. Within group comparisons were made between the start and end peak 
density, change in subclass percentage and any change in phenotype. Between group 
comparisons were made depending upon the intervention type (control or intervention group). 
The coefficient of variation for the analysis of LDL-subfractions were <S%. 
ii Non-esterified fatty acids (NEFA) 
NEFA was also analysed by standard automated spectrophotometric methods using reagent 
kits from Wako Chemicals GmbH, Neuss, Germany and following equations: 
NEFA + ATP + eoA - SH Acyl-COA-Synthelase) Acyl-eoA + AMP + PPi 
Acyl - eoA + 02 + Acyl-CoA-oxidase) 2,3 - trans - Enoyl- eoA + H 202 
H 202 + 4 - Aminophenazone + MEHA Peroxiase) Quinoneimine + 4H 20 
CV =2.0% 
3.4.10 Assessment of metabolic syndrome status 
All patients were assessed for metabolic syndrome using the most recent definition from The 
International Diabetes Federation worldwide definition of the metabolic syndrome 
(International Diabetes Federation, 200S). This states that for a person to be defined as 
having the metabolic syndrome they must have: 
• Central obesity - as defined for specific ethnic groups 
Plus any two of the following four factors 
• Raised triacylglycerides: > 1.7mm01l1 or on specific treatment for this lipid 
abnormality 
• 
Reduced HDL cholesterol: < 1.03 for males and < 1.29 for females or on specific 
treatment for this lipid abnormality 
7." 
• Raised blood pressure: systolic > 130 or diastolic > 85 mm/Hg or treated 
hypertension 
• Raised fasting plasma glucose: ~ 5.6mmolll or previously diagnosed T2DM . 
Following the criteria, patients who had central obesity determined by the waist 
circumference and ethnicity, were selected. As all patients had T2DM, the presence of one 
other factor allowed them to be defined as having metabolic syndrome. Numbers with 
evidence of the metabolic syndrome were assessed at the start and end of the study. 
3.4.11 Study procedure 
Once the general baseline measurements had been taken, then patient was informed of their 
randomised treatment group which was either the control or intervention group. The 
following describes what happened in each of these groups. 
3.4.11.1 Control group 
Patients assigned to the control group continued with standard care, and followed procedures 
that all patients would receive at the hospital regardless of participation in the present study. 
Therefore the diet and lifestyle advice received by those in the intervention group could be 
compared with actual clinical practice. 
'Standard clinical practice' 
Standard practice varies from one hospital to the next and also evolves with time. At the time 
of the present investigation the following describes what could be expected by a patient with 
T2DM as they started insulin therapy. All patients requiring insulin therapy were usually 
seen by the hospital endocrinology team as their diabetes was not optimally controlled. 
General Practitioners (GP) start very few patients on insulin therapy. Within the hospital, 
most patients were seen in an annual outpatients clinic and more frequently if there are 
particular medical problems. A multidisciplinary team was available at the outpatient 
appointments, including physicians, diabetes specialist nurses, dietitians, podiatrists and 
psychologists. At the annual appointment the patient was always seen by a physician and 
usually by a diabetes specialist nurse. A patient would be seen by a dietitian in three 
circumstances; if they were referred to one, if they requested to see one or if the dietitian felt 
that the patient would benefit from dietetic advice. Not all patients therefore receive dietetic 
advice every year, but the dietetic protocols state that each patient should see a dietitian at 
least once every 2 years or when there is a change in treatment, such as starting insulin 
therapy. Therefore. although the patients in the present investigation should have seen a 
dietitian through virtue of their change in treatment. this was not a certainty. Once the patient 
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completed the study they were asked if they had seen a dietitian in the past year and this 
information was recorded. At the end of the 6 months, medical records were examined to 
ascertain the extent and nature of 'standard care' including visits to a dietitian. 
ii 'Standard dietetic practice' 
If the patient was seen by a dietitian within the past year the appointment would follow the 
format of a general dietetic outpatients appointment. A general dietetic appointment for 
diabetes lasted between 20 and 30 minutes, occasionally longer if there are many issues that 
had to be discussed. At the appointment the dietitian would have taken a diet history by 
patient recall, then discussed the key areas of diet in diabetes, focusing upon specific areas for 
that patient with reference to the diet history. The information given by the dietitian 
conformed to the recommendations made by Diabetes UK, used evidence-based practice and 
always individualised the advice to the patient. Written information was usually provided, 
with the key dietary targets for that patient also noted. Any questions that the patient had 
were answered. Generally no follow up appointment would be arranged. 
3.4.11.2 Intervention group 
The patients that were randomly assigned to the intervention group had considerably more 
intensive dietetic input than those in the control group. The intervention for this study 
followed that of the "Lifestyle Clinic", which was originally developed as a weight 
management clinic (Frost et aI., 2002) and based upon the interventions used in the Diabetes 
Prevention Programme (DPP) (DPP Research Group 2002). This was an intensive dietetic 
clinic, which focused upon all aspects of diet and lifestyle, which are known to influence 
weight. The lifestyle clinic used a more holistic approach, aiming to improve overall health 
through motivational interviewing, initiation of patient empowerment and providing support 
and advice, with the overall aim of achieving a 500kcal per day energy reduction. A more 
comprehensive description of the lifestyle clinic is described as follows. 
Lifestyle clinic procedure 
The lifestyle program consisted of six outpatient appointments over a six month period. The 
duration of the appointments was flexible depending upon patient requirements. but was 
approximately 90 minutes for the first appointment and 30 minutes thereafter. The patients 
were seen monthly with a slightly longer period between the fifth and final appointments. 
The lifestyle clinic was a dietetic led clinic which. for the purpose of the present study. the 
dietitian was the author and sawall the subjects recruited into this study. Table 3-4 
summarises the main targets at each appointment and a copy of the booklets given to the 
patients at each appointment is provided on the CD in the back cover of this thesis. 
75 
Table 3-4 Summary of topics and details of each topic covered in the Li festyle 
Clinic 
\ t 
1 
2 
3 
5 
A es food intake 
Increase physical 
activity 
Per onali ed energy 
prescription 
Emotional eating 
Oi cussion on fat 
Food labels 
Carbohydrates 
Purcha ing food 
hain of event 
Hunger scale 
Review of previou 
topic 
Reyiew of achievement 
and re 'ult 
teach app i nun nt. targ ts 
, limits 
(GI) 
nt 
and 
rt. 
I' mad f r th pati nt n an indi\iduall ed ba-.i and \\en: 
do umcnt d. hi \11 nt f th s targets \'Ver ub. quell! app Int!l1 nl. 'II 
K and e\ iden e-ba ed practn:e \\ <1 rcc )mmcndati ns Ill' rm to th made b iabete 
central to [he riginal dc-.iell f b k.1 ls u ed. The dinl aim" to Illtlk.e pcrrnant:1l1 hanet: to 
the ea t in~ and lilest 'Ie patterns f the patient to\\ard" the IdcJI. 
ii Principles of motivational interviewing 
Alongside the information giving as detailed in Table 3-4, the Lifestyle clinic has evolved to 
encompass a style of consultation know as motivational interviewing. Motivational 
interviewing has been defined as 'A directive, patient-centred counselling style for increasing 
intrinsic motivation by helping patients explore and resolve ambivalence' (Miller W.R .. 
2(02), which means that the focus is on the patients concerns and perspectives and not those 
of the health care professional. Motivational interviewing works by building intrinsic 
motivation and tackling ambivalence through exploring the decisional balance between the 
pros and cons of status quo and of change. Crucially motivational interviewing involves not 
telling the patients what to do, but rather encourages them to generate their own solutions. 
This differs from standard dietetic care which tends to be more didactic and driven by setting 
specific goals. 
3.4.12 Endpoint data 
Six months after the baseline measurements were made, regardless of randomised group. the 
patients had the baseline measurements repeated (endpoint). 
3.4.13 Statistics 
All data were tested for normality using Kolmogorov-Smirnov statistic. Parametric tests were 
used for the data found to be normally distributed. Intra-group analysis was conducted using 
paired T-tests, analysing the difference from the start and end measurements. Paired T-tests 
were carried out on all the patients collectively and the control and intervention groups 
separately. Independent T-tests were used for inter-group analysis, comparing the start and 
end measurements, in addition to the absolute change and percentage change in each 
parameter. For the independent T -tests the randomised groups were the independent variable 
to which all other parameters were compared (unless otherwise stated). For comparisons of 
more than two groups ANDV A was performed. 
Pearson Chi-squared tests were used to explore the relationships between categorical data. 
such as the randomised group compared to the direction in which blood pressure changed. 
Finally, correlation analysis was used to discover the direction and the strength of 
relationships between two variables. for continuous data Pearson correlation was used and for 
categorical data Spearmans Rank correlation was used. 
Two sets of analysis were performed. the first set was on the basis of a completers analysis in 
those subjects who provided data at all times points. A further analysis was carried out using 
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an intention-to-treat (ITT) basis to allow for the variation caused by drop-outs. Baseline 
weight carried forward were used where values were missing in the ITT analysis. 
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3.5 Results 
3.5.1 Baseline characteristics 
Baseline characteristics were a~~e~~ed and no differences in any criteria were found between 
the groups (Table 3-5). There were no centre differences in baseline characteristics '>0 all data 
were analysed together. 
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Table 3-5 The baseline characteristics of all patients and of the individual groups 
All patients Control group 
Comparison between 
Characteristic Intervention group (n=25) control and intervention (n=50) (n=25) Chi squared 
Sex (n) Male 26 13 13 NS 
Female 24 12 12 NS 
White 31 15 16 NS 
Ethnicity (n) Black 13 6 7 NS 
Asian 6 4 2 NS 
Hammersmith 20 11 9 NS 
Centre (n) Charing Cross 15 8 7 NS 
Royal Surrey 15 6 9 NS 
n Mean SD n Mean SD n Mean SD T-Test (p) 
Age (years) 50 55.8 11.3 25 56.6 11.2 25 55.1 11.6 0.66 
Duration of T2DM (months) 50 95.3 59.1 25 93.8 54.5 25 96.8 64.4 0.86 
Time since insulin initiated (weeks) 50 2.5 1.1 25 2.6 1.1 25 2.3 1.1 0.31 
Total initial insulin units 50 31.4 9.0 25 33.3 7.8 25 29.5 9.8 0.13 
Height (m) 50 1.68 0.1 25 1.67 0.1 25 1.69 0.1 0.53 
Weight (Kg) 50 93.4 16.4 25 90.2 16.9 25 96.6 15.6 0.18 
HMI (kglm2) 50 32.9 4.8 25 32.1 4.3 25 33.8 5.3 0.22 
Waist (cm) 50 111.3 12.0 25 109.7 11.0 25 112.8 13.0 0.38 
Hody fat (c.:f) 47 36.4 8.8 25 35.4 7.4 22 37.5 10.2 0.26 
Systolic HP (mmlHg) 50 143.0 23.5 25 143.9 27.1 25 142.2 19.9 0.80 
Diastolic BP (mmlHg) 50 80.2 11.5 25 79.5 14.1 25 80.9 8.4 0.67 
HbAlc (cit) 43 9.7 1.4 23 9.7 1.2 20 9.6 1.7 0.98 
Glucose (mmolfl) 44 11.4 3.2 24 11.8 3.0 20 11.0 3.4 0.88 
Total cholestcrol (mmolll) 45 4.4 1.0 25 4.6 1.0 20 4.1 0.8 0.06 
HDL-cholcstcrol (mmolfl) 45 1.2 0.3 25 1.2 0.3 20 1.1 0.3 0.13 
LDL-cholcstcrol (mmolll) 43 2.5 0.8 24 2.6 0.8 19 2.3 0.8 0.10 
Ratio total:LDL Chol 44 3.8 1.0 24 3.8 1.0 20 3.7 1.1 0.66 
Triacylglyccridcs (mmolll) 44 1.8 1.0 24 1.8 0.9 20 1.9 1.1 0.91 
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All patients undertook baseline measurements within 4 weeks of commencing insulin therapy; 
the mean duration of insulin treatment was 2.6 weeks for the control group and 2.3 \\eeb for 
the intervention group (NS). 
3.5.2 Inter and intra group analysis of Weight change 
The primary outcome measure was change in body weight following the initiation of imulin 
therapy and dependent upon the randomised groups. 
3.5.2.1 Differences in weight and anthropometric changes between the groups 
Table 3-6 shows the change in absolute and percentage weight and anthropometric data for all 
patients that completed the investigation with results of independent T -Test comparisons 
between the two groups. Table 4-7 are the results of the same parameters. but is an intention 
to treat (ITT) analysis. Very few patients dropped out of the investigation (I patient in the 
intervention group and 2 in the control group) therefore the result ... from the completer:-. and 
the ITT analyses are virtually indistinguishable. For this reason all future analysi ... i ... reported 
on completers only basis. 
Table 3-6 Com pieters mean (SO) weight and anthropometric changes from 
baseline to 6 months 
951,; 
Independent T-Control group Intervention group confiderKl' Tl'\t interval 
Mean Mean Lower Upper T p 
change (SO) N change (SO) n CI CI 
Ahslliutc \\cight 
4.90.6) 25 -0.6(5.1) 25 3.0 8.1 -l.-l <0.001 (kg) 
Pl'l"Cclltagc \\l'ig hI 5.6 (-l,-l) 2-l -0.5 (-l.9) 2-l 3.3 8.6 -l.5 <0.001 (1/; ) 
BMI (kg/rn2) 1.7 (1.3) 25 -0.3 (2.0) 25 1.1 3.0 -l.3 <0.001 
HMI (I.;) 5.6 (-l,-l) 25 -0.5 (5.3) 25 3.3 8.9 -l.-l <0.001 
\\'ai\t circumfercllcc 5.3 C).O) 25 -O,-l (5.2) 25 2.8 8.6 .~.9 <0.001 (cm) 
\\'ai:-.t circul11krL'llCL' 
-l.9 (-+.6) 25 -0.1 (-l.6) (I; ) 25 2.-l 7.6 3.8 <0.00 I 
Hody fat (Ii; ) 1.5 (2.0) 25 -O,-l (2.X) " 0.5 3 .. ~ 2.7 =0.010 
Blld~ fat (Ii; chall~L') -+.8 (6,-l) '5 -0.1 (7.3) " 0.7 8.7 2.3 =0()2-l 
SI 
Table 3-7 Intention to treat mean (SO) weight and anthropometric changes 
from baseline to 6 months with baseline weights carried forward 
95lk 
Independent T-Control group Intervention group confidence 
interval Test 
Mean N Mean chan~e (SO) chan~e (SO) n Lower Upper T P 
Absolute weight 4.6 (3.7) 27 -0.6 (5.0) 26 2.7 (kg) 7.6 4.3 <0.001 
Percentage weight 5.1 (4.5) 27 -0.5 (4.8) 26 3.0 
«(Ir) 8.1 4.4 <0.001 
HMI (kg/m2) 1.6 (1.3) 27 -0.3 (1.9 ) 26 1.0 2.8 4.2 <0.001 
HMI (%) 5.1 (4.5) 27 -0.5 (5.3) 26 3.0 8.3 4 .. ~ <0.001 
Wai-,t circumference 4.9 (5.0) 27 -0.4 (5.0) 26 2.5 (cm) 8.0 3.8 <0.001 
Waist circumference 4.5 (4.6) 27 -0.1 (4.6) 26 2.1 7.2 
«(Ir ) 3.7 <0.001 
Hody fat (%) 1.4 (2.0) 27 -0.-+ (2.8) 2J 0.-+ 0.7 2.7 =0.011 
Hod~ fat (% chan~c) 4.5 (6.3) 27 -0.1 (7.1) 23 0.5 1.9 2.3 =0.027 
Table 3-6 (and Table 4-7 for the ITT) shows the absolute change and the percentage changc 
for all anthropometric data and compares the results of the two groups. Patients in the control 
group gained more than 5% body weight, whereas those in the intervention group managed to 
lose a small amount (0.5%). The difference between the groups equated to nearly 6'; . which 
was highly significant (p<O.OO I). The control group had a corresponding increase in BML 
waist circumference and body fat of approximately 57,. whilst the intervention group had 
minor decreases in each of these. The differences between the groups were highly significant 
throughout. These findings substantiate the first hypothesis which suggested that an intensive 
wcight management programme, as experienced by those in the intervention group. would 
prevent the iatrogenic weight gain caused by insulin therapy more than that which can be 
achicved through standard care. The findings superseded the expected 2kg difference 
het\\een the groups. which was the amount on which the original sample size was based. 
3.5.2.2 Weight change from baseline to 6 months 
Initially \\eight changc o\er the 6 month study period for both groups was analysed for each 
group (hgure 3-31. The control group had a highly significant increa:-.c in bod: weight owr 
the si\ month period. \\/1l'rea-, the interwntion gwup lost a small amount of \\ eight (l"S J. 
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Figure 3-3 Baseline and 6 month weight for the control and intervention group 
with error bars indicated standard error of the mean (SEM). ***p<O.001 from 
baseline to endpoint. 
3.5.2.3 Anthropometric changes from baseline to 6 months 
The control group had a highly significant increa e in wai t circumference in the 'ix month 
after insulin therapy wa started, while the intervention group had no change (Figure 3-4). 
Th increa e in wai t circumference i indicative of an increa e in central adipo ity. an effect 
of in ulin therapy, but prevented by intensive dietetic intervention . 
100 
Control and Intervention groups baseline and endpoint 
Figure 3-4 Baseline and 6 month waist circumference for the control and 
intervention group with error bars indicated standard error of the mean (SEM). 
***p<O.001 from baseline to endpoint. 
A with the increa e in body weight and wai t circumference in the control group, th r wa 
al 0 a highly significant increa e in BMI and percentage body fat for thi group, and imilarly 
a light decrea e in each parameter for tho e in the intervention group (Figure 3-5) 
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Figure 3-5 Baseline and 6 month BMI and percentage body fat for the control 
and intervention group with error bars indicated standard error of the mean 
(SEM). ***p<O.001 from baseline to endpoint. 
The intra-group analy is of the weight and anthropometric data pro ed the fir t hypothe i 
which tated that those in the control group would experience a tati tically ignificant 
increa in body weight, which would not be experienced by tho e in th inter ention group. 
The next ection hows the re ults of inter-group analy i , inve tigating in greater depth th 
hang s that occurred in econdary outcome mea ure in both group. 
The weight and anthropometric data clearly demon trated that the inter ention. which wa a 
di tetic led inten i e weight management programme, wa far uperior to tandard are in th 
pr venti n f weight gain followina the initiation f in ulin th rapy. Th impa t r the 
dir~ r nee in eight gain with resp ct (0 ardio a cular ri 'k marker and al ulated ri"k. r 
cardi \c'1~ ular e ent~ \,: ill b in ligat d thr ugh ut th n t f \\ ti n . 
3.5.3 Change in glycaemic control from baseline to 6 months 
I hc primar aim of in~ulin th rapy is t n )rmal, ... e glycaemi contI' I. a l11l:a urcti b) lib \ Ie 
anti ra ... ting glu mc. t the '>tart or the "tudy the c ntr I and ,nten cnllon group" h<ld I Ih/\ I . 
approaching 10% (9.7% and 9.6% re pectively). Both group experienced ignificanr 
improvements in HbAl c, decreasing to 8.5% and 8.7% respectively (Figure 3-6), pro ing the 
second hypothe is. There was no ignificant difference in the initial and final HbAlc 
between the group . 
It i worth noting that when a person is treated with oral hypoglycaemic agent. in ulin 
treatment is considered when the HbAlc is poorly controlled and exceed 8%. Rea onabl 
glycaemic control is considered to be when the HbAl c is below 7% (UKPDS Stud Group 
J998a). However after 6 months of treatment with insulin, the HbAlc remain higher than 
the level which i considered good control but more worryingly it remain higher than the 8% 
level in both the control and intervention group . 
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Figure 3-6 Mean HbA 1 c and fasting glucose at baseline and endpoint (baseline 
+ six months), with error bars indicated standard error of the mean (SEM), 
**p<O.01, *p<O.05. 
I · a~ting olu O~ al~ impr \cd in both gr u ) . Th .., in th ntr 1 gr up h'ld a hi gher 
initial fa~tino gluc ~e and e\p ri need larg r reducti n in thi.., thr uglnut th tuJy ( Figur~ 
J -6). The \: ide variati n r data in fa ling gill ~l'. I lcntiall) e\pl <lIn" the 1<1 k l)C 
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3.5.4 Comparisons of key outcomes between the groups 
Changes in glycaemic control, blood pressure and lipids were secondary outcome measures to 
changes in weight and anthropometric markers. Table 3-8 shows the absolute change in each 
of these parameters for the control and intervention groups and comparisons of change 
between the groups. There was no significant difference in any of the changes in secondary 
outcome measures between the control and intervention groups. 
Table 3-8 Changes in key outcomes from baseline to 6 months for completers 
Intervention 95% Independent Control group confidence group interval T-Test 
Mean Mean N Lower Upper T (SD) n (SD) p 
HbA1c (%) -1.2 (1.8) 23 -0.9 (2.0) 20 -0.9 1.5 0.52 0.604 
Fasting glucose (mmo1l1) -1.8 (4.2) 24 -0.4 (5.6) 20 -1.6 4.4 0.94 0.354 
Systolic blood pressure 3.8 (14.7) 25 -1.9 (14.0) 25 -13.9 2.5 -1.4 0.166 (mmlHg) 
Diastolic blood pressure 0.5 (8.5) 25 -2.0 (8.5) 25 -7.4 2.3 -1.2 0.303 (mmlHg) 
Total cholesterol (mmoll1) -0.05 (1.0) 25 0.2 (1.0) 20 -0.4 0.8 0.74 0.466 
HDL cholesterol (mmolll) - 0.07 (0.2) 25 -0.02 (0.2) 20 -0.1 0.2 0.95 0.348 
LDL cholesterol (mmolll) -0.1 (0.8) 24 0.1 (0.6) 20 -0.3 0.6 0.85 0.401 
Ratio T -Chol : HDL-chol 0.2 (0.8) 24 0.1 (0.9) 20 -0.6 0.5 -0.22 0.831 
Triac~lg1~cerides (mmolll) 0.1 (0.9) 24 0.1 (1.0) 20 -0.5 0.6 0.20 0.842 
3.5.5 Change in blood pressure from baseline to 6 months 
Although there were only small changes in blood pressure throughout the six month study, an 
important factor is the direction in which the blood pressure changed in the control and 
intervention groups. The control group had a mean increase in both systolic and diastolic 
blood pressure of 3.8mmlHg and O.5mmglHg (NS), whereas the intervention group had a 
mean decrease in both readings of 1.9mmlHg and 2.0mmlHg (NS) respectively. The were no 
significant differences in the changes in blood pressure between the two groups, however 
over the six month study period those in the control group were statistically more likely to 
have an increase in blood pressure and those in the intervention group statistically more likely 
to have a decrease in blood pressure (Chi squared=3.92, p<O.05). 
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Figure 3-7 Mean Systolic and Diastolic blood pressure at baseline and endpoint 
(baseline + six months), with error bars indicated standard error of the mean 
(SEM) 
The change in blood pressure, although not tatistically ignificant, i clinically ignificant. 
The National Institute of Clinical Excellence (NICE) in 2002 CHutchin on A., 2002) pro ided 
guideline on blood pre ure control in people with T2DM. The recommendation made by 
NI was that blood pressure hould be kept below 140/80mm/Hg a thi wa aociated 
with th lowe t ri k of diabetic complication. At the tart of the tudy both the control and 
inter ntion group exceeded the target set for y tolic blood pre ure, they were 143.9mmlHg 
and 142.1 mm/Hg re pectively. By the end of the tudy period the control group had an 
increa e in t Ii blood pre ure, diverging further from thi clinical! ignifi ant targ t. 
n the ther hand however the inter ention group had a decrea e in blood pre ure and b lhe 
end of th ~tudy managed to meet the NI E guid tine. 
3.5.6 Change in blood lipids from baseline to 6 months 
There \V re ont minor chang in bl ad lipid" through ul the "tud} pen d. he lipid pr file 
tended to \\ or!\en fr m the initial readin", t the cndpoint in b th gr up bUl n t ignili ~nll) : 
\\ itli the nl fa\' urable hange occurring in the t tal h )k"tcr)1 and I 01 -ell lie len)1 in tht: 
control group. There were no tatistical di fference in any of the lipids bet\! een the group 
either at the tart or at the end of the study. 
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Figure 3-8 Mean lipids at baseline and endpoint (baseline + six months), with 
error bars indicated standard error of the mean (SEM) 
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Figure 3-9 Mean HDL-cholesterol at baseline and endpoint (baseline + six 
months), with error bars indicated standard error of the mean (SEM) 
3.5.7 Cardiovascular risk score 
The ri k of coronary heart di ea e (CHD) and fatal coronary e ent and the ri k of a cerebral 
vascular accident (CY A) and fatal cerebral va cular event were calculated for each per on at 
the tart and end of the study period and the mean result u ed in the analy i (Figure 3-10). 
Unfortunately there was an increase in all core in both group in the ix month follo\\ing 
in ulin therapy, except for a very light dec rea e in r1 k of a fatal CHD event in the 
intervention group. The changes that occurred over the ix month and the differen e 
between the gro up were not significant. 
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Figure 3-10 Mean calculated coronary heart disease (CHD) risk and cerebral 
vascular accident (CVA) risk at baseline and endpoint (baseline + six months), 
with error bars indicated standard error of the mean (SEM) 
greater pI' P rti n of pati nt in th int r ention group had a decr a In ardi \ a ular 
ri..,k ~' re~ thr ugh ut the ~tud . The per ntag of pati nt that h d de r a .., in I Ink 
In the c ntr I and int nenti n or up~ w re 56.10c and 61.1 C;f. de rae In fatal H n k 
60.9 c(1 and 66.7C''r . d I' al.,e in V ril.,k ~ 1.7(:' and __ .2C'1c and deer a e in fatal \ \ n k 
'I. I d ') ') ') t' I hi' . qU:lred anal' i.., n the dire ti n r chan,!! III n k \\~re _~I . I an .1.1 .. 1 c re~pe IVC . • -
not ..,ignilicant. 
A person is considered at high ri~k of CHD if their risk score exceeds 157c (Guzder et aI., 
2005). At the ~tart of the study. 12 patients in the control group and 9 patient~ in the 
intervention group exceeded 15o/c CHD risk. By the end of the study there were t\\'o people 
less in each group that were considered to have a high CHD risk. 
3.5.8 Quality of life 
The individual levels of the ED-5D were analysed separately. then collaboratively as a profile 
with the corresponding health state score; the percentage self-rated score was also a,>sessed. 
Figure 3-1 I shows that the intervention group tended to have fewer problems (higher 
frequency at lower scores) with each variable at the start of the study. which were largely 
maintained throughout the investigation, with the exception of usual activities. During the 6 
months the control group had no changes in mobility, a slight improvement in usual activitil''> 
and a worsening of self-care, moderate to severe pain and anxiety and depression. The 
intervention group experienced a slight shift towards higher scores throughout the 
investigation in each variable. 
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Figure 3-11 Frequency of answers for each dimension on the E~-50 quality of 
life questionnaire at the start and end of the study for the control and 
intervention groups 
There were no difference between the tart and change in tari ff between the group . but there 
wa a signifi cant difference between the end tariff . with the int r ention group having a 
high r tariff than the contro l group, 0.79S v . 0.S84 re pecti ely (T=2 .S, CI -0.38 to -0.04, 
p=O.O 16). Th m an O-SO tariff emu lated the hift in the indi idual variable and wor ened 
o r th duration of the tudy. The control group had a ignificant decrea e in ED-SO tariff 
from c tart to end (T=2.2, I 0.0 I to 0.22, p=0.037). likely to be attributable to the wing in 
the dire tion of e tr me pain and e treme an iety and depre ion dimen ion. There wa. a 
non-significant decrea in th intervention group' tariff. 
Table 3-9 Changes in quality of life from baseline to 6 months for completers 
EO-50 Tariff 
P rcentage 
health rating ( (') -OA8 7 12 1,'. 12 14- () 1-
The self-rated perceived percentage health rating shows that the control group had a decrease 
of 0.5%, when the intervention group had an increase of 7.1 %, suggesting that the patients in 
the control group thought that their health deteriorated over the six months, whereas those in 
the intervention group had a perceived improvement. The differences, either between or 
within the groups with respect to the start, end and change in values was not significant. 
3.5.9 Metabolic Syndrome status 
As T20M for some is considered an extreme form of metabolic syndrome it is not surprising 
that the numbers of patients who could be classified as having metabolic syndrome were high. 
At the start of the study, 24 of 25 patients in the control group and 23 of 25 patients in the 
intervention group could be classified as having metabolic syndrome, by the end of the study 
period all completing patients in both groups could be classified as having metabolic 
syndrome. 
3.5.10 Medication 
Patients in the control and intervention groups started the study on 33.3 (SO 7.8) units and 
29.5 (SO 9.8) units of insulin respectively. Throughout the course of the study both groups 
had a significant increase in the number of insulin units taken. The control group had an 
increase of 25.2 units to 58.5 (SO 45.5) units (p=0.OO6), whilst the intervention group had an 
increase of 14.6 units to 44.1 (SO 18.6) units (p<O.OO I). Therefore the control group had an 
increase in insulin more than 10 units greater than the increase in units of the intervention 
group, which meant that by the end of the study the control group took 14 units a day more 
than the intervention group (p=0.13). 
At the start and end of the study period patients were asked what medications they were 
regularly prescribed. These were noted and any changes in diabetic, blood pressure or lipid 
medications that occurred in the six month duration of the study are documented in Table 
3-10. 
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Table 3-10 Medication changes occurring throughout the duration ot the study 
for patients in the control and intervention groups 
Drug Class 
Glycaemic contol 
Blood pressure 
Angiotensin Converting 
Enzyme inhibitors (ACE 
inhibitors) 
Calcium channel 
blockers 
Diuretics 
Lipids 
Statins 
Other 
Total 
Medications stopped 
Dose increases 
New medications 
Medication 
Metformin 
Ramipril 
Peripril 
Linsinopril 
Amilodopine 
Furosemide 
Simvastatin 
Atorvastatin 
Aspirin 
htimated net cost (f/month) 
Including additional insulin (£/month) 
Control group 
Stopped Additions 
1 
2 
Increased x 1 
Increased x 1 
Additions x -+ 
148.00 
185.00 
1 
2 
13 
Intenention group 
Stopped Additions 
60.00 
60.00 
2 
The control group had many more additions to regular medication than the intervention 
group. Eight of 25 patients (32('1<) in the control group had one or more new medications in 
the six months of the study compared to 3 of 25 patients ( 120'() in the intervention group. The 
additional medical consultation costs required for the prescription of new medications are not 
included in this model; if they \vere included the difference in estimated cost would be much 
higher than those stated. 
3.5.10.1 Subgroup analysis 
:\ small subsection of patients (n= I O. control=5. interwntion=5) had additional blood 
sampks taken which \\ere analysed in greater depth to the general cohort. This analvsis 
im'ohL'd il1\l'stigation of LDL-subfractions and non-esterified fam acids. ~ . 
LDL subtractions 
:\nalysis of I J)L sllbfractions pn1\ides greater information on the .... ubtle change .... that OI.XlIr to 
lipid protiles following changes in or differencl' .... between treatmenh, There were no 
significant changes in the percentages of LDL i and ii, LDL iii or the peak density in any of 
the groups, nor were there any significant differences in the start, end or change in each 
variable between the groups. However the trend in data shows that the intervention group had 
larger increases in the large buoyant LDL i and ii subfractions, (and sequentially larger 
decreases in the small dense LDL iii subfractions) than those in the control group. This meant 
that throughout the course of the investigation the intervention group tended to have a greater 
average improvement in the LDL subfraction profile than the control group. 
Table 3-11 Mean results of LDL-subfractions, peak density and assigned 
phenotype of all patients and for those in the control and intervention groups 
at the first and final appOintments 
Appointment 1 Last appointment 
Group LDL% Peak Phenotype (n) LDL% Peak Phenotype (n) 
i-ii iii Density A I 8 i-ii III Density A 8 glml glml 
All patients (n=lO) 68.3 31.7 1.028 7 2 1 70.4 29.6 1.027 7 I 2 
Control (n=5) 68.5 31.5 1.027 4 0 1 68.8 31.2 1.028 3 I 1 
Intervention (n=5) 68.2 31.8 1.029 3 2 0 72.0 28.0 1.027 4 0 1 
Patients were classified into the different phenotypes A or B, or I (for intermediate), 
depending upon the percentages of the LDL subfractions. In the control group the patient that 
was phenotype B at the start of the study remained so throughout the duration of the study. 
However another patient in the control who was phenotype A at the start of the study, finished 
as phenotype I. In the intervention group there were 2 patients with phenotype I at the start of 
the study and by the end these had changed to phenotype A for one patient and to phenotype 
B for the other. The results of the change in phenotypes involve too small a sample size for 
statistical analysis. 
ii Non-esterified fatty acids 
Non-esterified fatty acids (NEFA), also known as free fatty acids, are known to be high in 
people with insulin resistance. Twelve patients (control=6, intervention=6) had NEFA's 
measured at the start and end of the study period. The initial levels of NEFA for the control 
and intervention groups were similar, 645.0 ± 124.5 vs. 641 ± 19S.lllmolll. The control 
group had a 21.2% decrease in NEFA to 50S.5 ± IS91lmolll (NS, p=O.094) and the 
intervention group had a 29% decrease to 455.0 ± 229.71lmol/l (NS, p=O.225). The large 
standard deviations and small numbers could explain the lack of statistical significance. 
although the decreases experienced in real terms is clinically important. with the intervention 
group experiencing a larger drop in NEFA. 
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3.5.11 Relationships between factors 
Pearsons correlations were calculated to determine potential relationships between a number 
of factors and the changes that occurred throughout the duration of the study, for the whole 
cohort independent of the randomised group (Table 3-12). 
As expected, anthropometric data correlated with each other, meaning that as weight 
increased so did the BMI, waist circumference and percentage body fat. In addition, systolic 
blood pressure and HDL cholesterol correlated with percentage weight change and the final 
percentage body fat. Two factors on the ED-5D questionnaire were significantly correlated 
with weight change. As weight increased, the anxiety and depression score also increased 
and the percentage health rating decreased. This result indicates that with increasing weight 
there is increased anxiety and depression and a worsening of perceived health. 
Table 3-12 Relationships between weight, fat, insulin units and age in all 
subjects 
Factor Correlates with change in .. , n Correlation (r) I! 
BMI 50 0.985 <0.001 
Waist circumference 50 0.799 <0.001 
Weight change Percentage body fat 47 0.651 <0.001 
EO-5D anxiety and depression score 50 0.320 =0.023 
EO-5D percentage health rating 50 -0.296 =0.037 
Percentage weight Systolic blood pressure 40 0.288 =0.043 
change HDL cholesterol 45 0.329 =0.027 
Final percentage body Systolic blood pressure 47 0.329 =0.024 
fat HDL cholesterol 42 -0.499 <0.001 
Weight 50 -0.329 =0.020 EO-50 tariff change BMI 50 -0.355 =0.012 
Weight 50 0.358 =0.011 
ED-50 tariff at 6 months BMI 50 0.388 =0.005 
Waist 50 0.402 =0.004 
Weight 50 0.384 =0.006 
BMI 50 0.359 =0.011 Insulin units at 6 months Waist 50 0.294 =0.038 
Fasting glucose 44 -0.321 =0.033 
Weight 50 0.309 =0.029 
BMI 50 0.302 =0.033 
Waist 50 0.287 =0.043 Age Percentage body fat change 47 0.294 =0.045 
ED-50 pain score 50 0.442 <0.001 
ED-50 eercentage health ralin~ 50 -0.320 =0.023 
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A decrease in the ED-5D tariff over the six months correlated with increasing weight and 
BMI. The final ED-5D tariff correlated with change in waist circumference in addition to 
change in weight and BMI, indicating that as weight increased over the six months quality of 
life decreased. Interestingly the ED-5D tariff did not correlate with any other marker, 
including glycaemic control. 
The number of insulin units taken six months after its initiation significantly correlated with 
change in body weight, BMI and waist circumference, indicating that with increasing insulin 
doses all these other variables also increase. The higher insulin doses correlated with a 
decrease in fasting glucose, suggesting an improvement in glycaemic control, however this 
was not substantiated with an improvement in HbA Ie (r=0.077, p=0.625), which is arguable a 
better marker of glycaemic control. 
Increasing age is another factor to be considered. This analysis found that increasing age 
positively correlated with larger changes in each anthropometric measurement. Age also had 
a positive correlation with pain and a negative correlation with perceived health rating as 
determined by the ED-5D, meaning that as age increased quality of life outcomes worsened. 
3.5.12 Numbers seen by a dietitian 
At the end of the investigation patients were asked if they had been seen by another dietitian 
within the past year and dietetic records were crossed checked for verification. A period of a 
year was chosen, rather than the six month duration of the study to include dietetic 
consultations that may have occurred just prior to the initiation of insulin therapy. Nine of 50 
patients (18%) had been seen by a dietitian, of these 6 were from the control group (24%) and 
3 from the intervention group (12%). The average weight gain for those in the control group 
who saw another dietitian was 5.75kg (6.28%), slightly higher than the average for the group 
as a whole. 
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3.6 Discussion 
This study aimed to investigate the impact of insulin induced iatrogenic weight gain on 
cardiovascular risk and quality of life. The study also aimed to determine whether it was 
possible to prevent the iatrogenic weight gain with increased access to another format of 
dietetic care and compare the outcome of this care to standard care. 
For those in the intervention group, who managed to maintain their starting body weight 
following the initiation of insulin therapy, the changes in the measured variables can be 
attributed to the effects of insulin itself. For those in the control group, who gained weight 
following the initiation of insulin therapy, the difference in outcome between this group and 
the intervention group can be attributed to the iatrogenic weight gain. rather than insulin. 
3.6.1 Weight and anthropometry 
The first hypothesis was that patients with T2DM who start insulin therapy and have access to 
standard dietetic care would gain a significant amount of weight. This hypothesis was proved 
as the weight gain experienced by those in the control group was both clinically and 
statistically significant (4.9kg, 5.6%). Over a longer period of time slightly less weight gain 
(4.2±4.0kg (6%)) was found in similar patients by Dickinson et aI., (2002). A comparison of 
the differences in protocol and the results of these two studies illustrate some of important 
points. In the 5-10 years since the study by Dickinson patients have got heavier, reflecting 
the trends in increasing obesity nationally. Chronic hyperglycaemic, such as that experienced 
by patients with T2DM requiring insulin, causes glucosuria and results in weight loss. The 
baseline weight used in the study by Dickinson was the weight recorded a year prior to the 
initiation of insulin, reducing the influence of glucosuria and therefore suggestive of a cause 
for some of the iatrogenic weight gain. Finally, these and other studies (UKPDS Study Group 
1998a) indicate that most weight gain occurs soon after the initiation of insulin therapy and 
slows with time, suggesting that the first six months to a year after initiating insulin therapy 
is the ideal 'window of opportunity' for intensive lifestyle and diet advice to prevent weight 
gain. 
The 'window of opportunity' was exploited by those patients randomly assigned to the 
intervention group, who followed the Lifestyle clinic programme. The intervention provided 
patients with enough information. advice and support to cause a shift in eating and lifestyle 
habits which prevented weight gain. Other lifestyle interventions which have involved group 
meetings and group exercise sessions appear to be less effective than the one-to-one sessions 
of the Lifestyle clinic (Aas et aI., 2(05). Therefore the Lifestyle clinic package which 
includes motivational interviewing techniques results in superior weight outcomes than can be 
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achieved with standard care and appears to be preferable to other forms of lifestyle 
intervention for this patient group. 
Other anthropometric variables, such as the BMI, waist circumference and estimated total 
body fat all increased in parallel with weight as would be expected. Increases in weight and 
anthropometric measures are problematic, not only because of the detrimental effect on 
T2DM, but also because of the increased risk of obesity related co-morbidities, which have 
been discussed previously (Section 1.3.1). 
Weight gain is an undesirable side effect of insulin therapy, but has been shown to be 
preventable. The following section explores reasons why weight gain occurs after insulin 
therapy is started. 
3.6.1.1 Reasons for weight gain 
A comprehensive explanation for the iatrogenic weight gain following insulin therapy 
remains to be elucidated (Prentice et aI., 2005) however the process is likely to be 
multifactorial. Some of the iatrogenic weight gain can be attributed to the pathogenic process 
of glucosuria in poorly controlled diabetes. A decrease in HbAlc is indirectly proportional to 
change in body weight (Makimattila et aI., 1999). a relationship confirmed by the present 
investigation, although not significantly so (r=-0.174, p=0.264). Patients with the worst 
glycaemic control prior to insulin therapy would experience more glucosuria, and therefore 
more weight loss, than those with better control. The introduction of insulin therapy 
improves glycaemic control, reduces glucosuria and prevents energy lost through this 
mechanism (Yki -1 arvinen, 2001); patients then quickly return to their physiologically 
controlled body weight (Friedman, 2000; Larger et aI., 200 1 a). Regardless of the amount of 
weight lost through glucosuria the strongest predictive marker of weight gain following 
insulin therapy is previous maximum body weight (r=0.99, p<0.00(1) (Larger et aJ., 2001 b). 
Weight gain is common prior to the diagnosis of T2DM, but after it has been diagnosed there 
is a tendency towards weight loss, particularly at times of poor control (Looker et aI., 200 I). 
Therefore, a full assessment of weight history prior to starting insulin therapy would help 
predict weight outcomes and identify patients who may benefit most from a more intensive 
dietetic intervention. 
The action of insulin provides another explanation for weight gain. It is often argued that 
insulin is an anabolic hormone which stimulates lipogenesis (Kersten. 2(01) and the synthesis 
of human muscle protein (Wolfe. 2(00), both weight promoting processes. This study 
confirms previous research that weight gain directly correlates with insulin dose given 
(r=O.38, p=O.OO6 and r=0.62. p<0.02 (Henry et al.. 1993) respectively). However. weight 
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gain can only occur when an individual is in positive energy balance, regardless of insulin 
concentrations. A person with T2DM starting insulin therapy may experience positive energy 
balance for a number of reasons. Firstly the introduction of insulin therapy causes a 
correction of glucosuria which stops the loss of energy through this mechanism. Energy 
intake can also increase because of, snacking between meals to prevent hypoglycaemic 
events, or in response to actual or perceived hypoglycaemia. It is thought that insulin has an 
anorectic influence on appetite in the brain, as with leptin. In obesity there is a 
downregulation of leptin sensitivity due to permanently high circulating concentrations and it 
can be speculated that a similar mechanism applies to insulin. The hyperinsulinaemia that 
occurs in patients with T2DM could cause a downregulation of insulin sensitivity in the brain. 
reducing the anorectic properties of insulin, increasing appetite and food intake which 
promotes positive energy balance and weight gain. This mechanism remains speculative and 
would need further investigation, however it is apparent that patients who are very insulin 
resistant require very large doses of exogenesis insulin to achieve good glycaemic control and 
experience the most weight gain. Increasing insulin doses and increasing weight has the 
potential to enter a self perpetuating negative cycle, with insulin resistance central to the 
mechanism (Yki-Jarvinen et aI., 1997). It is widely accepted that adipose tissue. particularly 
visceral adiposity, releases free fatty acids which causes peripheral insulin resistance and ~­
cell destruction. However it is increasingly recognised that adipose tissue also has endocrine 
properties that can further compound the problem of insulin resistance. Although the full 
mechanisms are unclear, evidence suggests that adipose tissue produces mediators, known as 
adipokines, cytokines or adipocytokines, which modulate insulin signalling (Scheen, 2003; 
Schinner et aI., 2005). As adiposity increases, free fatty acid and cytokine release will also 
increase, worsening insulin resistance, and potentially making weight loss more difficult. 
Changes to diet and lifestyle, in particular increasing physical activity levels, is a solution to 
break this cycle. 
Weight gain can occur through less tangible and more subjective mechanisms. Anecdotal 
opinions of patients and health care workers often point towards changes in appetite and food 
intake following the introduction of insulin therapy, suggestions supported by some scientific 
research. Twenty years ago it was found that hyperinsulinaemia, independent of change in 
glucose, stimulated hunger, craving for sweet foods and increased food intake (Rodin et al.. 
1985), however there has been little research in this area since. with opinions split either side 
of the argument (Heller, 1994; Gielkens et aI., 1998). Hypoglycaemia per se has also been 
associated with increased food intake (Fonseca. 2003; Strachan et al.. 2004). It has also been 
shown that patients eat defensively to avoid hypoglycaemia. overcompensate actual or 
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perceived hypoglycaemic events (Green et al., 2000; Barnett, 2004) and justify increased food 
intake following insulin injections (Yki-Jarvinen et al., 1997). 
If the reasons for weight gain following insulin therapy are fully understood and the 
determinants of weight gain identified, intensive dietetic treatment can be targeted at patients 
who are likely to gain the most weight. In addition a programme such as the Lifestyle clinic 
which provides education, on going support and appropriate counselling can help tackle the 
complex psycho-social reasons for weight gain, whilst reducing insulin resistance and 
improving metabolic status. 
3.6.1.2 Adaptation of the Lifestyle clinic protocol 
The lifestyle clinic has strict criteria for patients to remain within the programme to ensure 
that only the most motivated patients have access to the highly specialised advice and that 
clinic continues to be cost effective (Frost et al., 2(02). If patients do not adhere to the 
requirements of the programme, such as keeping the food diary, attending appointments or 
achieving agreed weight loss targets, the patient is discharged, with the option of attending a 
less intensive dietetic clinic. Recent data obtained directly from the dietitian at Hammersmith 
Hospital NHS Trust where the Lifestyle clinic was developed indicated that nearly two thirds 
of patients are discharged before completing the six month programme. There was no 
discharge protocol for the present investigation as the main aim was to see if increased access 
to dietetic care at the time insulin therapy was initiated would improve outcome, findings 
which would be confounded if patients deemed to be unsuccessful were discharged. In 
addition, the effect of volunteering and being enrolled in a scientific study may help increase 
compliance to the recommendations given and contribute to the outcomes in intervention 
group. If the Lifestyle clinic was implemented specifically for patients who were starting 
insulin therapy screening and monitoring processes may be necessary to ensure optimal 
treatment allocation and cost effectiveness. The implementation of such programmes would 
only require minimal additional training for dietitians such as training in motivational 
interviewing techniques, meaning that initial outlay costs would be small. 
3.6.2 Glycaemic control 
Insulin therapy significantly improved glycaemic control, regardless of the level of dietetic 
intervention. However. the control group required on average 14 units of insulin a day more 
than the intervention group to elicit similar reductions in HbA I c. which although not 
statistically significant. indicates that the Lifestyle clinic has a positive effect on diabetes. 
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A decrease in HbAlc is undoubtedly associated with reductions in microvascular 
complications (DCCT Research Group, 1993; Klein, 1995; Turner et aI., 1996; UKPDS Study 
Group, 1 998a), with any reduction in HbAlc having benefits. The relationship between 
HbA 1 c and macro vascular disease is less defined. The American Diabetes Association has 
stated that "the role of hyperglycaemia in cardiovascular complications is still unclear" 
(Genuth et aI., 2003). A recent meta-analysis of the relationship between glycated 
haemoglobin and cardiovascular disease concluded that "improvements in glycaemia may 
lower the risk for cardiovascular disease" (Selvin et aI., 2004) a finding which is not 
particularly compelling. The lowest risk of cardiovascular disease was associated with 
HbAlc <6%, a level suggestive of normal metabolism and rarely achieved by people with 
T2DM. Glycaemic control is just one part of T2DM and provides an indication of the degree 
of metabolic abnormality, which may produce the links between HbAlc and cardiovascular 
disease; however despite intense research a direct causal relationship has not been found 
(Beckman et aI., 2002). 
Although insulin therapy improved glycaemic control, the HbAlc of both groups remained 
worryingly high (>8%). The reduction in HbA 1 c observed would be sufficient to reduce 
diabetic symptoms, but grossly insufficient in minimising the risk of diabetic co-morbidities. 
It is therefore suggested that when insulin therapy is used, it should be given in a much more 
aggressive manner so that the most benefit can be derived and the negative effects 
outweighed. 
3.6.3 Blood pressure 
Tight blood pressure control is vital for people with T2DM for the reduction in risk of 
microvascular and macrovascular disease (UKPDS Study Group 1998c; Adler et al.. 2000). 
The UKPDS found that tight blood pressure control (-144/82mmHg) was associated with a 
24% reduction in diabetes end points and a 32% reduction in diabetes related deaths (UKPDS 
Study Group 1 998c), but required intensive treatment with numerous antihypertensive 
medications. The national blood pressure guidelines set for people with T2DM is 
140/80mmHg (Hutchinson A., 2002) and it is recommended that pharmacotherapy should 
continue to be added until the blood pressure meets the target. 
The diastolic blood pressure for both groups at the start and end of the study met the national 
guidelines for people with diabetes (Department of Health 200 I). At baseline systolic blood 
pressure exceeded 140mmHg for both the control and intervention groups. The systolic blood 
pressure increased for the control group over the study period, despite the introduction of 8, 
and an increase in dose of 2, antihypertensive agents. The intervention group experienced a 
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reduction in systolic blood pressure, managing to achieve the recommendations by the end of 
the study, with the addition of just 3 antihypertensive agents. 
Therefore, it can be concluded that the iatrogenic weight gain caused by insulin increases 
systolic blood pressure, confirmed by the correlations between percentage weight change and 
final percentage body fat with systolic blood pressure. The changes made to diet and lifestyle 
by those in the intervention group counteracted the increase and actually brought about a 
decrease in blood pressure. Patients with T2DM starting insulin who receive standard dietetic 
care require greater medical management of blood pressure than similar patients who have 
increased access to dietetic advice. 
3.6.4 Lipids 
This study was not sufficiently powered to investigate changes in blood lipids and therefore 
the minor changes that occurred in the lipid profiles were not statistically significant. Both 
the control and intervention groups had a tendency towards a worsening lipid profile during 
the study period. The only favourable change was the reduction in total cholesterol and LDL-
cholesterol for those in the control group; however a subgroup analysis indicated that those in 
the intervention group had a greater improvement in the LDL-subfractions. Unfortunately the 
sample size for the LDL-subfraction analysis was too small to identify trends in LDL 
phenotypes, but would be worth further investigation. 
Non-esterified fatty acids (NEFA) or free-fatty acids are associated with T2DM through 
insulin resistance (Boden and Shulman, 2002). A subgroup analysis revealed that both the 
control and intervention groups experienced improvements in NEFA. with the intervention 
group experiencing greater reductions. The improvement seen in the control group can be 
attributed to the reduced hyperglycaemia, as chronic hyperglycaemia ('glucose toxicity') 
contributes to insulin resistance and high levels of NEF A (Rossetti et aI., 1990). The 
additional reductions in NEFA achieved by the intervention group as compared to the control 
group can be attributed to the difference in weight gain; as obesity, in particular central 
obesity, is correlated with insulin resistance and therefore NEF A (Pascot et aI., 200 I: Karter 
et al.. 2005). Insulin therapy therefore reduces levels of NEFA by improving glycaemic 
control despite causing weight gain, however further reductions of NEF A can be achieved 
during insulin treatment if weight gain is prevented. 
Further investigation in a larger sample is needed to determine the full effect of insulin 
therapy per se and the effect of weight gain following insulin therapy on lipids. particularly 
lipid sub-fractions. The interplay between NEFA. insulin therapy. insulin resi..,tancc and 
change in body weight also warrants further investigation. As gross measures of lipids . ..,uch 
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as total cholesterol and triacylglycerides are strictly controlled with pharmacotherapy in 
T2DM, it is perhaps the analysis of subfractions and the more novel lipid markers that 
provide a better indication of metabolism and treatment success. 
3.6.5 Cardiovascular risk score 
There was no significant benefit of tight glycaemic control on the risk of macrovascular 
disease in the UKPDS (UKPDS Study Group 1998a) and it was suggested that "follow up is 
required to determine the risk-benefit ratio of the glycaemic improvement, side effects. 
changes in body weight, and plasma insulin concentration" (UKPDS Study Group 1995). 
The present investigation aimed to differentiate between the effects of iatrogenic weight gain 
on cardiovascular risk (control group) and the effects of insulin in the absence of weight gain 
(intervention group). It was hypothesised that weight gain would have a detrimental effect on 
calculated cardiovascular disease risk as compared to those who did not gain weight. The 
results indicated that there was a worsening in each score for both groups during the six 
months, but in all comparisons the null hypothesis was accepted because the differences were 
not significant. Despite this the control group experienced greater increase in the risk of 
CHD, fatal CHD and fatal CV A, but not in risk of CV A, indicating that increasing body 
weight does impact negatively upon overall cardiovascular disease risk. The lack of 
significant difference can in part be explained by the strict control of the cardiovascular 
disease risk factors which are used for UKPDS risk engine calculation. It would be expected 
that if a patient's blood pressure, lipids or glycaemic control exceeded the recommended 
target levels, additional pharmacotherapy would be instigated to counteract the rise and 
therefore reduce cardiovascular risk. Indeed, a third of patients in the control group and 12% 
of patients in the intervention group had additional antihypertensive agents or lipid lowering 
medications prescribed throughout the study period and all patients had increases in insulin to 
improve glycaemic control. To fully assess the effects of initiating insulin therapy and the 
associated weight gain no other changes should be made to pharmacotherapy, but this would 
be unethical. 
Insulin therapy may increase cardiovascular disease risk, but close control of the effects 
through additional medication negates this increase. The minimisation of iatrogenic weight 
gain through diet and lifestyle modification has the effect of decreasing the need for the 
additional pharmacotherapy. Contrary to these findings, the UKPDS found a slight decrealie 
in cardiovascular disease risk with intensive diabetic management. Difference in glycaemic 
control could explain the disparity as both the intensive and conventional treatment groups in 
the UKPDS achieved much lower HbAlc's than this study. It is therefore suggested that if 
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insulin therapy is to be used for the treatment of T20M, tight glycaemic control should be 
strived for, otherwise there is the potential of upsetting the risk to benefit ratio. 
3.6.6 Quality of life 
The analysis of quality of life revealed some of the most interesting and unexpected findings 
of the study. The group as a whole had no change in quality of life following the initiation of 
insulin therapy, supporting the findings of other studies (de Grauw et al., 2001; Pitate et al.. 
2(05). The lack of change may be attributed to the balance between the health benefits and 
the added demands associated with insulin. Also the patient may have had time to consider 
starting insulin and had the opportunity to make an informed choice to do so, which may have 
alleviated some anxiety prior to the initiation of insulin. 
The control group experienced a significant decrease in the E~-50 tariff and a slight decrease 
in self rated health, whereas the intervention group experienced no change in tariff and a trend 
for improvement in self rated health; discrepancies attributable to difference in weight gain 
between the two groups. Increasing body weight following insulin therapy correlated with a 
low final E~-50 tariff, a decrease in E~-50 tariff, a decrease in patients' self rated health and 
an increase in anxiety and depression. These findings indicate that insulin therapy per se has 
no effect on quality of life, but iatrogenic weight gain as a result of insulin therapy has a 
distinct negative impact on a range of quality of life factors. This should be an important 
consideration when counselling a patient about starting insulin. 
Although the difference in weight gain between the two groups is considered the primary 
reason for change in quality of life, a confounding factor is the effect of the intervention itself. 
The Lifestyle clinic provides the patient with regular contact with a health care professional, a 
continued programme of education and an opportunity to ask questions and voice concerns. 
The Lifestyle clinic also aims to improve patient empowerment and autonomy over good 
diabetes control. The provision of the Lifestyle clinic may have an additional positive effect 
on quality of life, especially with patient perceived health rating, which is not obtained 
through standard care. In the Lifestyle programme the patient sees the same dietitian 
throughout, providing excellent continuity of care which does not frequently occur with 
standard care. The continuity of care for those in the intervention group could have increased 
patient satisfaction with the treatment received and provides one explanation for the minimal 
drop out rate from the study even though it required quite a lot of time and considerable 
motivation to complete. Therefore the difference in quality of life between the control and 
intervention groups can be attributed to both the outcome (prevention of weight gain) and 
process of the Lifestyle programme. 
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When considering insulin therapy the patients' age i~ considered in terms of treatment aim..,. 
but age needs to also be considered in terms of the effect of insulin therapy on qualit:- of life. 
Increasing age correlated with larger increases in pain and worsening patient percei ved health 
rating in the six months following insulin therapy, signifying that insulin therapy has a greater 
negative impact on the quality of life for older patients. 
Quality of life is often overlooked when insulin therapy is considered. understandably ..,() a .... 
research indicates that insulin therapy has a neutral impact on quality of life. Weight gain a.., 
a result of insulin therapy has a detrimental effect on quality of Ii fe. an outcomc that can be 
counteracted with a supportive, intensive programme of diet and lifestyle advice. 
3.6.6.1 Sample size required to achieve significant differences 
The primary outcome measure for the present investigation \\'a .... the differencc In wcight 
change between the two groups, which was .... ucce ........ fully achic\cd. Sl'c()lldary outcome 
measures were other factors which impact upon cardiova .... cular ri .... ". howcvcr .... tati .... tical 
differences in these factors were not found. The following table (fable 3- U) illu..,tratc.., the 
required sample size needed to achieve a significant difference in each factor u .... ing thc mean 
results and standard deviations found in the present investigation and provides information for 
further studies that was not available at the time that this .... tudy wa .... commenced. 
Table 3-13 Power calculations comparing the means achieved in present 
investigation to establish required sample size of each group to achieve a 
significant difference of p<O.05 between the independent groups (with an 80% 
power) 
Difference in Common Predicted . ,ample Factor Standard size for each 
means deyiation grou~ 
Weight 5.56 -L-l 10 
Waist circumference 5.66 5.1 13 
Percentage body fat 1.91 2.-l1 25 
S~stolic BP 5.7~ l-l.-l 100 
Diastolic BP ~.5~ S.) 179 
HilL-cholesterol 0.O5-l 0.19 I l)() 
Ratio total: HDL cholesterol 0.56 0.86 3716 
CHIl risk 0.1 ~ 7.6 hJSl4 
Fatal CHIl risk 0.31 6.5 6702 
(,VA risk 0.086 2.13 9720 
Insulin dose 10.6 29.S 1~6 
Tahle 3-13 include .... the \ariahle.., \\hac the inlcn ention ~n)up ;\chie\,co Jll(lre L\\ourahk' 
n:.,ulh than the control ~rullp. 
numbers required in each group are achievable in an intervention planned around one 
investigator, as they are less or, in the case of percentage body fat, are equal to the sample 
size of the present investigation. To achieve a significant difference in blood pressure, HDL-
cholesterol and insulin dose one to two-hundred people in each group \\ould be required. The 
numbers needed for composite measures such as total: HDL-cholesterol ratio and the 
estimated risk of CHD and CV A events are considerably higher. However, predicting the 
sample size for composite measures, particularly with regards to the CHD and CV A risks is 
perhaps fallacious as it depends on a number of related variables, therefore the estimated 
sample size as shown above is likely to be a vast overestimation. 
3.6.7 Medications 
The control group had more than three times the number of medications added in the six 
month period than the intervention group. Increased use of pharmacotherapy increases 
regular medical costs and indicates that a patient requires more intensive management of their 
diabetes. The difference in medication changes is a confounding variable, which is not 
possible to control for due to ethical practices. It can be assumed however that the difference 
in cardiovascular disease risk variables, such as lipids and blood pressure, between the control 
and intervention groups would have been larger if the changes to pharmacotherapy had not 
been made. 
3.6.8 Numbers seen by dietitian 
The protocol for a dietetic referral for a patient with T2DM includes when there is a major 
change in treatment, such as when insulin therapy is started. Despite the protocol only 18% 
of the whole cohort was seen by another dietitian. Fewer patients in the intervention group 
were seen by another dietitian than those the control group, potentially because staff knew 
that the patients were receiving dietetic follow-up as part of the study and therefore did not 
refer those in the intervention group as frequently. Only a quarter of patient-. in the control 
group saw a dietitian around the time of starting insulin, which suggests that there has been no 
improvement in dietetic resources within the diabetes framework over the past 5-\ 0 years 
(Dickinson et aI.. ~OO~), despite the National Sef\'ice Framework for diabete" being pUbJi"hed 
in 2001. 
3.6.9 Limitations of the study 
,\ limitation of all "tudies that require participant con"L'nt is "l'lection bia", Patient-, with the 
most ~Onl'l'r11 regarding their weight are more Iikl'l~ to volunteer to t~lke part in a "tud~ where 
there i" a chance of entering a programml' in \\hich :"OC:( will rL'cl'i\'e advice aimed to prewnt 
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weight gain. The effect of selection bias could work in both directiom.: it could include 
patients who are activity trying to lose weight or patients who feel that they are likely to 
experience significant weight gain, such as those with recent weight loss as a result of 
glucosuria. The similar degree of weight gain of those in the control group as compared with 
previous retrospective studies (Dickinson et aI., 2002) indicates that the effect of selection 
bias was minimal. 
Ideally patients should have been recruited into the study in the -+ weeks prior to starting 
insulin; however in practice this did not happen and all patients were seen within -+ weeks 
after starting insulin. There were several reasons for this discrepancy. Insulin therapy 
requires major lifestyle change and patients often delay initiating treatment. therefore there 
was often uncertainty as to when, or if, insulin therapy would be initiated. At the other 
extreme, patients were started on insulin therapy on the same day the hospital consultant 
recommended insulin treatment and therefore no prior warning was given. The effect of 
seeing patients up to four weeks after starting insulin rather than just before are speculative. 
After four weeks of insulin therapy, some weight gain may have already occurred, as well as 
changes to glycaemic control and quality of life, but the assumption has to be made that the 
changes that may have occurred would be similar for both the control and intervention group. 
This study, using completer'S analysis, shows what can be achieved as 'best effect' rather 
than standard clinical practice. The most motivated patients who are likely to adhere to 
recommendations given, seeing the same dietitian over a number of scheduled appointments, 
dealing with concerns as they arise and a low attrition rate provides information that the 
intervention is the 'best effect' that can be achieved. The challenge to clinical practice is to 
implement a similar programme which would aim to produce the same favourable outcomes. 
3.6.10 Further work 
The study has revealed a number of interesting findings, but equally has raised a number of 
questions that would warrant further research. The following provides suggestions of some of 
the potential future research. 
Firstly, as with all short term interventions, to be able to assess true treatment efficacy, long 
term success should be measured. To evaluate long term success patient'> could be followed 
up annually and comparisons made between those who followed the Lifestyle clinic and those 
who did not. 
Further work. should include finding the determinants of \\eight gain following thl' initiatil)n 
of insulin therapy. This would im'olw asking questions regarding prn ious highest body 
weight. recent \\l'ight history and dietary history. This would re\eal ho\\ pre\ious weight 
10:-; 
impacts upon outcome in both the control and intervention groups and would indicate whether 
resources should be targeted at those patients who are likely to gain the most weight. 
Similarly a questionnaire regarding patients' level of motivation to make positive changes to 
diet and lifestyle should be asked, to assess whether patients with the highest motivation have 
the best outcomes. By investigating the determinants of weight gain and their interactions 
with outcome, treatment can be targeted at those patients who will benefit most. 
The integral relationship between change in body weight, insulin therapy and NEFA should 
be investigated in patients who are very insulin resistance. These patients require large 
amounts of exogenous insulin to correct the glucose toxicity, which in turn would cause 
significant weight gain compounding the problem of insulin resistance. Investigations into 
the changes in NEFA as a result of the fluctuation of each of the influential components 
would strengthen the knowledge into the efficacy of treatment strategies. 
Insulin induced iatrogenic weight gain is most rapid soon after treatment is initiated. Further 
work should investigate the use of weight loss pharmacotherapy, such as Sibutramine or 
Orlistat, during this time. Comparisons between the efficacy of pharmacotherapy and 
Lifestyle interventions can then be made, with the hope of developing guidelines to help 
identify which weight gain preventing strategy would be most appropriate for each patient. 
3.7 Conclusion 
Insulin therapy is undoubtedly a necessary treatment for patients with T2DM, particularly as 
~-cells fail and glycaemic control deteriorates. However, it appears that when used, treatment 
with insulin may not be intensive enough to achieve the required targets for optimal 
glycaemic control. If insulin therapy is not used effectively the negative side effects, such as 
weight gain and the effects of weight gain, may outweigh the minor benefits, potentially 
negating its use. The negative side effect of weight gain following insulin therapy is 
preventable through an intensive programme of diet and lifestyle advice and has wider 
benefits in terms of improving quality of life outcomes and reducing pharmacotherapy needs. 
If a dietetic led intensive lifestyle programme is made available for patients with T2DM as 
they start insulin therapy, targeted treatment would be necessary to ensure best use of this 
limited resource and to achieve optimal outcomes. Fortunately dietitians would only require 
minimal extra training to be able to deliver this type of advice; however such programmes are 
resource intensive. Perhaps when the National Service Framework for diabetes is fully 
implemented sufficient resources will be available in the future. 
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4 A pilot study investigating the effects of commencing 
insulin therapy on postprandial lipid handling in adults with 
type 2 diabetes 
4.1 Introduction 
4.1.1 Normal postprandial metabolism 
Postprandial metabolism can be described as the way the body disposes of glucose, lipids and 
amino acids after digestion. A cascade of processes occurs after food is eaten, which are 
largely controlled by the action of insulin. Following a meal, glucose and amino acids are 
absorbed from carbohydrate and protein respectively and taken into the portal circulation; the 
liver then controls the amounts that enter the peripheral circulation. Fat is absorbed as 
chylomicrons into the lymphatic system and then enters the peripheral circulation without 
hepatic control (Bender, 1997). In response to the increased concentration of glucose and 
amino acids in the portal system the ~-cells of the pancreas are stimulated and secrete insulin. 
4.1.1.1 Non-esterified fatty acids 
In the fasted state non esterified fatty acids (NEFA) are released by the adipocytes following 
the release of hormone sensitive lipase (HSl). HSL hydrolyses stored triacylglycerides 
producing glycerol and NEFA. NEFA binds to serum albumin for transport to muscle, liver 
and other tissues where they are used for energy. Insulin inhibits the action of HSL; therefore 
in the postprandial state there is a suppression of NEFA release . 
.t.1.2 Postprandial insulin action 
Insulin is secreted by the ~-cells of the islets of Langerhans of the pancreas in respon"e to 
increased glucose concentrations. Insulin acts through membrane receptors to promote the 
cellular uptake and storage of glucose and metabolic fuels (Gaw. 1999). Without insulin 
glucosl' is unable to enter cells. Following its release, insulin contributes to a number of main 
proCl'SSl''' (adapted from Harvey. 1994): 
• UTects on carbohydrate metabolism 
In the liver. insulin reduces glucose production by inhibiting gluconeogenl'"j" and 
glycogen breakdown. In"ulin increases glycogen "ynthe"j" in lllll"ck and lin~r and 
inl'rell"es glucose uptake in muscle and adipose tis"lle by increa"jng the number of 
glllCl)"e tran"porters in the cell membrane 
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• Effects on lipid metabolism 
Within minutes of insulin secretion there is a reduction in fatty acid release due to 
an inhibition of HSL activity in adipose tissue. Insulin increases the activity of 
lipoprotein lipase which promotes hydrolysis of triacylglycerides in chylomicrons 
and very low density lipoproteins (VLDL), enabling NEFA release and uptake into 
muscle as fuel and adipocytes for triacylglyceride synthesis. This aids clearance of 
circulating lipids i.e. reducing postprandial lipaemia. 
• Effects on protein synthesis 
Insulin stimulates the entry of amino acids into cells, that are then used for protein 
synthesis 
In healthy subjects, insulin is released in parallel with glucose absorption, peaking within one 
hour of food consumption. As glucose concentration is bought back within the normal ranges 
insulin secretion is reduced to pre-prandial levels within approximately -+ hours (Harbis et a1.. 
2004). 
4.1.3 Postprandial metabolism in the presence of Type 2 diabetes 
Insulin is linked with postprandial metabolism as it controls both the hepatic and peripheral 
uptake of glucose and lipids from the blood to the tissues. In the presence of T2DM the 
amount and effectiveness of insulin is compromised and therefore postprandial metabolism is 
disturbed 
Obesity, and in particular, central obesity has been shown to have a negative impact on 
postprandial metabolism, directly attributable to insulin resistance (Mekki et aI., 1999: 
Vansant et aI., 1999; Guerci et aI., 2000; Mamo et al., 2001). Insulin resistance impairs 
postprandial lipid clearance causing an accumulation of chylomicrons and a delay in 
triacylglyceride disposal (Kalant et aI., 2000; Harbis et aI., 200 I). Insulin resistance and 
insulin insufficiency also result in an exaggerated postprandial glucose profile and incomplete 
suppression of NEF A (Frayn, 1998). 
4.1.4 Importance of postprandial metabolism 
Impaircd postprandial metabolism is emerging as an independent ris\-.. factor for C\,D (Roche 
and Gibncy, 2000). A mechanistic route for the relationship between postprandial 
metabolism and atherosckrosis has been suggested by Mero et al.. (199S). \krll et al 
proposcd that the cxtcnded time o\er which triacylglyceride rich lipoproteins remain in the 
circulation postprandially impacts negati\t:ly upon LDI, and HDL metabolism. hy enriching 
thesc partides \\ith triacylglyceridL's and thcrdl\ increasing athcwsderotic ri s\-.. , 
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Additionally, impaired postprandial NEFA suppression, as found in people with insulin 
resistance and T2DM, results in continued exposure to elevated NEF A concentrations which 
has been linked to endothelial dysfunction and CVD (Balletshofer et aI., 200 I: Wheatcroft et 
al.,2(03). 
4.1.5 Aim 
The aim of this study was to investigate changes in postprandial metabolism within the first 
six months of a person with T2DM starting insulin therapy. 
As described in the previous chapter, insulin therapy can be associated with significant weight 
gain. The original aim of this study was to compare changes in postprandial metabolism of 
those who gained weight following the initiation of insulin therapy compared to those who 
were weight stable. However, this aim was unable to be achieved when recruitment to this 
study proved to be extremely problematic. Therefore, due to the small numbers finally 
recruited, it is only possible to describe trends in postprandial metabolism following the 
initiation of insulin therapy. 
4.1.6 Hypothesis 
To date, the changes 10 postprandial metabolism of people with T2DM following the 
initiation of insulin therapy has not been investigated. The disturbances in postprandial 
metabolism that occurs in T2DM are a result of both insulin resistance and insulin 
insufficiency. It is hypothesised that the effect of administrating exogenous insulin depends 
upon the overriding insulin factor; therefore two hypotheses can be made. 
• Patients who are most insulin insufficient will experience an improvement In 
postprandial metabolism once the insufficiency is corrected with insulin therapy. 
• Patients who are highly insulin resistant will experience most weight gain as a result 
of insulin therapy which will compound the disorder and worsen postprandial 
metabolism. 
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4.1.7 Method 
4.1.7.1 Study design 
This was a prospective case only study design which allowed changes in po tprandial gluco e 
and lipid metabolism over time to be investigated. A cohort of patients from a larger tudy 
were recruited and followed for 6 months. Subjects with T2DM were recruited when the 
started insulin therapy (+ 2.5 ± 1.0 weeks) and followed-up as a cohort six month later (mean 
29 ± 4.2 weeks). Investigations were carried out at 2 time points, at the ba eline and after the 
6 month period (endpoint). The study design used a repeated measures test meal procedure to 
allow measurement of changes in postprandial lipids and gluco e before and after in ulin 
therapy. Figure 4-1 summaries the study procedure. 
Patient with T20M started insulin 
therapy and recruited in RCT 
1 
Patient informed of Patient ex 
Patient does additional study ~ not want ___ 
investigating postprandial 
from the 
further tre 
ciuded 
study , 
atment 
ted. metabolism 
! 
Patient wishes to 
participate 
CONSENT FORM 
signed 
J __ 
Patient continues 
with RCT for 6 
months 
10 participate 
Baseline 
postprandial 
measurements 
conducted 
-
Postprandial 
study repeated 
unaHec 
-
t---
~ 
Ser lal blood samples taken at: 
5 minutes before meal 
Every 30 minutes for 2 hours 
Every hour for next 4 hours 
Blood samples analysed for: 
Glucose 
T riacylglycertdes 
NEFA 
• Insulin 
Figure 4-1 Flow diagram of study procedure 
".1.7.2 Sample size 
Initiall the study aimed to compar 2 groups of patient" oth 'v\ ith T2 and htl\ Ing JU t 
started insulin rh rap, but with on gr up foIl wing a programme )f dl t and life t) I' advict: 
d . j" Llb.I·"C l~ PI"O\ d l 1-.. •• ~ ll't:Il1I.'I .)' and the other not. H wever, recruitment an retention \. , l',-
IU 
difficult, therefore, the groups were amalgamated and rather that comparing differences the 
decision was made to examine changes in postprandial metabolism in people with T2DM 
during the first six months of starting insulin therapy. Therefore any patients who agreed to 
participate in this study were recruited and the target number was negated by virtue of 
recruitment difficulties. 
4.1.7.3 Ethics 
Ethical approval was received from the following centres: 
• University of Surrey Advisory Committee on Ethics, Guildford, Surrey 
• Hammersmith, Queen Charlotte's and Chelsea and Acton Hospitals research 
ethics committee, Hammersmith Hospital, London 
• South West Surrey Local Research Ethics Committee, Royal Surrey County 
Hospital, Guildford, Surrey 
Full informed consent was obtained from each subject prior to inclusion into the study. 
4.1.7.4 Recruitment 
Patients were recruited as a subset from the study previously described in chapter 3. The 
inclusion and exclusion criteria are described in section 3.4.5. 
A total of 50 subjects were asked if they would participate in this study, 43 declined to take 
part. Of the 7 subjects recruited, 6 completed the baseline measures but then 2 withdrew from 
the study. This resulted in a total number of 4 subjects completing the study in its entirety. 
The principal reasons for declining to take part were: 
• Patients not wishing to commit to two complete study days 
• Patients unable to take additional time off work 
• Patient not keen to have intravenous cannulae placed 
4.2 Methodology 
Patients were asked to fast for 12 hours over night prior to the day of the study. This was 
requested both verbally and in writing. They were also asked to refrain from strenuous 
exercise in the 24 hours before the study. On the day of the study patients came into the 
investigation unit between 8.00am and 9.00am. An intravenous cannulae was introduced into 
the arm of the patient by an appropriately trained phlebotomist. The study started between 
8.30am and 9.30am. 
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The study started when the fir~t blood sample was taken via the cannulae. To take a blood 
sample approximately 4ml of fluid was withdrawn from the cannulae. so that whole blood 
reached the end of the tap where the syringe was attached. A 20ml blood ~ample was "lowly 
taken with a new syringe. After the sample was taken the cannulae was flushed with 5ml 
Sodium Chloride to keep it patent. A blood sample was taken as such at the appropriate time" 
(Table 4-1). When the timing of the required samples increased to an hour an extra flush of 
Sodium Chloride was done at 30 minutes, again to keep the cannulae patent. 
After the first blood sample was taken the patient was asked to eat a high fat meal. Thi" 
consisted of a high fat muffin and high fat milkshake (see recipe in Appendix G). The meal 
needed to be consumed within 10 minutes and the time at which the meal was finished wa" 
taken as time O. 
Table 4-1 Timing of postprandial blood samples 
- 5min (5mins before meal) 30 mins 60 mins (1 hour) 
90 mins 120 mins (2 hours) 180 mins (3 hours) 
240 mins (4 hours) 300 mins (5 hours) 360 mi ns (6 hours) 
4.2.1.1 Meal content 
The nutritional composition of the high fat meal was analysed WinDiet (Table -l-2). 
Table 4-2 Macronutrient composition per muffin and milkshake and total for 
whole meal 
Nutrient Muffin Milkshake Total 
Energy kJ 1329 1836 3165 
Kcal 319 440 759 
Total fat (g) 21.0 19.6 40.6 
Of which are (g). .. 
Saturated fatty acids 3.0 12.1 15.1 
Polyunsaturated fatty acids 12.5 0.5 l3.n 
Monounsaturated fatty acid" .fA 5.5 9.9 
('arbohydrate (g) 30.3 53.8 8~.1 
Of which are (g) ... 
'-
0 l3A Starch IJ.-l 
Sugar" 10.6 53.8 6~A 
(Non-milk extrin"ic "ugar,,) 15.9 38.7 29.6 
Protein .f. I 10.1 1~.2 
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4.2.1.2 Handling of postprandial blood samples 
The baseline and serial blood samples of 20ml that were collected in the "yringe via the 
cannulae during the postprandial study were decanted into separated test tubes for analy"i". 
Each test tube contained an appropriate preservative which allowed different components to 
be measured. Swift handling of blood once it has been collected was required to prevent the 
sample from clotting. 
The 20ml sample taken at each time point was decanted as follows: 
• IOml into EDT A for measurement of TAG and non-esterified fatty acid (NEFA). 
• 5ml into lithium heparin for measurement of insulin 
• 5ml into fluoride oxalate for measurement of glucose 
Once the sample has been decanted into the respective tubes, they were mixed then spun in a 
centrifuge at 3000rpm (2000G) for 15 minutes. The plasma from each sample was drawn off 
with a sterile pipette and frozen at -80°C in clearly labelled bottles. 
4.2.1.3 Analysis of blood samples 
All samples were frozen at -80°C and then transported on dry ice to, and analysed 
simultaneously, at Southampton University. The analysis of glucose, triacylglyceride:-. and 
NEFA is described in Section 3.4.9. The coefficient of variation was less than Yic for each of 
the analysis. The analysis of insulin is described below. 
Analysis of insulin 
Insulin was analysed using a method known as DELFIA (Di"sociation-enhanced lanthanide 
fluoroimmunoassay). The DELFIA insulin assay I" a solid phase "andwich 
fluoroimmunoassay. The samples were reacted with immobilized HUI-OI8 monoclonal 
antibodies, directed against a specific antigenic site on the insulin molecule. Biotinylated 
OXI-005 anti-insulin antibody was then reacted with the solid-phase antibody-antigen 
complex. Biotinylated OXI-005 was bound with Europium-labelled streptavidin. Potential 
background interference from proteins. bilirubin and NADH was removed by wa"h cycle:-. 
after each reagent wa:-. added. At low pH, enhancement solution was added to di""ociate 
europium (Eu"+) from the solid phase bound europium-labelled antibodie" to form a 
homogenou:-. and long-lived highly fluorescent Eu-( 2-NTA).,(TOPOh .. chelate :-.olution. 
l\1ultiple reading:-. were then taken by a time-resohed fluorometer. Europium tluore"cence 
\\<1:-. proportional to the imulin concentration in each :-.ample. The codlicient of \ariatiun of 
thl' insulin analv:-.i:-. \\a:-. Ie:-.:-. than 5o/c. 
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4.2.1.4 Calculation of insulin resistance 
Insulin resistance was calculated use the latest version of the homeostasis model assessment 
index (HOMA2) (Diabetes Trial Unit 2004). The HOMA model exploits the concept 'that 
fasting plasma insulin and glucose levels were determined, ill part, by a hepatic-beta cell 
feedback loop' (Turner et aI., 1979). Fasting glucose levels reflect insulin le\els so that 
elevated glucose levels are a measure of insulin insensitivity. Pancreatic p-cell function and 
insulin sensitivity enable a steady state of plasma glucose and insulin levels in an individual 
allowing the construction of a mathematical feedback model (Matthews et al.. 1985). 
4.2.2 Data analysis 
With only four patients recruited results are analysed on an individual basis and trends were 
examined. Formal statistical analysis was not possible. 
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4.3 Results 
The baseline and final characteristics for each patient are shown in Table -+-3. The group \\a" 
heterogeneous. Three patients were male and one was female. The female patient \\a" the 
youngest and had the highest BMI, waist circumference and percentage body fat. The mal~ 
patients had very similar BMI's, but waist circumferences varied. All patients gained weight. 
except patient I who lost 2kg. 
Table 4-3 Baseline characteristics and changes in weight, waist, BMI and body 
fat for each subject over 6 months 
Baseline characteristic Change from baseline to six months 
Patient Age Weight BMI Waist Body Weight \\' ai~t ';'C HoJ\ fat Sex Fat years kg kg/m2 Cm ';'r kg 7c Cm l7r change c,:; 
I Male 06 92.0 29.0 110.0 - -2.00 -2.17 -2.00 -1.82 - -
2 Male 53 106.2 28.8 109.0 21.0 5.'+0 5.08 '+.00 3.67 1.50 7.1'+ 
3 Female 40 97.9 38.7 119.0 '+3.3 3.20 3.27 10.00 8.'+0 1.80 '+.16 
4 Male 73 85.8 29.0 98.0 25.8 6.80 7.93 13.00 D.27 .. uo 162~ 
Mean 58.0 95.5 31..+ 109.0 30.0 3.'+ 3.5 6.3 5.9 25 9.2 
SO 14.6 8.7 4.9 8.6 11.7 3.9 .+ 3 6.7 6.5 1.5 6.3 
Fasting blood samples were taken at baseline and endpoint as described in the prc\lou" 
investigation, Table 4-4 shows the results of the fasting blood sample" for the individual 
patients. 
Table 4-4 Fasting baseline and 6 month biochemistry for each subject 
T-Chol HDL- LDL- ~EF.\ Imulin HhAlc Glucose Chol Chol Ratio 
I \(; 
Patient \" isit ('7cl (mmollI) (~mollI) Iml/II 
mmollI 
9.5 D.5 .+2 1.23 2.13 3.38 1.90 .+65 3.10 
2 9.3 11.5 3.3 1.26 1.60 259 1.13 602 35() 
2 9.'+ 15.8 5.5 1.38 3.36 3.99 1.68 .+55 500 
2 7.7 8.+ 3.8 1.25 2.13 3.04 0.92 273 15.90 
-' 1 7.8 6.6 5.2 O.S'+ 3.60 6.20 1.52 ~25 32.50 
2 9.0 13.2 5.6 0.9'+ 3.88 5.96 1.72 759 ~ ~()() 
8.8 10.+ '+.9 0.97 3.'+S 5.08 1.10 .+~~ 260 
2 7.9 1'+.6 5.2 0.97 3.~l) 5.3'+ 175 .+80 52() 
There \\a~ a gl'neral trend ()f impro\cl1ll'l1t in glycaemic control and lipid bil)chemi,,(r~ in (\\0 
of the male patients from ba~cline to ~i \ month~. In one male patient and thc female patient. 
II S 
glycaemic control deteriorated over the ~IX months and there was a tendency towards a 
worsening lipid profile. 
4.3.1 Glucose 
Fasting readings for the postprandial glucose profiles started generally higher than IOmmol/1 
at baseline and improved after six months of insulin treatment (Figure 4-2). Patient I had the 
lowest fasting glucose and the best postprandial glucose profile at baseline, but experienced a 
worsening in postprandial glucose metabolism over the six month study period, despite being 
the only patient who lost weight. Patients 2 and 4 had the most marked improvement in 
postprandial glucose profile over the six months, replicated by a 1.77c and O.9S1c decrease in 
HbAlc respectively; however these patients experienced the most weight gain and the highest 
increase in waist circumference. 
There was a mean trend towards improved postprandial glucose metabolism over the SIX 
month study period, with a lower blood glucose level recorded at each time point. 
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Figure 4-2 Individual and mean (with SEM) postprandial glucose profiles at 
baseline (blue lines) and endpoint (red lines) 
4.3.2 Triacylglycerides 
There were no changes in postprandial triacylglyceride clearance in patient~ I and -+ in the six 
months of insulin treatment, but there were improvements for patients 2 and 3 (Figure -+-3,. 
Patient I had low fasting triacylglyceride levels and a low response to the high fat meal, 
atypical of the usual postprandial response for a person with T2DM. In the other three 
patients, triacylglyceride levels continued to rise after the 6 hour study period, at baseline and 
six months. The prolonged lipaemia is typical of patients with T2DM, therefore there was no 
peak in the postprandial triacylglyceride curve during the study period, which would occur in 
healthy subjects. The mean trend indicates that postprandial triacylglyceride clearance 
improves in people with T2DM following the introduction of insulin therapy, but that 
clearance of triacylglyceride rich particles remained abnormal. 
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Figure 4-3 Individual and mean (with SEM) postprandial triacylglyceride 
profiles at baseline (blue lines) and endpoint (red lines) 
4.3.3 Non-esterified Fatty acids 
The suppression of NEFA in the postprandial phase improved noticeably in patients 2 and -+ 
(Figure 4-4). Patient 3 had high fasting NEFA and a large suppression profile at baseline. 
which was less pronounced after six months treatment with insulin. None of the patient" had 
complete suppression of NEFA either at baseline or after six months of insulin treatment. 
However, the mean results indicate that there was a reduction in fasting NEF A and ... lightly 
more suppression of NEFA at all time points after 6 months of insulin treatment compared 
with baseline result. 
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baseline (blue lines) and endpoint (red lines) 
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4.3.4 Insulin 
Patient 3 had re idual endogenou insulin, a hown by an in ulinaemic re pon e to the m al 
at ba eline and ix months (Figure 4-5). Patient 3 had markedly the highe t BMI hich \>\ 
approaching 40kglm2, compared with BMI' all below 30kglm2 for the other patient . Patient 
1 had a very slight postprandial insulin respon e, which did not change from ba eline to i 
months. Patients 2 and 4 had flat postprandial insulin profiles both at baseline and endpoint, 
indicating virtually no endogenous insulin. The mean trend in po tprandial in ulin Ie el 
hawed very little change from baseline to endpoint. 
4.3.5 Insulin resistance 
In ulin resistance was calculated u ing HOMA at ba eline and ix month from the fa ting 
glucose and insulin levels. The results in Table 4-5 how that all patient had an increa In 
in ulin resistance over the ix month period. Patient 3 who wa the mo to erweight and had 
are idual insulin re ponse was markedly the mo tin ulin re i tant at ba eline and i month. 
Patient I wa the only patient who 10 t weight over the ix month and had the mallt 
increa e in insulin resi tance. Patient 2 gained 5.4kg of weight and had the highe l increa 
in in ulin re istance, although patient 4 who gained 6.8kg over the tudy period had Ie 
marked increase in insulin re istance. 
Table 4-5 The baseline and six month estimations of insulin resistance 
patient Vi it 
2 
2 
1 
2 
1 
2 
1 
2 
Gluca e 
(mmol/I) 
9.14 
16.20 
15.06 
9.06 
14.06 
12.19 
13.61 
10.90 
through HOMA calculations 
In ulin Beta ell 
(mUll) function (%B) 
3.10 15 .3 
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5.00 .4 
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Figure 4-5 Individual and mean (with SEM) postprandial insulin profiles at 
baseline (blue lines) and endpoint (red lines) 
1~6 
4.3.6 Summary of results 
Patients 2 and 4 responded more to insulin, experiencing the greatest improvement In 
glycaemic control and more suppression of NEFA. Alongside the improvement In 
postprandial metabolism these patients experienced the most reduction in fasting glucose, 
HbAlc and lipid profile. Patient 3 was the only patient with residual endogenous insulin, but 
was the most overweight. In this patient the need for exogenous insulin is likely to be due to 
insulin resistance rather than insufficiency. 
4.4 Discussion 
The aim of the study was to investigate the change in postprandial metabolism in patients 
with T2DM during the first six months of being treated with insulin therapy. Comparisons 
were to be made between patients who were able to maintain their body weight by following 
an intensive dietetic intervention to those who gained weight as a result of insulin therapy. 
Unfortunately recruitment to the study proved to be extremely difficult as patients were not 
keen, or were unable, to commit to two full study days when there was no direct advantage to 
them by completing the study. In future, if similar studies were undertaken, it would be 
recommended that an incentive be used to promote recruitment 
Despite only a small number of patients being involved in the investigation, some interesting 
trends were found. The patients who derived the most benefit from insulin therapy had the 
least (smallest) postprandial endogenous insulin response. After six months of treatment with 
insulin these patients had the greatest improvement in NEFA suppression and the largest 
reduction in postprandial glucose levels. The trade off for the improvement in postprandial 
metabolism was weight gain, as these patients gained more than 5% body weight. The 
reciprocal relationship between improved postprandial metabolism and weight gain can be 
explained in part by the pathogenesis of T2DM. 
Type 2 diabetes is a progressive disease in which endogenous insulin decreases gradually 
over time (Stumvoll et aI., 2005). When insulin insufficiency becomes too pronounced, 
glycaemic control worsens and glucose is excreted in the urine, finally resulting in weight 
loss. Exogenous insulin is then used to correct glycaemic control and it appears that the most 
improvement occurs in patients with the lowest endogenous insulin levels who have worst 
initial control and speculatively the highest previous weight loss as a result of poor control. 
This finding supports the hypothesis that the greatest benefit of insulin therapy is derived in 
those who are most insulin insufficient. The benefit in postprandial metabolism for these 
patients appears to occur in spite of discernible weight gain. 
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The second hypothesis stated that patients who were highly insulin resistant would gain the 
most weight, contributing further to the insulin resistance, which would cause a worsenino of 
eo 
postprandial metabolism. All patients had an increase in insulin resistance during the first "i\ 
month'"> of insulin treatment, however just one patient could be regarding a" highly insulin 
resistant at baseline. The baseline BMI, waist circumference and percentage body fat of thi" 
one patient wa'"> distinctly characteristic of insulin resistance (Little and Byrne, 2001; Janssen 
et aI., 2(02), which was confirmed by HOMA. This patient did gain weight, but the weight 
gain did not exceed that of other patients. After six months of insulin therapy in the pre"ence 
of insulin resistance there was no noticeable improvement in postprandial glucose metabolism 
but a trend for improvement in triacylglyceride clearance and a reduction in fasting, but not 
postprandial NEFA levels. The hypothesis regarding the initiation of insulin therapy in 
insulin resistant patients was not supported, as weight gain was not more pronounced nor was 
there a worsening in postprandial metabolism. However, these initial findings in a very "mall 
sample would need further investigation in much larger groups. 
Further work into the changes in postprandial metabolism following the initiation of in"ulin 
therapy should include analysis of the degree of insulin resistance as measured ideally by 
euglycaemic clamp techniques or estimated with calculations such as the fasting homeostasi" 
assessment model (HOMA). Analysis of insulin resistance and changes in postprandial 
metabolism following insulin therapy would elicit the true impact of insulin resistance or 
insufficiency on outcome. Further work should also include analysis of the impact of weight 
gain following insulin therapy, as with the initial aim of this investigation. to determine the 
influence that weight change has on postprandial metabolism. 
4.4.1 Conclusion 
Postprandial metabolism is an exciting area of research which has the potential to reveal in 
greater depth the metabolic status of a given condition such a" T2DM and the effect of 
changes in treatment or condition. From this pilot study it appears that the introduction of 
insulin therapy to the treatment of T2DM may result in an improvement in postprandial 
glucose, triacylglyceride, and NEFA metabolism. The improvement can be attributed to the 
addition of insulin therapy and occurs regardk"" of weight gain; howewr, more re"l'arch i" 
needed. 
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5 A study examining the effect of Sibutramine and Lifestyle 
advice on weight outcomes in obese females with and 
without Type 2 diabetes. 
5.1 Background 
The randomised control trial demonstrated that people with T201\1 have great difficulty in 
losing weight. Other studies have substantiated this by indicating that weight loss is more 
difficult in the presence of T2DM (Wing et a\., 1987; Guare et a\., 1995; Hensrud, 20n 1). 
Options for weight loss for overweight people, other than through diet and exercise 
modification, are medication and surgery. Surgery is generally considered a last resort when 
all other options have been exhausted. In recent years there has been much interest in the 
development of "anti-obesity" drugs. The first generation of weight loss medications were 
amphetamine based and were withdrawn due to associated side effects including addiction 
and increased cardiovascular risk. In recent years, two new medications have become 
available; these are Orlistat (Xenical) and Sibutramine (Reducti\). Orlistat (Xenica\) is a 
pancreatic lipase inhibitor which works in the gut lumen to reduce the absorption of fat. 
Sibutramine is a serotonin and noradrenaline reuptake inhibitor. This chapter describes a 
study where the potential additive effect of Sibutramine to Lifestyle intervention in assisting 
weight loss in T2DM is examined. 
5.2 Weight loss and Sibutramine 
5.2.1 Background 
Sibutramine inhibits the reuptake of serotonin and noradrenaline, leading to cerebral neurones 
being limited in the amount of these naturally occurring chemicals they are able to reabsorb, 
consequently increasing their concentration. This causes the person to lose weight in three 
ways: 
• promoting satiation - causing earlier meal termination 
• enhancing satiety - prolonging the duration of the feeling of fullness and reducing the 
need for snacking between meals 
• preventing the reduction in thermogenesis that occurs a" a re"ult of weight 10",", 
In e""ence. Sibutramine makt'" the individual feels fuller earlier at meal timL''' and 1;;1\L''' a 
prolonged feeling of fullnes" which both a""i"t in reducing intak.e of food and energy and 
ha\'l' a metabolic ad\antage. which all enclHlrage negati\e energy balance and will, therefore 
induce' \\eight lo"s, 
5.2.2 Current Sibutramine research 
Sibutramine was originally developed as an anti-depressant. However. when tested it was not 
effective as such but there was a significant side effect of weight loss (Luque and Rey, 2(02). 
In 1995, the first studies were published describing the use of Sibutramine, when it wa~ a 
novel weight reducing agent. Table 5-1 summarises early research publications U~Ing 
Sibutramine. 
These studies provided evidence that Sibutramine was efficacious in causing weight lo~~ in 
both animals and humans. The studies also provided information on: 
• Therapeutic dose range - minimum dose required for significant effect and the 
maxi mum dose necessary 
• Mechanism of action - inhibition of the reuptake of serotonin and noradrenaline 
• Consequences of action - hypophagic consequence of altered brain chemi~try 
• Thermogenic effect - preliminary investigations, remains controversial either: 
• no change in thermogenesis 
• increase in thermogenesis 
• prevention of the decline in thermogenesis which usually occurs \vith weight 
loss (this suggestion has most recent support (Lean, 2001: Finer, 2002: Liu et 
aI., 2002)) 
• Comparisons with similar compounds - Sibutramine shown to have novel action and 
superior weight loss effects 
• Preliminary investigations into safety profile 
Table 5-1 Early Sibutramine research 
Authors Subjects (n) Study aim Study design Results Comments I Main conclusions 
and year and 
(REF) duration 
Ryan et al.. Humans Preclinical studies Placebo controlled Sib has dose response wt loss profile with doses Initial promise of Sibutramine being a potential wt 
1995 8 weeks into medication randomised control trial varying from 1 mg to 30mg. Majority of weight loss loss agent 
potential (RCT). occurring in first 12 weeks. weight loss continuing at 
24 weeks 
Brayet al.. Humans Clinical study Double blind placebo Dose response in humans. Significant difference in First suggestion of the necessary therapeutic dose. 
1996 (n=173) investigating dose controlled RCT. dose doses >lOmg. Most weight loss achieved with doses 
24 weeks required range I mg to 30mg. >15mg. Weight regain when medication stopped. 
Side effects generally mild. 
Gundlah et Animals - Analysis of Microdialysis in the Sibutramine confirmed to be a serotonin reuptake 
al .• 1997 Rats Sibutramine action hypothalamus inhibitor rather than a serotonin releaser. 
on 
neurotransmitters 
Jackson et Animals- Investigating Use of antagonists to Identified that ~ l-adrenoceptors. 5HTI2C-receptors Sibutramine causes hypophagia due to inhibition of 
al.. 1997b Sprague mechanism of examine pharmacological and particularly a l-adrenoceptors involved in reuptake of noradrenaline and serotonin and 
Dawley rats action mechanism Sibutramine action. Also identified numerous subsequent activation of these systems. 
receptors not involved. 
Jackson et Animals - Comparing Comparison between For reduced food intake. require both a serotonin Combining the actions of serotonin reuptake 
al.. 1997a Sprague Sibutramine to wider spectrum reuptake reuptake inhibitor and a noradrenaline reuptake inhibitors and noradrenaline reuptake inhibitor 
Dawley rats other monoamine inhibitors and selective inhibitor. such a'i Sibutramine. Selective reuptake proposed as a novel approach to obesity treatment. 
reuptakc inhibitors reuptake inhibitors inhibitors are ineffective for weight loss. 
-
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Hanotin et Humans Comparing weight Double blind RCT Sibutramine weight loss = 4.5kg. Dexfenfluramine Sibutramine causes superior weight loss to the 
aI .• 1998b (n=226) loss results of comparing I x I Omgld weight loss = 3.2kg (p<0.05). Comparable numbers serotoninergic releasing agent Dexfenfluramine 
12 weeks Sibutramine and Sibutramine to 2x 15mgld of adverse effects. Significant increase in heart rate 
Dexfenfluramine Dexfenfluramine with Sibutramine (3.6bpm) 
Hanotin et Human Assessing efficacy Double blind placebo Significant difference between placebo and IOmg and IOmg and 15mg doses of Sibutramine equally 
aI .• 1998a (n=235) and tolerability. controlled RCT. 15mg dose of Sibutramine (p<O.Ol), but no difference effective for weight loss and significantly more so 
12 weeks Multicentre trial. between these doses. No significant changes in than placebo. Sibutramine considered well 
hunger, satiety or cravings. Significant increase in tolerated, notably with respect to the absence of 
heart rate (4bpm, p<O.OOl) with IOmg and 15mg cardiac changes. 
doses, no other BP or ECG changes. 
A'itrup et Discussion Review of Reviewing impact of Sibutramine has duel mechanism of action, reducing Sibutramine able to shift energy balance from 
al.. 1998 Sibutrarnine and Sibutramine on energy food intake by enhanced satiety and stimulating positive to negative, by influencing both energy 
energy balance. intake and output thermogenesis through activation of the sympathetic input and output. 
nervous system. 
Hansen et Humans Compare the acute Double blind placebo Sibutramine caused significant increase in basal Confirmation that Sibutramine has a thermogenic 
al.. 1998 (m=ll) thermogenic effect controlled ReT cross energy expenditure and during the postprandial effect and that a quarter of the rise in heart rate is as 
Acute study of Sibutramine on over with wash out period (p<O.02). Increase in energy expenditure went a consequence of this thermogenesis. 
basal energy period. Assessing energy in conjunction with increase in plasma epinephrine, 
expenditure and expenditure through heart rate BP, and plasma glucose (<0.05). About I 
diet induced indirect calorimetry in 25% of the increase in heart rate attributed to increase 
thermogenesis both fasting and fed states in thermogenesis. 
with 30mg dose. 
Seagle et Humans Effects of Randomised clinical trial. Body weight significantly reduced with Sibutrarnine Affirmed that Sibutramine was effective for weight 
al.. IIJIJX (f=44) Sibutrarnine on 3 groups: placebo. compared to placebo, but no differences between the loss, but did not show evidence of effect to 
X weeks. weight loss and 10mgld dose and 30mgld doses. No difference in RMR both 3-hour post dose metabolic rate 
resting metabolic dose. or after 8 weeks of treatment. 
----- -
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rate (RMR) 
Walsh et Humans Comparison of RCT receiving either Trend indicating correlation between weight loss and Sibutrarnine tends to limit the decline in REE which I 
al., 1999 (f=19) change in resting lSmgld Sibutramine or I decline in REE that usually occurs is lost with usually occurs with weight loss. The prevented 
12 weeks energy expenditure placebo Sibutramine treatment. There was an increase in fat decline was calculated to be equivalent to about 
(REE) following free mass REE was increased with Sibutramine by lOOkcals/d, thus assisting with weight loss. 
weight loss with 2.2% and decreased in the placebo treated group by 
and without 5.8%. (p=O.ll) 
Sibutramine. 
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5.2.3 Recent research on Sibutramine (2000 - present) 
The weight loss effects of Sibutramine were well established and reproducible by the start of 
2000, by which time the medication had already been available for clinical use in the United 
States of America for three years (under the trade name Meridia). Therefore. there wa~ a shift 
in the focus of research from the physiological action of Sibutramine to its wider effect'>. 
Since 2000 Sibutramine research has centred on a number of topics, namely weight 
maintenance following weight loss, treatment in the presence of other medical conditions 
such as hypertension, dyslipidaemias and T2DM, and comparisons between Sibutramine and 
Orlistat. The available research is summarised in Table 5-2. 
Table 5-2 Recent Sibutramine research - building the evidence base. 
Authors Subjects (n) Study aim Study design Results Comments I Main conclusions 
and year and 
(REF) duration 
Longer term weight loss and weight maintenance 
James et Humans. To assess the Double blind placebo 43% of Sibutramine group maintained at least 80% Sibutramine effective in causing short term weight 
al..2000 European efficacy of controlled RCT. 6 month original weight loss compared with 16% in placebo loss, but also longer term weight maintenance, 
STORM wide (n=605). Sibutramine in weight loss phase with group (p<O.OOI). See Figure 5-1. resulting in improvements in generalised obesity 
study 2 years. weight maintenance Sibutramine followed by associated risk factors. 
I 
. group. following randomly assigned 
Sibutramine aided lOmgld (up to 20mgld) 
weight loss Sibutramine or placebo. 
van Baak et As above To establish which Additional analysis to the Factors found to be significant = treatment type Treatment with Sibutramine had largest influence 
al.. 2003 determinants are STORM study. multiple (Sibutramine or placebo) (p<O.OOl). percentage of on weight loss, but other factors should also be 
STORM important for regression of a number of initial body weight lost (p<O.OOl) and leisure time considered for long term outcome. 
study weight maintenance factors activity (p=0.OO2). contributing 9%, 8% and 3% 
group. respectively to the variation in weight loss. 
Wirth and Humans To assess Double blind parallel Weight loss in continuous Sibutramine group, Intermittent treatment with Sibutramine equally 
Krause. (n=1102) effectiveness of group placebo controlled intermittent Sibutramine group and placebo group = effective for weight loss and associated benefits as 
2001 48 weeks Sibutramine for ReT. Patients receiving 7.9kg. 7.8kg and 3.8kg respectively. Significant continuous treatment with Sibutramine. but with a 
long term weight either continuous 15mgld difference between Sibutramine groups and placebo tendency towards fewer side effects. First 
loss. Sibutramine. intermittent (p<O.05), no significant difference between 2 suggestion of effective outcomes with intermittent 
l5mg/d Sibutramine or Sibutramine groups (p=0.28). BP stable in all groups. Sibutramine treatment. 
placebo Adverse events lowest in intermittent group. 
~ 
-
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Hauneret Humans To assess Double blind placebo Weight loss and weight loss targets Sibutramine and Sibutramine effective in primary care and produces 
al .• 2004 (n=362) effectiveness of controlled RCT. placebo: 8.lkg and 5.lkg (p«)'oOI), achieved 5% superior results to a weight loss programme without 
54 weeks Sibutramine in Multicentre. Randomised weight loss; 62.6% and 41.4% (p<O.OOl), achieved Sibutramine. More weight loss achieved and more 
primary care to 15mgld Sibutramine or 10% weight loss 40.8% and 19.0% (p<O.OOl). patients exceeding the 5% and 10% weight loss 
setting. placebo in conjunction Weight loss accompanied by improved lipid profile. targets. 
with weight loss 
programme 
Hypertension and heart rate 
James et As above To assess the Double blind placebo 5% withdrawal rate from Sibutramine arm compared Close monitoring of patients BP required early on 
al..2000 efficacy of controlled RCT. 6 month with less than 1 % in the placebo arm due to in the prescription of Sibutramine ~ ensure 
Sibutramine - weight loss phase with hypertension. Mean changes in systolic/diastolic BP patients worse affected by increases can cease 
hypertension Sibutramine followed by were 0.1I2.3mrn/Hg and -4.7/-1.6mm/Hg (p<O.OOI) medication. Otherwise increases in BP and HR. 
results. randomly assigned and heart rate (HR) 4.1 bpm and -1.9bpm respectively although significant are not very large. The 
IOmgld (up to 20mgld) (p<O.OOl). benefits of Sibutramine outweigh adverse effects. 
Sibutramine or placebo. 
McMahon Humans. To assess the Double blind placebo Range of outcome measures. weight and lipid Sibutramine both effective and safe in obese 
etal..2000 multicentre efficacy and safety controlled RCT. findings comparable to previous. Discontinuation patients with well controlled hypertension provided 
USA. (n=224) of Sibutramine in Treatment with due to hypertension = 5.3% in Sibutramine and 1.4% adequate monitoring to allow identification of high 
I year patients with Sibutramine or placebo. in placebo. Diastolic BP changes 2mm1Hg and - risk patients. 
hypertension l.3mm1Hg (p<O.05) and HR changes 4.9 and Obpm 
(p<O.05) respectively 
Faria e! 011.. Human~ To assess effects of Randomised control trial. No change in office or 24 hour BP with either No change in 24 hour BP. contrary to suggestions 
2(X)5 (n=X6). Sibutramine on 10mg Sibutramine or Sibutramine or placebo. Significant increase in office from previous studies. attributed to balance between 
24 weeks abdominal fat mass, placebo. heart rate of 4bpm (p=0.02). the increase in BP due to Sibutramine and the 
insulin resistance decrease as a result of weight loss. Although no 
and BP in pair matched control group with similar amounts of 
hypertensive weight loss without assistance of Sibutramine. 
-- ---- - --
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patients 
Jordan et Humans Investigate Combined analysis 2 Change in BP for Sibutramine and placebo groups; Sibutramine unlikely to "elicit a critical increase in 
al .• 2005 (n=1336) influence of placebo-controlled trials. systolic -O.lmmlHg and -O.2mm/Hg (p=O.9), diastolic BP. even in hypertensive patients." Advised that 
48 weeks Sibutramine on BP (Wirth and Krause, 2001; O.3mm1Hg and -O.8mm1Hg (p=O.49) respectively. close monitoring required for the few patients who 
Hauner et aI., 2004) BP response no worse in hypertensive patients. experience clinically significant and sustained 
increase in BP and need the medication to be 
discontinued. 
Dyslipidaemia 
Dujovne et Humans Investigating the Double blind placebo Patients on Sibutramine lost significantly more In patients with low HDL and high TAG treatment 
al.. 2001 (n=322) effect of controlled RCT, patients weight than placebo 4.9kg vs. O.6kg (p<O.05). with Sibutramine alongside dietary intervention 
24 weeks Sibutramine on with high TAG and Low Triacylglycerides decreased in the Sibutramine produces more favourable results than dietary 
weight loss and HDL randomised to group, but increased in the placebo group (p<O.05), intervention alone, due to the higher amounts of 
i 
lipids in patients 20mg/d Sibutramine or HDL-cholesterol also increase more in the weight loss achieved with Sibutramine. 
with dyslipidaemia placebo alongside Sibutramine group than the placebo group (p<O.05). 
American Heart Changes in lipid variables ran in parallel to amount of 
Association diet. weight lost. 
Sibutramine and Orlistat 
Kaya et a1.. Humans Comparison of the Short term, open label. Groups i-iv lost 12.7kg, 9.3kg. 13.7kg and 6.2kg Sibutramine has weight loss advantage over 
2004 (n=83) efficacy of RCT to i) Sibutramine respectively. Treatment with medication resulted in Orlistat. No additional weight loss benefit derived 
12 weeks Sibutramine lOmg/d. ii) Orlistat significantly more weight loss than diet (p<O.OI). by combining medications, especially with respect 
Orlistat. 3x 120mg/d. iii) Group i. lost significant more than ii. (p=O.02). Group to minimising side effects and cost. Larger and 
combination Sibutramine + Orlistat or iii. lost significant more than ii (p<O.OOI). but not longer term studies required. 
treatment or diet iv) diet only significant more than i. 
only intervention. 
TlDM 
Sanchcz- I Humans with Assess effect of Double blind placebo Sibutramine treated group lost 4.lkg (p<O.OOI) and I Treatment with Sibutramine in people with T2DM 
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Reyes et TIOM Sibutramine on controlled RCT to had an improvement in HbAlc from 8.9% to 8.3% results in greater weight loss and significant 
al .• 2004 (n=86). weight and IOmgld Sibutramine or (p<O.OOl). Placebo group lost 1.3kg (NS) and had an improvements in glycaemic control. results 
12 months glycaemic control placebo increase in HbAlc from 9.0% to 9.1 % (NS) unachievable with placebo 
McNultyet Humans with Evaluate effects of Double blind placebo Significant weight loss with both Sibutramine doses; Sibutramine can be an effective addition to 
al.. 2003 TIOM Sibutramine on controlled ReT to 15mg = 5.5kg. 20mg = 8.0kg (both p<O.OOl), but not metformin treatment in TIOM, resulting in 
(n=195). weight, metabolic Sibutramine 15mgld or with placebo = 0.2kg (NS). Metabolic control significant weight loss and improved metabolic 
12 months control and BP in 20mgld or placebo improved most in patients achieve> 1 0% weight loss. control 
patients with Increases in BP seen with Sibutramine, but less 
TIOM treated with evident in highest weight losers (>10%). 
metformin. 
Serrano- Humans with Investigate effects Double blind placebo Weight loss significant greater with Sibutramine than Sibutramine results in greater weight loss in 
Rios et al.. TIOM of Sibutramine on controlled ReT to placebo, 4.5kg vs. 1.7kg (p<O.OOI). Improvements in patients with TIOM who are treated with 
2002 (n=IIO) body weight in 15mg/d Sibutramine or HbAlc proportionate to weight loss regardless of sulphonylureas. Glycaemic control improves with 
6 months patients with placebo treatment type. weight loss and therefore is more likely to improve 
TIOM on SU to a greater degree in those treated with 
Sibutramine. 
Gokcel et Humans with Investigate effects Double blind. rank- Sibutramine caused significantly greater Weight loss as a result of Sibutramine treatment can 
al..2001 TIOM on of Sibutramine in randomised placebo improvements in BMI (-3.92 vs. -0.92), HbAlc (- significant improve glycaemic control in patients 
maximal patients with poor controlled study. patients 2.71 vs. -0.53). fasting glucose, 2 hour postprandial who are poorly controlled, potentially delaying 
OHA (n=50) glycaemic control assigned to 2x 1 Omgld glucose and insulin resistance (all p<O.OOO I) than progression to insulin therapy. 
6 months (HbAlc >8%) Sibutramine or placebo placebo. 
I-"ujioka et Humans with To determine Multicentre Double blind Sibutramine resulted in significantly greater weight Sibutramine resulted in significant reductions in 
al .. 20m poorly efficacy and placebo controlled ReT; loss than placebo; 4.3kg vs. O.4kg (p<O.OOI) (4.5% body weight, improving glycaemic control. 
controlled tolerability of to dietary counselling vs.0.5%). In those treated with Sibutramine weight Sibutramine was well tolerated. with few side 
TIDM Sibutramine in with Sibutramine (up to loss correlated with improvements in HbA 1 c (r=O.36, effects in those achieving more than 5% weight 
(n=175) poorly controlled 20mg/d) or placebo p=O.OOI). BP and HR increases not seen in loss. 
24 weeks TIDM Sibutramine treated patients who achieved >5% 
------
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weight loss 
Systematic reviews 
Arterburn Systematic Determine the MEDLINE, EMBASE Mean weight loss (minus placebo) was 2.78kg in 3 Sibutramine effective for weight loss but associated 
et al.. 2004 review of29 efficacy and safety and Cochrane library months and 4.45kg in a year. Modest increases in with some positive and some negative changes in 
human studies of Sibutramine review of placebo heart rate and BP. No evidence of decreased obesity cardiovascular and metabolic risk factors. 
controlled RCT associated mortality and morbidity risk. Insufficient evidence to accurately determine long 
term risk-benefit profile. 
Norris et Cochrane Determine the MEDLINE, EMBASE, Mean weight loss over 12-52 weeks was 5.lkg. Sibutramine effective for weight loss and has some 
al.. 2005 review of22 efficacy of different Web of Science and associated with a 0.5% decrease in HbAlc. metabolic advantage for patients with nDM. 
studies in weight loss electronic databases 
humans with pharmacotherapy in review of RCT in nDM 
nDM nDM 
L- __________ 
'------------
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5.2.4 Summary of recent Sibutramine research (2000 - present) 
5.2.4.1 Longer term weight loss and weight maintenance 
Maintaini ng weight loss over time is an enduring problem a hown b abe it re ear h. 
Evidence indicates that weight 10 s with Sibutramine is greate t initially and low ith tim. 
but i effecti ve in weight mai ntenance phase over a 24 month period (Figure 5-1). 
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Figure 5-1 The mean bodyweight changes during weight-loss and weight-
maintenance phases. Taken from the STORM study (James et aI. , 2000) 
In the STORM study (van Baak et aI. , 2003) the pre cription of ibutramine wa the primary 
factor in determining weight maintenance, but not to the exclu ion of other factor uch a 
encourag ing phy ical activity. Re earch hawed that intermittent u e of medication can 
prod uce replicable degree of weight 10 over a year when compared to continuou u , 
sugge ting a potential long term weight 10 trategy. Ad antageou Iy, longer term wight 
los with Sibutrami ne has been shown to be achievable in both primary and econdary car 
. tting , however further re earch i required to a e whether thi ucce could b 
tran f rred to other etting uch a a dietetic outpatient clinic. 
5.2.4.2 Blood pressure and heart rate 
ibutramin ha b n a ' ociated with an increa e in blood pre. ure and h art rat and thu 
pot ntiall ac rbating cardia a ular ri k. Th general n. en u r pini n I th.l 
ibutramine au e. appr imatel a 4 b at p r minute ri in heart rat and ha \ ry IIltk r 
n err t n s t Ii bl d pr sure. Ho\ ever. the data n dia...t Ii bl d pre ure an.: mort.: 
\ari d. Th ov rail pattern f \iden indicat ... that dia~t Ii bl d pre ..,ur d e In r'.l > 
marginall with ibutramine, but that thi ... rise I... lint ra ted \\ hen \\ eight I Ll~cd- r 
fhe re .... ponsc in bl d pr "' ... L1re i ... n t diller nt in pe pIe \\ith \\ell ntr lied h pertCIl 1011 . A 
I ( 
number of investigations indicate that there are a small minority of people (approximatel~ 
5%) who have increased blood pressure sizeable enough to warrant the discontinuation of 
Sibutramine. These findings helped produce the NICE patient monitoring guideline .... for 
Sibutramine so that patients at risk of hypertension can be identified early. 
5.2.4.3 Change in lipids and treatment in patients with dyslipidaemia 
Numerous studies regarding Sibutramine investigated change in lipids as secondary measure ..... 
with one study investigating the effect of Sibutramine in patients with dyslipidaemia. 
Generally there was an improvement in the lipid profile for patients treated with Sibutramine. 
although the improvement was consistently attributed to weight loss. The improved lipid 
profile was similar in patients with and without dyslipidaemia..... Sibutramine resulted in 
superior improvements in lipids than either placebo or dietary intervention due to higher 
amounts of weight loss achieved. 
5.2.4.4 Comparisons between Sibutramine and Orlistat. 
The UK has two weight loss medications presently available; Sibutramine and Orlistat. ,\ 
comparison of the efficacy of Sibutramine monotherapy. Orlistat monotherapy and the 
combination of Sibutramine and Orlistat showed that Sibutramine led to significantly greater 
weight loss than Orlistat and that there was no additional benefit in combining treatment..... A .... 
Sibutramine is a relatively new medication and appears to produce better weight 1m .... result<.,. 
it is used in the present investigation. 
5.2.4.5 Sibutramine and type 2 diabetes 
Studies have shown that the amount of weight los .... achieved by patient.... with T201\1 treated 
with Sibutramine was between ..t-kg and 5.5kg in six month .... to a year. (Fujioka et aI.. 2000; 
Gokcel et aI., 200 I: Serrano-Rios et aI., 2002; McNulty et al.. 2003; Linne and RO ........ ller. 
2004). These studies consistently showed clinically and statistically .... ignificant imprmelllt'l1t.... 
in ~Iycaemic control and a trend towards improved lipid profiles. all occun'il1~ in parallel to 
de~ree of weight loss. The improvement .... were attributed to the weight 10 ........ that occurs 
becau .... e of the medication rather than a metabolic and pharmacological effect of the drlI~ 
itself. To date there arL' no studies that directly compare the effecti\ene"" of Sibutramine in 
patient.... both with and without T2DM in term .... of weight 10 ........ and change .... in lipid profi Ie" 
that are likely to follow weight los .... 
I -+ I 
5.3 Gaps in knowledge 
The data regarding Sibutramine gathered from research is growing but there still are "ome 
unanswered questions. It appears that in all studies patients have been selected by virtue of 
their being overweight or obese. The NICE guidelines (NICE., 2001), and the 
recommendations in the British National Formulary (Royal Pharmaceutical Society of Great 
Britain., 2005), state that prior to prescribing Sibutramine patients should previously haw had 
serious, but unsuccessful, attempts at weight loss. This, however, is not mentioned as part of 
the inclusion criteria in any publication to date. 
Previous investigations have not compared weight loss and other outcomes in overweight 
patients with and without T2DM whilst following a 'Lifestyle' intervention with or without 
the addition of Sibutramine. 
5.4 Aims 
The three main aims of this study were: 
1. To investigate differences \0 weight loss between overweight patients 
with, and without, T2DM whilst following an intensive Lifestyle 
intervention programme. 
11. To investigate if weight loss can be improved in overweight patients with 
and without T2DM, for whom Lifestyle intervention alone was 
unsuccessful, with the prescription of Sibutramine in addition to diet and 
Lifestyle intervention within a hospital outpatient setting. 
111. To examine and compare cardiovascular risk markers such as 
biochemistry and blood pressure for each treatment and diagnosis 
5.5 Hypotheses to be tested 
The three hypotheses to be tested were: 
• People with T2DM lose weight less readily than those without diabetes whilst 
followi ng intensi w Lifestyle intervention. 
• 
• 
The introduction of Sibutramine in conjunction with Ii restyle advice l'nhances \\l'lght 
loss owr Iikstyle advice alone for owrweight patients with and without T2()\1. 
TI1L're will be an improvement in cardiovascular ris\... markers \\ hich is proportional to 
thl' degree of \\l'ight loss. 
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5.6 Method 
5.6.1 Study design 
This was a retrospective case-control study analysing data collected during clinical practice. 
5.6.2 Patient referral 
Patients are referred to hospital dietitians for weight loss via a number of routes. These can 
be a referral from their general practitioner, a hospital doctor or consultant, another health 
care professional or the patient can self-refer. Once a referral is received. the dietitians 
involved in the obesity services screen the referrals and determine the most appropriate clinic 
for the patient to attend. At the Hammersmith Hospital NHS Trust, the main options 
available for weight loss advice are an appointment in the general outpatients clinic or entry 
into the intensive weight management programme (the Lifestyle clinic as described in Section 
3.4.11.2). In addition, there is also a specialised obesity clinic for morbidly obese patients. 
The 'Sibutramine' clinic is a relatively recent addition to the obesity services and is run by the 
author. It is available to those who have attended other outpatient clinics for weight loss, but 
have been unsuccessful, despite their concerted efforts to lose weight. The large majority of 
the referrals for the 'Sibutramine clinic' are from the Lifestyle clinic, although a few are from 
the general outpatient clinics (Figure 6.2). Therefore, all those who attend the 'Sibutramine 
clinic' have failed to lose weight using other dietetic treatment options. 
Referral to Dietitians for weight loss from GP, hospital 
doctor, other health professional or self referral 
( Assessed by Dietitian ) 
( General O/P clinic 1 
"----) ( lifestyle Clinic 
"'"--
Unsuccessful weight loss 
) 
( Sibutramine CliniC ) 
Figure 5-2 Referral process for patients requiring weight loss advice at the 
Hammersmith Hospital NHS Trust. 
5.6.3 Sample size 
In this study there were four group of patient, two group of 10 and two of 9, therefor in 
total, data from 38 patients contributed to the analy i . The four group w re dependent on 
the treatment for weight los (Life tyle advice alone or Life tyle ad iee plu ibutramine) and 
the pre ence or not of T2DM. The following table demon trate the e group and in bold lh 
code which will be u ed to identify each group. 
Table 5-3 Groups used in analysis comparing weight loss rates, groups 
determined by presence or absence of T2DM and weight loss treatment type. 
Sibutramine treated «L)S) Lifestyle intervention (L) 
Pre ence of T2DM on Sibutramine T2DM folio\! ing life tyle 
LD (L)SD 
T2DM (D) (n=9) cl inic (n=9) 
"Healthy" Non-T2DM on Sibutramine Non-T2DM follo\'ving 
L (L) 0 
overweight (0) (n= I 0) life t Ie linie (n= I 0) 
~ th e data were ted from a n di telic led lini u Ing ibulramlne r r Ihe Ilr..,1 
time. a menl nl ampl wa n . ar . The , ampl iz \\a.., determin d b) Iht.: number of 
paticllt~ laJ..ing ibulramine wh had mpleted i\ m nth r rht: pr gramme al Iht.: lime ( I 
the ~lud . 
The primary outcome measure was weight change over time. Secondary outcome mea ur 
were change in cardiovascular risk marker both among and between group. 
5.6.4 Study patients 
Patients who had completed 6 months on Sibutramine were pair matched with tho e ',: ho had 
completed the Life tyle clinic only (Figure 5-3). All patient included in thi anal i \\ re 
female. The variables used to pair match were age (± 5 year ), ethnicity (White. Black. or 
Asian), history of diabetes and finally, in the presence of diabete , the type of diabetic 
medication. Patients ' demographics and medical hi storie were confirmed b checking the 
ho pital information system and medical records. Wherea patient' ethnicit wa determin d 
by asking the patient "What ethnicity are you?" and pro iding a number of option for 
example, Black UK, Black African, Black Caribbean or Black Other. For the diabetic group, 
ethnicity wa equally matched. However, for the overweight group, tho treated ith 
Sibutramine had one Ie s White per on but an additional Black per on and vic er a F r the 
Lifestyle treated group (NS). 
Patients seen for weight loss 
Lifestyle Clinic 
Unsuccessful weight loss 
Sibutramine Clinic 
'" Female patients with and without 
T2DM completing 6 months 
weight loss programme selected 
for retrospective study 
~ 
Lifestyle Clinic 
"Successful" patients results 
entered into database 
Patients from database 
pair matched With patients 
who had completed 
Sibutramme cliniC 
Figure 5-3 Flowchart of retrospective case-control study design 
d lIe ted \\a <1\ [11 nth a thl I the durati)11 )1' Th tim p ri d \ r whi h til ata ~ere ~ 
thl.: mai n part f the Til L fe t'-I' P'lll"llt \\~re ekLled Irom a pr gramm . I .... J e < ... 
d I T he 1 I fc t., kelt nt had bel: 11 database of patient .... ~ h had c mplet t It! pr gramme, 
runnin o for a number Or) ar'> and the databa.... wa ..... 1 c mp Ill: 01 all the patient n 
through the programme by a number of different dietitians. Patients who could be most 
closely pair matched with Sibutramine patients were selected from the database. The lifestyle 
clinic ran as described in Section 3.4.11.2. 
5.6.5 Measurements 
The measurements that were taken as part of standard care and used in this analysis were 
weight, height, blood pressure and blood biochemistry. Weight was measured and recorded 
to the nearest 0.1 kg on Marsden MPHR 300 weighing scales. Height measurements were 
taken as described in section 3.4.8.1, and blood pressure as described in section 3.4.8.6. A 
fasting blood sample was taken from each patient by a phlebotomist or the author and 
analysed by the hospital biochemistry laboratory for glucose, HbA I c, total cholesterol, HDL-
cholesterol, LDL-cholesterol and triacylglycerides. 
Data on weight were extracted from the dietetic record cards. Blood pressure and 
biochemistry measurements were taken at baseline (the patients' first appointment) and then 
after six months and were used in the analysis. To investigate weight loss over time the 
weights recorded at each appointment were used for the analysis. Calculations were executed 
to determine each weight for an exact number of weeks from baseline. Interim weights were 
then calculated so that each patient had an estimated or actual weight recorded for each of the 
24 weeks. For example if a patient weighed lOOkg at week 4 then 96kg at week 8 the 
estimated weight for weeks 5, 6, and 7 could be calculated to be 99kg, 98kg and 97kg 
respectively. To make the data more comparable between the patients percentage weight 
change from baseline was calculated. 
5.6.6 Procedure 
5.6.6.1 Lifestyle Clinic 
The procedure of the Lifestyle clinic is explained in full in Section 3.4.11.2. 
5.6.6.2 Sibutramine treated patients 
Sibutramine clinic 
Patients who were unsuccessful with weight loss despite concerted effort were referred onto 
the author who screened them to see if they were suitable for the prescription of Sibutramine. 
The guidelines set down by the National Institute of Clinical Excellence (NICE .. 200 I) were 
used to produce the screening tool (Figure 6-4). If the patient met the prescription guidelines 
the author discussed the case with a hospital endocrinology physician who wrote the first 
1-l6 
pre cription for lOmg of Sibutramine for the patient. Sub equent pre cripti on were obtained 
from the patient own genera) practitioner (GP). 
Patient unable to lose weight despite 
previous serious attempts through diet KEY 
and lifestyle modification 
• Yes 
... 
Is patients BMI >30kg/m2 or >27kg/m2 ~ No 
with associated risk factors . 
... 
Is patients aged 16 - 65 years 
Continue with 
~ . appropriate diet and 
Is patient pregnant, planning on 
...,.. 
lifestyle advice 
becoming pregnant or breastfeeding ,. 
... 
Does patient have a history of CHD , 
cardiac arrhythmias or stroke 
~ 
Does patient have history of 
significant eating disorder or 
psychiatric illness 
~ 
Does patient have history of Is BP well controlled 
hypertension . on medication 
... 
Average of 3 blood pressure readings 
> 145/90mm/Hg 
1 I Recommend anti-~ hypertensive 
Sibutramine may be used to assist with 
weight loss. Dietitian discusses patient 
case history with endocrinology consultant, 
who signs first prescription for Sibutramine, 
subject to agreement of treatment 
1 
Dietitian writes to GP requesting follow on 
prescriptions for Sibutramine and providing 
information on patient status and dietetic 
monitoring procedure. 
Figure 5-4 The screening protocol for the prescription of Sibutramine 
imilar di ( and life!'>t Ie ad\i \\ t\~ gi \ en l lhe 1 alt enl'> pre'> nn\.:d Ibutr'ulline tt) tho' 
following the [i fc!'>t 'Ie inten enti n nl . '> the lmg\.: l11a.l )nt\ o/" lll) pre rit d 
Sibutrall1illc had c mplded p'lrt r a il r the ll fe'>l) It: -lJl1ll. tht: l )1 1 ' U \ LrL'd in un t IUtlll 
I I 
consultation~ with the dietitian were more flexible and individually detennined. focus,>ing 
more on the areas where the patient had struggled most and reinforcing the area,> where 
change had successfully been made. 
Patients were advised about the action of Sibutramine and with the enhanced satiating effect-. 
of Sibutramine in mind, patients were strongly advised to reduce portion sizes by eith~r 
reducing the amount of food prepared or getting used to leaving food on the plate at the end 
of the meal. In addition, it was advised to reduce snacking frequency and the amount eaten 
between meals. Advice was given, not only on the quantity of food, but also the quality of 
food consumed. The recommended diet was to reduce fat particularly saturated fat. increase 
low glycaemic index carbohydrates and have at least five portions of fruit and vegetables each 
day. Patients were therefore advised to maximise the potential of the medication and plan 
healthy meals and snacks and eat smaller quantities. 
A main aspect of the advice given focused upon the patient making gradual. but long term and 
sustainable changes, including having a constructive attitude toward,> diet and lifestyle. At 
the time of the study the patient-. were only allowed to be on the medication for up to a year 
and patients were informed that for long term success, old weight gaining habit-. had to be 
changed for new positive weight reducing behaviour pattern ..... 
Patients were seen, ideally, once every 2 weeks for the first 3 months, then on a monthly basi .... 
for the next 3 months and after that. every three months or as required. This frequency of 
visits was governed by the monitoring requirements for Sibutramine which are di .... clI'>'>ed in 
the next section. 
ii Monitoring requirements for Sibutramine. 
As Sibutramine is a relatively new medication availabl~ in the United Kingdom it-. U'>e \'> 
strictly managed and thorough monitoring procedure'> are necessary. Clo,>e monitoring \'> 
primarily required due to early reports sugg~ .... ting that there could be a dangerou..,J) high 
increase in blood pressure after the initiation of Sibutramine. which in..,tigated the 
development of specific monitoring guidelines (Figure 5-5). 
Patient commenced on Sibutramine , 
KEY to take 1 Omg daily 
,. Yes ... 
• Monitor BP and heart rate 
~ No 
• Fortnightly for first 3 months ~ 
• Monthly for next 3 months 
• Then at least every 3 months 
... 
Has BP increased by 1 Omm/Hg or 
r-- more from initial reading or is > 1451 
/ 
"'" 
90mm/Hg 
Discontinue 
treatment ~ ... 
\. .J Has heart rate increase by more than t '-- 1 Obpm from initial reading 
I ... 
I Is there evidence of 2kg weight loss ~ Consider increasing dose after 4 weeks of treatment from 1 Omg to 15mg 
I ... 
L-
---
Is there evidence of 5% weight loss 
after 3 months of treatment 
... 
Continue to monitor patient for up to a 
years treatment 
Figure 5-5 The monitoring guidelines and procedures required while a patient 
is prescribed Sibutramine 
5.6.7 Statistical analysis plan 
Re ult were analy ed in a number way. Compari on · between group w re c nducted 
u ing th 4 individual group which were; (L)SO. (L) D, LO and LD. Primaril dire t 
compari on were made where there wa a common term (S L, 0 or D), which highlighted 
pot ntial differ nee that the diagno i made on the effectivene of treatment or th effe t f 
different tr atment when there wa the arne diagno i . Therefore, to how th ffe t f th 
diagno i , tho treat d with ibutramine () ill be compared ith each other ((L \ 
(L) D) a, will tho e following Lif t Ie ad ice anI (L v . LD). Lik.ev.i . l ,,11 \\ tht 
eff f differ nt treatm nt t p , c mpari n will be mad between the \ meieht 1:,r )UP 
((L) . L ) and aLa th gr up \\ ith T _DM ((L 0 \' . L ). Limited anul i \\ ill b~ 
e\ llted wh r there i n ith r a c mm n diagn "i n r lr atm nt typ ((1) \ I 0 Jnu 
L) ~. (L) ), as r suIts r th 'e would b f liltl \ alll . 
I l 
Table 5-4 Main group comparisons to be conducted within the results 
Comparing differences in diagnosis 
(L)SO vs. (L)SD 
LO vs. LD 
Overweight vs. T2DM 
Comparing differences in treatments 
(L)SO vs. LO 
(L)SD y,>. LD 
Sibutramine treated \s. Lifestyle treated 
Additionally analysis was carried out by combining groups with common temlS. Therefore. 
all those treated with Sibutramine were compared to all those following Lifestyle adyice only 
«L)SO+(L)SD vs. LO+LD) and similarly with diagnosis «L)SO+LO v'>. (L ISD+LDL these 
combined groups will be referred to as Sibutramine ys. Lifestyle and Oyerweight y,>. Diabetic 
respectively. Table 5-4 summaries the main analysis that will occur between the groups. 
All data were entered into SPSS for statistical analysi,>. Percentage weight 1o,>,> for each 
person was calculated per week and means calculated for each group. Percentage weight 1o,>,>. 
rather than actual weight loss, was used throughout the majority of the analy,>i,>. as patient'> 
with a higher starting weight had a greater actual weight los'> due to proportionality (r=0.352. 
p=0.033) (excluding one outlier). Analysi,> of percentage weight los'> abo allowed for direct 
comparisons between the groups, unlike actual weight, where each group had a different 
baseline weight. 
Data were tested for normality and parametric testing was able to be used. Paired T -te'>ts were 
conducted to investigate change within a group and independent T-te'>ts were used to compare 
changes between groups. To compare categorical variable,>. X2 Chi-squared test'> were u,>ed. 
Weight loss and time interactions were investigated using one-way repeated mea,>ure,> 
ANOV A for weight change every -+ weeks. Pearsons correlation analysis was conducted to 
assess the relationship between continuou,> variables. 
5.7 Results 
5.7.1 Patients 
5.7.1.1 Baseline Characteristics 
All the patients in this study were female; therefore the baseline characteristics of each group 
were compared in terms of age, ethnicity, initial weight and BMI and in the presence of 
diabetes, the diabetic medication type. 
The following table (Table 5-5) summarises the baseline characteristics for each group. 
Table 5-5 Baseline characteristics of each individual group, determined by 
diagnosis and treatment type 
Group Age (years) Ethnicity (n) Initial weight (Kg) Initial 11\11 (kg/m:) 
Mean SO White Black Asian \1ean SO \kall SI) 
(L)SO 40.4 8.9 6 3 106.4 16.8 40.0 7.'1 (n= 10) 
(L)SO 
43.7 11.8 5 4 0 113.2 22.6 41. 1 6.9 (n=9) 
LO(n=IO) 38.8* to.2 7 2 100.2 16.1 37.1 'i.'1 
LO (n=9) 48.9* 8.7 5 4 0 118.3 40. 1 43.8 13.6 
*p<O.05 between the groups highlighted. (L)SO, Sibutramine overweight group; (USD. 
Sibutramine T2DM group~ LO. Lifestyle overweight group; LD, Lifest~ Ie T2D\1 group. 
All groups were well matched in terms of ethnicity. In the Sibutramine treated group. tho .... e 
with T20M tended to be slightly older and heayier that those with simple obesity (~S). Thi .... 
trend was replicated in lifestyle treated group. but those with T20\1 were .... ignificantly older 
(T=2.30. CI 0.87 to 19.3 p=0.03-t.). There \\ere no significant differences in the H\tr .... 
between any of the groups. 
5.7.2 Weight loss 
5.7.2.1 Final weight losses between groups 
\lean ahsolute and percentage \\eight changl'. and initial and final H\lr ..... well' calculated fl)(' 
each group and comhination of gl\)UP" (Tahle )-6). In addition the nUl1lhel"" and pl'rcentagc 
I:' I 
of each group achieving 5 and 10% weight loss targets were calculated. as these targets have 
been shown to have clinical significance and are achievable (SIGN 1996). 
Table 5-6 Weight loss data for each group and group combinations including 
absolute weight loss, percentage weight loss, 8MI at the start and end of the 
study period (with standard deviations) and numbers achieving 5% and 10% 
weight loss. 
Weight loss 
Achieving Achie\'ing 
Paired T-Tt" B:\II 5 Cc weight 1O(i- weight 
loss loss start to end (p) 
Kg % Start End n ()c n (' Weight B\II ( (Cd 
(L)SO (n=10) 10.74 9.66 40.07 36.00 (7.49 ) (1,74) (7.50) (5.78) 8 80 3 30 0.001 0.002 
(L)SD (n=9) 6.36 5.81 41.10 38.78 (3.10) (0.91 ) (6,94) (7.12) 6 66.6 0 0 <0.001 <0.00 I 
LO (n=10) 9.89 9.55 37.06 33.40 (7.68) (2.08) (5.49) (·l61 ) 6 60 5 50 0,003 0.002 
LD (n=9) 5.26 4,54 43.73 41.83 (3.53) (0.94) (1356) (1."144) 444 0 0 0,002 0,001 
T2DM (n=18) 5.81 5.18 42.41 (3.27) (2.77) (10.54 ) 
40.30 10 (10,55) 55.5 0 0 <0.001 <0,001 
Non-DM I 10.31 9.60 38.56 34,70 14 70 8 O'wt (n=20) (7,40) (5.91 ) (6.58) (526) ·w <0.001 <0.001 
Lifestyle 7.70 7.18 4(),21 37.39 10 52(1 5 26.3 <0.001 <0.001 (n=19) (6,36) (5.64) (10.45) (10.47) 
Sibutramine 8,67 7.84 40.55 37.31 14 n,7 3 15.8 <0.001 <0,001 (n=19) (6.11 ) (473) (7.06) (()42 ) 
All pts (n=38) 8.18 7.51 40.38 37,35 24 (J~2 8 21.0 <0.001 <O,()O I (6.18) (5.15) (8,57) (8.57) 
(L)SO, Sibutramine overweight group; (L)SD, Sibutramine T20M group; LO, Lifestyle 
overweight group; LO, Lifestyle T20M group. 
All groups lost a significant amount of \\eight and had significant changes in their \-1\1)'s 
throughout the 2-1- weeks. The owrweight groups both singularly and combined had the 
highest mean \\'eight losses. all close to I 00'c. The groups which contai ned people \\ ith 
diabetL's lost the least \\L'ight, particularly those foll(l\\ing Li fest) Ie interVL'ntion (1.1)) which 
had a mean \\eight loss of less than )I; , 
Fc\\L'I' people \\ith diabetes with both treatments (LD and (L)SI)) achic\ed 5% \\elght Ill"" 
than those \\ith simple obesit J (LO and (LlSO) (;'\S). In the Lilestyle trl',lled grllup' peoplL' 
with simpk obesity \\erl' significantly more liJ....l'I J tIl achil'\L' the lOt; weight Ill"" LlrgL't (Chi 
Sq=6.107 p=O.013) than those with T2DM. When treated with Sibutramine a similar pattern 
emerged, although not statistically significant (chi sq=3.206, p=0.073). When combining 
groups of the same diagnosis (LO+(L)SO and LD+(L)SD), similar numbers achieved 59£-
weight loss (overweight 70% vs. T2DM 55.6%) (NS), however none of the patients with 
T2DM achieved 10% weight loss whilst 40% of patients without T2DM exceeded this target 
(Chi-Sq =9.12, p<O.Ol). This demonstrated that those with T2DM were significantly less 
likely to achieve the 10% weight loss target than those with simple obesity. 
The final weight loss data clearly demonstrate that patients with T2DM lose less weight and 
are less likely to achieve weight loss targets than those with simple obesity. The next few 
sections investigate in greater depth the patterns of weight loss and when the difference in 
weight loss between groups actually occurs. 
5.7.2.2 Differences determined by diagnosis during Lifestyle intervention 
The initial aim of the investigation was to determine the impact of the diagnosis on Lifestyle 
intervention treatment efficacy, to see if there were any differences in weight loss between 
those with simple obesity and those with T2DM. Figure 5-6 presents the weight loss over 
time of these two groups. 
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Figure 5-6 Mean percentage weight loss over time in the Lifestyle treated 
groups (Lifestyle overweight (LO) and Lifestyle T2DM (LD)) with error bars 
indicating standard error of the mean (SEM) 
Figure 5-6 shows that the T2DM group had much lower weight 10 than tho e without 
T2DM whilst following the Life tyle programm. The difference bet en the group wa.., 
perceptible from the fir t few week and became greater as time progre ed. The dif~ r nc 
in weight los wa ignificant from week 11 to the end of the tudy period, week 24 (p<O.OS). 
This supports the first hypothe i which stated that whil t following Life tyle interv ntion 
patient with T2DM have greater difficulty in 10 ing weight than tho e with impIe abe it . 
5.7.2.3 Differences between Lifestyle intervention and treatment with 
Sibutramine 
Th n xl aim wa to investigate if, with th addition of ibutramin, \,\ ight I .., can be 
impro ed in tho e with impJe ob it and, p rhaps m r imp rtantl . in th e \\llh 121 I 
Overweight groups 
T determin v h ther ight 10, ~ an be impr \ d \\ ith i lItrLlllllllC 111 tho t.:: Wilh Ilnpl 
ohe ' it th (L) and gr up were Illpared ( -igure 5-7) . I hL: (1 ) , group In t 
~ignifi antI) III r weight in th fir.'.l ~ week. r treatment than the L ~n)up (p<O,04 , 'I Ill'fl' 
were no signi ficant differences at any other time point with weight 10 pattern b oming 
vi rtually indi tingui hable. At the end of the 24 week period there v as ju t 0.11 q. differen e 
in the total weight los . 
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Figure 5-7 Mean percentage weight loss over time in the overweight groups 
following different treatment (Sibutramine overweight ((L)SO) and Lifestyle 
overweight (LO)) with error bars indicating SEM 
After the immedi ate hart term effect (2 week ), th addition of ibutramine app ar<., n t t 
lead to a igni f icant improvement in weight 10 for people ith impl abe it). H \\evcr, 
tho e tr ated w ith ibutramine had pre iou un ucce ful attempt at weight 10 \\ithin the 
Lif , ty l cli nic, a were perhap mar re i tant to weight 10 from the out<.,et. The 
introduction of ibutramine ha th r for allowed ov r'Weight indi\ idual.... \Vh htH 
prev i u, ly fa iled to I e weight through life t I inter\, nti n [ I \\ Ight at the tllnc ratc 
tI .... th f r whom lif , ty le int rv nti n a ue e fuJ. 
II pati nt~ tr at d v ith ibutra1l1ine had art e \\el ht previ u I) by attt.: ndin!! thl' 
sam h ~pi t a l di teti d part1l1 nl, with III .... t ha\ pre\ I 1I I) I lIo\\eu I an. raIl. nl lhl' 
i fe .... t I PI' gra1l11l1. Th s pr .... ribed ibutramin wh had t l'cn tre<Hed \\ ith Lik t) 1 
intcnention f r greater than 10 \\ e\...s h,ld their prc\i u \\ei1:-11110 II r the III' ti e \\ 'l'l\ () 
the L ife"t Ie l inie aee unted r r; thi" prl'\'inu \\el!"!hl I) \\ill be I\lll)\\1l .t' tht.: " run-in" 
weight as it is weight loss achieved during the run-in to the present investigation. Seven of 
the 10 patients in the Sibutramine overweight ((L)SO) group had completed a to week run-in 
period and achieved an average weight loss of 0.70%. When the run-in weight loss was taken 
into consideration, no differences in the outcomes were found, with all previous findings 
maintained. 
ii Groups with T2DM 
For patients with T2DM, the introduction of Sibutramine caused greater weight loss in the 
first 5 weeks of treatment ((L)SD vs. LD) (p<0.05) (Figure 5-8), but from 6 weeks onwards 
the weight loss was statistically similar. At the end of the study period there was a 1.27% 
difference in weight loss in the two groups with diabetes, with the LD group achieving a 
4.53% weight loss from baseline weight and the (L)SD group 5.81 % weight loss. Importantly 
the difference between the groups crosses the clinically significant 5% weight loss target as 
discussed in Section 5.7.2.1. 
Sibutramine therefore induced statistically more weight loss early on in its' prescription than 
the first few weeks of Lifestyle advice alone. The addition of Sibutramine made it possible 
for patients with T2DM to achieve a mean weight loss exceeding 5%. 
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Figure 5-8 Mean percentage weight loss over time in the groups with T2DM 
following different treatments (Sibutramine T2DM ((L)SD) and Lifestyle T2DM 
(LD)) with error bars indicating SEM 
As with the overweight groups the majority of patient with T2DM had pre iou Iy attempted 
to 10 e weight in the Lifestyle clinic and again were tho e deemed un ucce ful at weight 10 
following Life tyle intervention. Seven of the 9 patient (77.8%) had adequate run-in wight 
to use in the analysis. The average weight 10 during the run-in period for tho e in the (L) D 
group wa 1.76%. Stati tical analysi wa repeated comparing the LD and (L) 0 group, 
but adju ting for the prior weight loss. With the adju [ment, the (L) D 10 t ignificantly m r 
weight than the LD group for the fir tIS week of treatment (p<O.OS). The final weight 1 ... <., 
by th (L)SD group including the run-in weight wa 7.18% compared to 4.S-+% a hie\ db 
th LD group. 
Th introduction of Sibutramin had ther fore allow d p~ tients \/vith 
pI' u Iy failed to 10 int rv Ilti n t e 
those ~ I' whom li~ st Je fuJ. Th r r r . it appear" thal lrealmt:nt 
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th s \ ith simple b ' it . 
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5.7.3 Percentage weight change combining groups with the same 
diagnoses, but different treatments 
To investigate in greater depth the impact that the diagno i of T2DM h on outcome. both 
gro ups with T2DM were combined (LD + (L)SD) and then compared 'With the ombined 
overweight groups (LO + (L)SO) (Figure 5-9). 
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Figure 5-9 Percentage weight loss over time of all patients with T2DM 
(Lifestyle T2DM + Sibutramine T2DM) and all patients with simple overweight 
(Lifestyle overweight + Sibutramine overweight) 
igure 5-9 how that tho e with T2DM 10 t Ie weight that tho e 'W ithout T2DM through ut 
the whole 24 we k p riod. The diff rence bet een the group wa ignificant fr m week. n 
(p=O.02) and r mained ignificant throughout th whole , tud . be oming highly igni fi ant 
fr m w k 17 nward (p<O.O 1). B w ek. 24 th e with T2DM had I ... t 5.1 c( ( _.77) 
b dwight whi le th e with ut T2DM had 10 t 9. 1% b dwight 5. I ) (=2 I 1.3 
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5.7.4 Percentage weight change combining groups with the same treatment, 
but different diagnoses 
To investigate the efficacy of each treatment, group of the arne treatment ha e to be 
combined (LO + LD vs. (L)SO + (L)SD). Thi compari on will indicate the eff ct of the 
Life tyle intervention compared to intervention with Sibutramine in group con i ting f 
tho e with T2DM and those without. Figure 5-10 show the re ult of thi compari on. 
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Figure 5-10 Percentage weight loss over time of all patients following lifestyle 
advice (Lifestyle overweight + Lifestyle T2DM) and all patients following 
lifestyle advice with the additional prescription of Sibutramine (Sibutramine 
overweight + Sibutramine T2DM). 
hos treated with ibutramine 10 t ignifi antI m re wight In the fir\t 
treatment (p<O.05), but the diff ren di appeared a time progre d. The p tt rn r \\ tght 
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5.7.5 Rate of weight loss and time interactions 
There was a significant and extremely strong time effect for weight loss in each group (Table 
5-7). The effect of time on weight loss was greatest in the Lifestyle treated groups and les'-, so 
in the Sibutramine treated groups. 
Table 5-7 Mean weight loss over four week periods for all patients and 
individual groups, with statistics of time interactions 
Time period All patients LO LD (L)SO (L)SD 
weeks 
0-4 -2.39 (1.69) -2.28 (1.81) -1.18(1.08) -3.58 (1.72) -2.4 I ( 1.24) 
4-8 -1.60 0.28) -2.09 (1.30) -1.39 (1.39) -1.54 (I.4lJ) -1.34 (0.70) 
8 -12 -1.33 (1.09) -1.78 (1.05) -0.92 (0.78) -1.2.+ (1.36) -1.35 ( 1.07) 
12-16 -1.15 (1.37) -1.77 (1.94) -0.60 (1.12) -1.55 (1.0'+) -0.57 (.7'+) 
16- 20 -0.63 (0.92) -1.09 (1.11) -0.12 (0.63) -0.97 (0.98) -.026 (0 . .+ 1 ) 
20-24 -0.40 (1.26) -0.54 (1.37) -0.33 (1.12) -0.79 ( 1.27) 0.12 (1.27) 
Wilks Lambda 0.26 0.07 0.07 0.11 0.11 
F 18.81 12.71 10.53 7.96 (d.~ 
P <0.0005 0.007 0.020 0.020 0.049 
Eta squared 0.740 0.927 0.929 0.888 0.888 
(L)SO, Sibutramine overweight group; (L)SD, Sibutramine T2DM group; LO, Lifestyle 
overweight group; LD, Lifestyle T2DM group. 
All groups experienced rapid weight loss initially, decreasing progressively with time. The 
Sibutramine treated groups had notably the most weight loss in the first four weeks. The 
T20M groups had generally less weight loss at each time interval than their non-T20M 
counterparts. 
5.7.6 Metabolic and blood pressure changes 
The final aim of the investigation was to ascertain the influence that the treatmenh and 
diagnoses has on the cardiovascular risk markers. 
5.7.6.1 Change in biochemistry from baseline to endpoint 
Table 5-8 shows the biochemical variables for each group and combination'. or group" at the 
start and end of the 6 month treatment period. 
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Table 5-8 Results of biochemical data collected at the start of treatment and post treatment, including means (standard deviation) 
and results of paired T-Tests of each group. 
Glucose HbAlc (%) Cholesterol HDL-Chol LDL-Chol Ratio TAG (mmol/l) (mmoVl) (mmol/l) (mmoVl) (mmol/l) 
Start End Start End Start End Start End Start End Start End Start End 
(L)SO (n=8) 5.24 5.24 5.41 5.09* 4.81 4.76 1.25 1.35 2.97 2.92 3.86 3.55 1.31 1.07 
(0.66) (0.86) (0.62) (0.60) (0.99) (0.92) (0.22) (0.22) (0.74) (0.81) (0.55) (0.60) (0.45) (0.35) 
(L)SI) (n=8) 8.83 7.56 7.79 6.78 4.40 4.39 1.45 1.38 2.19 2.49 3.38 3.30 1.65 1.28 
0.27) (2.24) ( 1.50) (2.16) (0.87) (0.94) (0.77) (0.28) (0.70) (0.96) (0.98) (0.87) (1.00) (0.55) 
to (n=9) 5.28 5.29 5.46 4.89** 4.80 4.82 1.32 1.46** 2.97 2.91 3.88 3.47 1.58 1.57 
(0.78) (0.94) (0.70) (0.68) ( 1.32) ( 1.25) (0.46) (0.43 ) (0.77) (0.60) ( 1.29) ( 1.03) (0.99) (1.14) 
LD (n=9) 7.12 6.20 7.09 6.50 5.12 5.13 1.21 1.31 3.30 2.89 4.29 4.12 1.41 1.73 
( 1.77) (1.28) ( 1.31 ) (0.76) (0.66) (1.02) (0.20) (0.34 ) (0.48) (0.78) (0.75) ( 1.25) (0.64) (1.41 ) 
T2D\1 (n= 17) 7.93 6. X"+:: 7.44 6.64* 4.78 4.78 1.33 1.34 2.78 2.70 3.86 3.73 1.53 1.51 
(2.65) ( 1.87) (1.41) ( 1.58) (O.S3) (1.03) (0.54) (0.30) (0.81 ) (0.86) (0.96) ( \.13) (0.83) ( 1.07) 
'\;on-I>\I 5.26 5.26 5.44 4.98** 4.81 ..+.79 1.29 1.41 ** 2.97 2.91 3.87 3.51 * lA6 1.33 
(n=17) (().70) ((l.S7) (0.64) W.(3) ( 1.1..+) ( 1.07) (().34 (0.34) (0.73) (0.69) (0.99) W.X3) (0.77) (0.88) 
Lifl,,,t\ Il- 6.20 5.7"+ 6.27 5.6()* ..+.96 4.98 1.27 1.38 3. I3 2.90 4.09 3.79 1.50 1.65 
(n=IX) (\ .6.~) ( 1.89) ( 1.32) ( 1.(9) (1.03) ( 1.12) (0.33) (().38) (0.64 ) ({).67 ) ( 1.(5) ( 1.16) (O.S2) ( 1 .25) 
Si hll t rami Ill' 7 .().~ 6.40 6.67 5.98* 4.61 4.58 1.35 1.37 2.58 2.70 3.62 3A2 IA9 1.18 
(n= 16) (2 t H) (2.().~ ) ( 1.(7) ( 1.80) (0.93) (0.92) W.56) W.24) (C).80) (0.89) ((U~ I) (0.73) (0.7(» (0.46) 
--
\11 pt" (n=34) (l.5!) 6.05* h.47 5.83** 4.80 ..+.79 1.30 1.37 2.87 2.81 3.87 .H)2 I A!) 1.43 
(2 .. Q) ( 1.65) ( 1.4!» ( 1.46) W.(8) ( 1.03) (0.45) ( 0.32) (0.77) (0.7X) ((). ()o) ((). !)!» ((). 7(» (0.(0) 
*pdl.O~. **pdl.(11 (LlSO, Sihlltraminl' ()\l'rwl'ight group; (LlSD, Sibutramine T2Dl\1 group; LO, Lifestyle ovenVl'ight group; LD, Lifl'Styll' 
'1'21>\1 group. 
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Over the 24 week period, all biochemistry tended to improve in conjunction with the weight 
loss that occurred throughout the 6 months treatment period. Fa.<-,ting glucose improved in all 
groups with the exception of the LO group which had a minor increase of 0.0 I mmol!1. The 
fasting glucose improved significantly for all patients collectively and for those with T20M. 
All groups and combinations of groups showed significant improvements in HbA I c. except 
for the individual groups with diabetes «L)SD and LD), who had improvements, but did not 
reach level the of significance, possible due to the small numbers involved. 
All markers of lipid metabolism tended to improve. Total cholesterol changed marginally 10 
all groups, but the cholesterol profile improved to a greater degree. HOL-cholesterol le\el 
increased significantly in the non-T2DM group and the LO group. it also increased in all 
other groups except the (L)SD group, where it worsened slightly, although not significantly. 
There were no significant changes in the LOL-cholesterol in any of the groups O\l'r the 6 
months, but they mostly tended to decrease. The changing lipid profile caused every group'." 
ratio of total cholesterol to HOL-cholesterol to decrease. significantly so in those without 
T2DM. There were no significant changes in triacylglycerides. although again. most group" 
had an improvement, with the exception of the Lifestyle treated group as a whole and the LO 
group. 
5.7.6.2 Analysis of biochemical changes between groups 
The fasting blood glucose of people with T2DM decreased by 1.08mmol!l (SO 1.99), whibt 
those without T2DM had a decrease of just 0.01 (SO 0.45) ('1'=2.2. ('I 0.08 to 2.09. p=0.035). 
However when the change in fasting glucose was calculated a" a percentage of starting 
glucose, the significance disappeared (J=2.0, ('I -0.32 to 20.5-+. p=0.057). There were no 
other significant differences in biochemical change between the groups. 
5.7.6.3 Correlations between weight loss and change in biochemistry 
There were no significant correlations between percentage weight los" at the end of the "tud) 
and the change in any biochemical markers (Table 5-9). probably due to the "mall "ample "ill' 
in\'olwo and the wide variation in data. 
r 
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Table 5-9 Correlations between percentage weight loss at 24 weeks and 
percentage change in biochemical markers 
Clueose HbAle T-Chol HDL-Chol LDL-Chol Ratio T \{; 
0.077 -(). 172 0.003 -(). 1 ~() () 107 0.224 ()()Sl) 
0.67 0.32 0.99 0.31 ()~'i o 20 0.61 
De pite the lack of significant correlations, the analy i indicate that with weight 10 there 
tended to be an improvement in all biochemical variable except HbA I c. 
5.7.6.4 Blood pressure 
Elevated blood pressure is an independent ri k factor for coronar e ent (KPD tud 
Group t 998c; Adler et aI., 2000). The LO group had the highe t initial and final blo d 
pressure in the study, but it is the only group that doe not have trict guidelin n blo d 
pressure management. It is recommended that people with T2DM hould maintain blo d 
pressure below 140/80mmlHg (Hutchinson A., 2002) and for the continued pre cripti n of 
Sibutramine the blood pressure ha to remain below 14S/90mmlHg, the e guidelin c v r 
each of the three remaining group. 
-
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Figure 5-11 Blood pressure readings at the start of treatment and the end of 
treatment 
Th r suIt ( igure 5-11 ho that tolic bl od pre~~ure d r a ed In all gr up ( ) '1 h~ 
dia. t Ii bl (L) 0 e.r up and lht.: I r up and r~l1lai lll!d 
irtuall lin hang d for the L) group ( ). The L gr up e I enen ed an in 1"I.:a e in 
dia~t Ii hI d pre~ ... ure fr m 77mnllIle t 1.9mnll11g ( . . '1 h ha din> and final hlot I 
pressure and the changes in blood pressure were not significant either within the groups or 
between the groups. 
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5.S Discussion 
5.S.1 Simple obesity versus T2DM following lifestyle intervention 
This study has shown that significant and clinically important weight loss rates can be 
achieved in patients following a Lifestyle intervention. However those with T2DM lost 
significantly less weight than those without diabetes. The difference was small initially but 
increased as time progressed. In addition people with T2DM were significantly less likely to 
achieve the clinically important 10% weight loss targets. These findings support a consensus 
that people with T2DM have greater difficulty in losing weight than their non-diabetic 
counterparts (Wing et al., 1987; Guare et al., 1995; Hensrud, 2001). 
There are a number of potential reasons why people with T2DM have greater difficulty in 
losing weight than those without diabetes. One hypothesis suggests that people with T2DM 
have a reduced resting metabolic rate (RMR), which in itself has been implicated with weight 
gain (Ravussin et al., 1988). Investigations into energy expenditure however, have found 
that there are no differences in RMR between those with T2DM to those without (Fontvieille 
et al., 1992; Bitz et al., 2004). Indeed after adjustment for fat-free mass, fat mass, age and sex 
both of these studies actually found that people with T2DM had an increased sleeping energy 
expenditure and basal metabolic rate than those without diabetes, therefore eliminating this 
hypothesis. Another suggestion as to why weight loss may be slower in people with T2DM is 
because of altered fatty acid metabolism, but this has been attributed more to the iatrogenic 
effects of treatment with sulphonylureas than to the diabetes itself (Avignon et aI., 2000). 
Marked insulin resistance for those with T2DM could be a physiological reason for the 
reduced weight loss compared to those without diabetes. By virtue of the diagnosis, those 
with T2DM will be more insulin resistant than those without T2DM, reducing weight loss 
through a number of mechanisms. To maintain blood glucose within normal physiological 
ranges hyperinsulinaemia occurs in those who are insulin resistant, however high levels of 
circulating insulin are more likely to result in weight gain rather than loss. To ascertain the 
full implications of endogenous insulin levels and insulin resistance on weight loss these 
variables should be measured. 
Other, perhaps more tangible, reasons for the difference in weight loss between those with 
and without diabetes are the complex psycho-social factors regarding weight. People with 
T2DM generally have a long history of overweight and obesity, often having tried numerous 
weight loss strategies. As unsuccessful attempts at weight loss mount, self confidence in 
ability to achieve targets tends to diminish. Therefore when patients with T2DM are referred 
for weight loss, often they expect to fail, which influences their ability to succeed. Also there 
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is a greater push from the medical profession to encourage weight loss in the presence of 
T2DM compared with simple obesity. This is because diet and lifestyle seem to have higher 
priority with this co-morbidity. From experience, patients who are overweight and have 
T2DM are more likely to be referred to dietitians for weight loss advice by the medical 
profession, without the patient expressing a direct wish to lose weight. However people in a 
dietetic clinic who are overweight, but do not have T2DM, are more likely to have actively 
sought dietetic support for weight loss themselves and therefore be more prepared and 
motivated to lose weight. People with T2DM often experience a range of emotions including 
depression and gUilt which may impact on their ability to lose weight (West and McDowell, 
2002). It has been suggested that dietary restriction, unsuccessful attempts at weight loss and 
weight fluctuations are in fact physiologically damaging to people with T2DM (Clark, 2004). 
The full effect of psychological factors that prevent weight loss in people with T2DM needs 
further investigation. 
Sociological issues compound the problem of weight loss in people with T2DM. For the 
large majority of people who develop T2DM, there is a long history of diet and lifestyle 
factors that drive the condition. These are largely a poor diet, with an excess of energy and 
low levels of physical activity. These longstanding lifestyle factors are extremely hard to 
change, more so in people with T2DM rather than those with simple obesity as they are likely 
to be more established (Vijan et aI., 2005). 
The difference in age and starting weight between those with and without T2DM were 
confounding factors in the study. In the lifestyle treated groups, those with T2DM were 
significantly older than those without T2DM and weighed, on average, 18kg more, which 
although was not significant is likely to be a result of a type 1 error, rather than an absence of 
a true difference. As age increases the body composition changes; there is an increase in the 
proportion of fat mass and a decrease in muscle mass (Gallagher et aI., 1996). Fat is 
metabolically inactive compared to muscle, therefore the change in body composition causes 
a decrease in the basal metabolic rate, which can make weight loss more difficult. In 
addition, as obesity increases, activity levels decrease (Prentice and Jebb, 1995; Heini and 
Weinsier, 1997) which reduces energy expenditure and again makes weight loss more 
difficult. The difference in age and initial body weight between those with and without 
T2DM was greater in the Lifestyle treated groups, than the Sibutramine treated groups. 
However the difference in weight loss was so pronounced that it is fair to conclude that 
people with T2DM find it significantly more difficult to lose weight. resulting in slower and 
less weight loss. 
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5.8.2 Addition of Sibutramine 
Both groups treated with Sibutramine had unsuccessful previous attempts to lose weight via 
the Lifestyle programme, which was a unique feature of this investigation, as previous studies 
have selected patients who were overweight, then randomly assigned them to treatment. 
Patients in this study may be more resistant to weight loss, and lose less weight with 
Sibutramine, than an overweight group who had not been through an intensive programme of 
advice. 
5.8.2.1 Effect in overweight groups 
The addition of Sibutramine in the overweight group led to a significantly greater weight loss 
in the first couple of weeks, indicating that the medication has the greatest influence early in 
its use. After the first couple of weeks the pattern of weight loss for both overweight groups 
was very similar and virtually indistinguishable in the last 10 weeks of the intervention 
period. From this two main conclusions can be made. Firstly, the results indicate that people 
who are overweight can, with the correct treatment, successfully lose nearly 10% body 
weight. Initially the treatment should be intensive diet and lifestyle but if this is unsuccessful 
other solutions should be sought, such as medication. Secondly it suggests that weight loss 
patterns are fairly predictable when a treatment is successful. The amount of weight loss 
found in this study is comparable to or greater than that of similar patients in other studies 
(James et aI., 2000; Hauner et aI., 2004). The fact that the weight loss matched or exceeded 
that found in other studies is a very positive finding, as these patients were previously found 
to be resistant to weight loss. The encouraging results are likely to be due to a combination of 
the prescription of Sibutramine and the continued intensive diet and lifestyle advice received 
in a dietetic outpatient department. 
5.8.2.2 Effect in T2DM groups 
The effect that Sibutramine had on people with T2DM was more pronounced than those 
without diabetes. There was a significant difference in amount of weight lost early on in the 
treatment period, but this disappeared a quarter of the way through, likely to be a result of the 
small sample size. Vitally, at the end of the study, the mean weight loss of the group treated 
with Sibutramine was greater than the clinically significant 5% weight loss target (SIGN 
1996). In the Lifestyle treated groups there was a significant difference in weight loss 
between those with and those without T2DM. a difference which was lost with the addition of 
Sibutramine. 
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Patients who do not achieve specific weight loss targets in the Lifestyle clinic are discharged 
before completing the six month programme. Therefore the patients from the Lifestyle 
programme involved in this study were those deemed to be successful. The successful 
Lifestyle patients with T2DM did not achieve an average of 5% weight loss. Patients treated 
with Sibutramine were those who failed to lose weight in the Lifestyle clinic and therefore 
deemed to be more resistant to weight loss; however this group managed to exceed the 5% 
weight loss target. It could be argued that in the correct circumstances patients with T2DM 
who wish to lose weight should be given the best opportunity to do so, which may involve 
having a first line treatment of Lifestyle intervention in conjunction with pharmacotherapy, 
rather than just Lifestyle advice alone. It is predicted that this more aggressi ve treatment 
would achieve greater weight loss in patients most receptive to advice (the 'successful' 
patients in the Lifestyle programme) and at least 5% weight loss in those most resistant. 
5.8.3 Weight loss patterns 
The one-way repeated measures ANOVA's showed that all groups followed a similar pattern 
of weight loss, which is rapid initially and slows with time. Weight loss strategies therefore 
appear to be most effective in the few months after initiation, independent of treatment type, 
suggesting that a "pulsing" of weight loss interventions may produce greater results. The 
STORM study (James et aI., 2(00) showed that treatment with Sibutramine beyond the six 
month period was effective in allowing weight to be maintained, but not to be decreased 
further. Intermittent treatment with Sibutramine has been tested in one study (Wirth and 
Krause, 2001). where Sibutramine was prescribed for 12 week periods with 6 a week break. 
This study showed that there was no difference in weight loss between those patients treated 
intermittently to those who were treated consistently. Therefore speculatively, if a 6 months 
weight loss phase was alternated with a 6 months weight maintenance phase, weight could be 
reduced in a stepwise fashion. The weight loss phase could involve medication in 
conjunction with diet and lifestyle modification, whilst the weight maintenance phase would 
continue with the diet and lifestyle changes but without the medication. However this 
treatment plan has the potential to be labour, cost and time intensive and would require 
consistent commitment and motivation from the patient and health professional. The 
treatment of obesity would need to shift from short term quick remedies to long term 
management of a chronic condition. 
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5.8.4 Biochemistry 
5.8.4.1 Glycaemic control 
The HbAlc showed the most improvement in biochemistry, which is both cIinicalJy and 
financialJy important for people with diabetes. When the HbAlc approaches 8%, more 
aggressive management of glycaemia is considered. AlJ patients with T2DM in this study 
were treated with OHA, with most being on maximum, or near maximum doses. The initial 
HbAlc in these patients was 7.44%, not far from the point at which treatment with insulin 
would be considered. By the end of the study period, the HbAlc decreased significantly to 
6.64%, indicative of much better glycaemic control. It has been shown that HbAlc decreases 
proportionally to weight loss (Fujioka et aI., 2000; Serrano-Rios et aI., 2002; McNulty et al., 
2003), and indeed those with T2DM treated with Sibutramine who lost more weight had 
larger decreases in HbAlc that the Lifestyle only group (1.01 % and 0.59% respectively). The 
1 % decrease in HbAlc with a 5% weight loss compares welJ with a review paper titled "The 
importance of obesity in diabetes and its treatment with Sibutramine. " (Van Gaal and Peiffer, 
2001). This paper showed that a weight loss of 5% resulted in approximately a 1.2% decrease 
in HbAlc, when weight loss increased to 10% initial body weight, the corresponding decrease 
in HbAlc was approximately 1.7%. This is important as the UKPDS (Stratton et aI., 2000b) 
showed that a 1 % in HbA 1 c was associated with a: 
• 21 % reductions in risk for any end point related to diabetes 
• 21 % for deaths related to diabetes 
• 14% for myocardial infarction 
• 37% for microvascular complications 
The results showed that the risk for microvascular disease was greater than that of 
macrovascular disease as glycaemic control worsened, but that any reduction in HbA 1 c is 
likely to reduce the risk of complications, with the lowest risk being when the HbA 1 c is less 
than 6%. This builds the argument towards more aggressive management of weight loss in 
people with T2DM through use of pharmacotherapy such as Sibutramine. The greater weight 
loss results achieved with pharmacotherapy consequentialJy causes larger reductions in 
HbA I c and the small initial outlay of the medication reduces long term costs through much 
reduced rates of mortality and severe co-morbidities. 
5.8.4.2 Lipids 
The lipids showed a consistent tendency towards improvement with weight loss. but few of 
the changes were significant. The HDL-cholesterol improved significantly in people without 
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T2DM, particularly in those following Lifestyle intervention, which can be attributed to 
higher levels of physical activity in the Lifestyle group. Physical activity, even at a modest 
level, has been shown to have a beneficial effect on HDL-cholesterol, particularly in women 
(Skoumas et aI., 2003). Increased physical activity is recommended with both treatments; 
however the Lifestyle only group, in contrast to the Lifestyle group treated with Sibutramine, 
had an exercise tolerance test both at the start and at the end of the treatment period, which 
has shown a highly significant increase in exercise tolerability (Frost et al., 2002). The 
additional motivational factor of knowing that exercise tolerance will be repeatedly measured, 
could mean that those in the lifestyle groups adhered more to exercise recommendations than 
those in the group treated with Sibutramine. It is suggested that to improve treatment efficacy 
further with Sibutramine, exercise tolerance should be measured periodically. 
There are two reasons why the changes in lipids were not significant. Firstly the study was 
not powered to identify significant changes in lipids and secondly derangements in lipid 
profiles tend to be intensively treated, particularly in those with T2DM. If a lipid variable 
was outside clinical recommendations, treatment with a counteractive medication is likely to 
be instigated. Despite the lack of significant changes, there was a consistent trend towards an 
improved lipid profile. This is to say that total cholesterol decreased, as did LDL-cholesterol, 
the ratio between total to HDL cholesterol and triacylglycerides, whilst the HDL-cholesterols 
increased. The culmination of all these changes would decrease the risk of obesity related co-
morbidities. 
5.8.5 Blood pressure 
Blood pressure tended to be well controlled at the start of the investigation and improved 
throughout. As with lipid variables, blood pressure is strictly controlled, especially for 
patients with T2DM and by virtual of the prescribing guidelines, for those prescribed 
Sibutramine 
Systolic and diastolic blood pressure tended to improve in all groups. A reduction in blood 
pressure is particularly important for those in the Sibutramine treated groups as early research 
suggested that Sibutramine caused an increase in blood pressure (Hansen et aI., 1998; James 
et aI., 2000; McMahon et al.. 2000). It is proposed that rather than a slight increase in blood 
pressure in the majority of people, it is perhaps the large increases in blood pressure 
experienced by a small minority which triggered the conclusion that Sibutramine causes 
blood pressure to rise. Abiding by the NICE guidelines (NICE. 2001) Sibutramine was 
discontinued for all patients who experienced large increases in blood pressure (>lOmmIHg 
or > I 45/90mmlHg). As changes in blood pressure tend to occur early on in the prescription 
of Sibutramine patients are unlikely to reach six months treatment. therefore would not be 
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eligible for this study. In addition it has been shown that blood pressure does not tend to 
increase in patients on Sibutramine when weight loss exceeds 5% (Fujioka et at., 2(00). 
Favourably, blood pressure tended to decrease with weight loss as a result of Lifestyle 
intervention and treatment with Sibutramine. Recommendations to monitor blood pressure 
during the treatment of Sibutramine are supported, for the identification of patients who 
experience a marked increase. However for the majority of patients, Sibutramine resulted in 
significant weight loss which results in a reduction in blood pressure similar to that seen with 
weight loss without pharmacotherapy. 
5.8.6 Limitations 
There were a number of limitations with the study that need to be considered when 
interpreting the results. Firstly the sample size was small, especially when conducting 
analysis for the individual groups. The small sample size could lead to type I errors, meaning 
that the results show that there was no difference between the groups, where in fact there is 
one; this limitation would be remedied by increasing the sample size. Calculations were 
made to estimated the weight loss between appointments; this assumes that weight loss is 
consistent between each appointment. This assumption could have affected the analysis when 
comparing the weight loss per week between the groups and when calculating the rate of 
weight loss. Despite this, the calculated weight loss per week is seen as the ideal compromise 
as the more accurate alternative would involve weighing each patient every week, which is 
not representative of or replicable in the clinical setting. 
There were a couple of confounding variables in the study. Firstly there was the age and 
weight difference of those with T2DM compared to those without, particularly in the 
Lifestyle treated group. Although no significant difference was found in age or BMI, it is 
likely that this is due to a type I error, that is to say that there were no differences found 
where there was in fact one present. An increase in sample size is likely to have revealed a 
statistical difference in both age and BMI. The effect that this had on the analysis was 
discussed in section 5.8.1. Another confounding variable was the fact that those treated with 
Sibutramine had more direct contact time with either the author who is a dietitian or at their 
GP surgery. This is as a result of the monitoring requirements of Sibutramine, which in the 
first 3 months state that blood pressure and heart rate needs to be measured. In comparison 
patients in the Lifestyle programme were seen 6 times over the six month period (monthly for 
the first 4 months, then 6 weekly for the last 2 appointments). The difference in contact time 
between those in the Sibutramine treated group to those in the Lifestyle group is compensated 
by regular phone calls from the dietitian to the patient in the Lifestyle treated group. 
Therefore although there is less direct contact in the Lifestyle group, the patients have similar 
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levels of support, opportunities to ask questions or raise concerns and access to diet and 
lifestyle advice. 
The screening process for the Lifestyle clinic aims to enrol people who are committed to 
weight loss, despite this, there is usually a large drop out rate, due to patients either not 
meeting weight loss requirements or not fulfilling the criteria of the clinic, such as attending 
appointments or keeping a food diary. Therefore, patients who complete the Lifestyle 
programme are those who are most motivated and most determined to lose weight, essentially 
making it a highly selected group. This does not diminish from the success of the Lifestyle 
clinic, but explains in part the success of the clinic. The patients treated with Sibutramine 
were those who were unsuccessful in the Lifestyle clinic, and therefore were perhaps less 
motivated to lose weight. In effect the Sibutramine group was less selective, therefore 
making the difference in weight loss between the groups smaller. To overcome this, a similar 
investigation could be carried out, but designed as a randomised control trial. 
5.8.7 Future work 
The findings of this investigation stimulate further research. The weight loss of those on 
Sibutramine exceeded those in the Lifestyle clinic and those treated with Sibutramine had 
been previously unsuccessful in the Lifestyle clinic. A randomised control trial would reveal 
the added benefit that Sibutramine has on weight loss without selecting those patients who are 
most resistant to diet and lifestyle advice. 
To treat obesity effectively the underlying cause needs to be elicited. Further investigation 
into the psychological and sociological reasons as to why people with T2DM find it difficult 
to lose weight, would help improve treatment strategies. 
5.8.8 Conclusion 
Intensive Lifestyle intervention can result in clinically and statistically significant weight loss 
in women with simple obesity but for those who are unsuccessful, treatment with Sibutramine 
should be considered. However, those presenting with T2DM are likely to be more resistant 
to Lifestyle advice alone and, if appropriate, may benefit from additional pharmacotherapy at 
an earlier stage than those without T2DM. This suggests that the NICE guideline stating that 
Sibutramine is 'only for people who have made previous serious attempts to lose weight' 
should be reviewed for people with T2DM. For patients with T2DM, unassisted attempts at 
weight loss are likely to be ineffective and will delay the likelihood of success with more 
aggressive intervention. 
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6 Overall Discussion 
Obesity and T2DM are the major world wide health problems that are increasing in 
prevalence each year. Treatments for managing the effects of obesity and T2DM are 
improving, but these tend to focus upon remedying individual co-morbidities, rather than 
treating or reversing the actual cause, obesity. It will be difficult to turn the tide on the 
obesity epidemic as it requires a supportive environment and a transformation in societal 
attitudes and opinions as well as huge motivation at the individual level to execute long term 
behaviour change. The gap between an environment that enables easy maintenance of a 
healthy body weight and the obesogenic customs of modern day life is progressively 
widening. Although there are many attempts to reverse the obesity trends these fade into 
virtual insignificance against the barrage of convenient energy dense high fat, high sugar 
foods and labour (energy) saving devices. The effects of obesity can, to a certain extent, be 
treated but come at a great personal, social and financial cost. Until recently obesity had not 
been tackled head on by health service providers, perhaps due to the inherent difficulties in 
achieving and maintaining weight loss and the lack of an evidence base on effective treatment 
strategies. As the problems of obesity have increased in profile and entered the public 
domain, perhaps the next step is to implement long term treatment strategies to prevent those 
of a healthy weight from becoming overweight and prevent the overweight from gaining more 
weight i.e. to aim for weight stability rather than promote weight loss. The changes need to 
be implemented consistently at every level from the Government to society and health service 
providers to individuals. 
There are distinct interrelationships between obesity, T2DM and cardiovascular disease. It is 
known that obesity has a direct causal influence on the development of T2DM through the 
release of free fatty acids and cytokines from adipose tissue which cause insulin resistance in 
body tissues and damage to pancreatic ~-cells which reduces insulin production. The same 
associating factors between obesity and T2DM cause a clustering of CVD risk factors; as a 
result, 80% of people with T2DM die from cardiovascular complications (Barnett, 2003). 
Although the mechanisms through which people gain weight and develop T2DM and CVD 
are vitally important, the focus of this thesis was on assessing dietetic treatment and assessing 
their clinical outcomes. 
Insulin therapy is used extensively to gain better glycaemic control for people with T2DM to 
reduce microvascular disease risk. However, the irony is that insulin therapy causes clinically 
and statistically significant weight gain which could negatively impact upon overall CVD 
risk. This thesis aimed to investigate the impact of insulin therapy on glycaemic control. 
173 
body weight and CVD and tested an intensive dietetic intervention to see if insulin induced 
iatrogenic weight gain could be prevented. 
The first aim was to gain an understanding of how insulin therapy affects glycaemic control. 
Through use of a continuous glucose monitoring system it was found that insulin therapy did 
not improve glycaemic control over 24 hours when compared to oral hypoglycaemic agents, 
instead it led to a wider daily variation in glycaemia. This suggests that insulin therapy may 
be inadequate in improving or achieving optimal glycaemic control. The complexity of 
T2DM, in particular with regards to insulin resistance, can make it extremely difficult to 
achieve good glycaemic control particularly as the disease progresses. Insulin therapy causes 
weight gain, which can worsen insulin resistance causing deterioration in glycaemic control 
and increasing the need for higher daily doses of insulin. This can result in very large doses 
of insulin required to normalise hyperglycaemia and can initiate a negative self-perpetuating 
cycle. The lack of improvement in glycaemic control with insulin therapy opposes those 
found in the largest investigation of treatment options for people with T2DM, the UKPDS 
(UKPDS Study Group 1998a). In the UKPDS glycaemic control was significantly improved 
with insulin therapy and after a similar duration of insulin treatment, the HbA 1 c remained 
over 1 % lower than in this study. One of the main differences in the patients of the UKPDS 
and the patients involved in this study were the baseline demographics, particularly body 
weight and BMI. The UKPDS population had an average BMI of 27.8kglm2 compared to a 
mean BMI of 37.0kg/m2 in this study. This fact alone is likely to increase the likelihood that 
the greater adiposity was a major contributory factor in preventing optimal glycaemic control 
in our study population. This finding led to the next investigation which focussed upon 
changes in body weight that occurs following the initiation of insulin therapy. 
Obesity management should be the cornerstone of treatment for T2DM, and is arguably more 
important as adiposity increases. Therefore, the next aim was to investigate whether it was 
possible to prevent weight gain following the initiation of insulin therapy with an intensive 
dietetic intervention. A comparison of cardiovascular risk outcomes of patients who followed 
standard care to those followed the intervention were analysed. The Lifestyle programme 
was effective in preventing iatrogenic weight gain; however such programmes are time 
consuming and require the individual to be receptive to advice and willing to make major 
lifestyle change. The benefit of the Lifestyle programme over that of standard care was 
apparent not only with weight, but also quality of life and the reduced need for additional 
medications. However, the analysis of cardiovascular risk outcomes were masked due to the 
intensive pharmacological treatment of individual risk factors in patients with T2DM 
followed in a tertiary treatment centre where this study was carried out. Despite this. 
outcomes tended to be more favourable and required less medical intervention in those who 
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followed the Lifestyle programme compared to those who had standard care. The provision 
of dietetic led intensive weight management clinics urgently need to be implemented 
nationwide. The National Service Framework (NSF) for diabetes (Department of Health 
2(01) states that structured care programmes are required for adults with diabetes; which 
could encompass dietetic led Lifestyle programmes. Dietitians provide an excellent resource 
to impart patient education in diabetes and weight management, and would require only 
minimal further training to become specialists within this area. Therefore at a relatively small 
cost the health service could work towards the targets set by the NSF and provide Lifestyle 
programmes which have proven clinical benefits and have the potential to reduce long term 
financial consequences. 
As knowledge expands new independent risk factors for cardiovascular diseases are 
identified, one of which is impaired postprandial metabolism. It is known that T2DM causes 
an alteration in postprandial metabolism which increases CVD risk, but it was not known how 
the initiation of insulin therapy affects postprandial metabolism, which was investigated in a 
pilot study. The pilot study showed that in the first six months of insulin therapy postprandial 
metabolism improved, regardless of the degree of weight gained. However the study did not 
ascertain whether there would be an additional benefit to postprandial metabolism if the 
patient lost weight in the period immediately after starting insulin therapy. Insulin resistance 
in these patients may be improved with weight loss, at the same time the insulin insufficiency 
is corrected with insulin therapy. Therefore, if weight loss could be achieved at this treatment 
time, both aspects of T2DM are being tackled and postprandial metabolism could improve 
further. This theory however, would require requires further investigation in a much larger 
sample of subjects. The Lifestyle programme was effective in preventing iatrogenic weight 
gain at the time insulin therapy was initiated, but subjects tended not achieve weight loss. 
This finding led to the evaluation of a more intensive weight loss strategy using 
pharmacotherapy to investigate whether the use of additional drugs could enable people with 
T2DM to lose weight. 
The final aim of the thesis was to assess the efficacy of two dietetic led weight loss 
interventions in people with and without T2DM. This showed that the addition of 
pharmacotherapy within a dietetic setting enabled greater weight loss for patients with T2DM 
than those following Lifestyle intervention alone. In addition, it was shown that people with 
T2DM seem to have greater difficulty in losing weight than those without diabetes; therefore 
obesity for those with T2DM should be tackled more aggressively from the outset. perhaps 
having a similar approach as hypertension treatment. If a patient with T2DM has high blood 
pressure. antihypertensive agents are continually added until the blood pressure is adequately 
controlled. However with regards to obesity, patients are often told to lose weight. but 
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relatively few are fortunate enough to have access to intensive dietetic programmes that 
would give them the skills and knowledge they require in order to change their diet and 
exercise patterns. In the clinical setting, if patients are not successful in losing weight. 
treatment is often withdrawn rather than intensifying, contrary to blood pressure management. 
This study has shown that it is possible to determine whether a weight loss strategy will be 
successful during the first 10 weeks of treatment. If there are no signs of success. then other 
more intensive strategies should be offered immediately rather than the current 6 months 
treatment plans or even worse, being discharged from care. It should be recognised that in 
certain circumstances maintenance of body weight is a valued treatment goal and should be 
regarded as a success. As more weight loss remedies become available and new strategies are 
learnt, a greater number of options will be accessible to enable each patient to be matched to 
the best treatment type. However, currently being able to triage patients into the optimal 
treatment strategy that would suit them is far from ideal. 
The dietetic outpatient framework provides an ideal forum in which patients can be screened 
and monitored for medications such as Sibutramine. In addition, new skills such as 
motivational interviewing techniques can be learned to increase the choice of methods 
dietitians can use to encourage weight loss. The role of the dietitian can successfully be 
extended to maximise the available resources and optimise outcome, however dietitians may 
have to shift work practices to encompass new skills. 
Diabetes is a multifactorial disease which is caused and exacerbated by obesity and physical 
inactivity. The resolution of obesity is not given high enough priority as change is difficult to 
achieve. Pharmacotherapy is constantly being developed which successfully tackles the 
single negative outcomes of obesity and diabetes. Diet and lifestyle modification however 
has a smaller effect on the individual entities than pharmacotherapy, but provides a holistic 
benefit to numerous factors which is difficult to quantify. Obesity is a chronic condition 
which requires long term management and should be treated earlier in the pathogenesis of 
T2DM. or preferable before the development of the disease, as this could prevent negative 
clinical outcomes and ultimately reduce financial and personal costs. 
6.1 Further work 
The individual studies of this thesis provide the impetus for considerable future research. The 
overriding theme that requires further investigation regards the influence of weight loss on 
insulin resistance and ultimately treatment success. Intervention studies of aggressive weight 
loss treatments in people with T2DM are needed. For example. a similar investigation of 
patients with T2DM who are starting insulin therapy could be undertaken. but including 
treatment with Sibutramine in conjunction with Lifestyle advice. This would determine 
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whether weight loss could be achieved at time insulin is initiated with similar analysis of 
cardiovascular outcomes and postprandial metabolism. 
In addition to intervention studies, investigations into the effects that insulin resistance has on 
treatment efficacy and clinical outcomes are required. This included investigating how 
insulin resistance affects the success of medical treatments, such as insulin therapy. and of 
dietetic interventions such as the Lifestyle clinic. 
Obesity and T2DM continue to stimulate much research. However due the difficulties 
experienced in treating obesity and limited resources. the effect of obesity and obesity 
management on T2DM is a relatively neglected area, which needs further investigation. 
6.2 Conclusion 
Obesity and T2DM are increasing in prevalence to pandemic proportions. Sadly current 
medical treatments focus upon patching over the clinical outcomes with vast polypharmacy 
rather than treating the direct cause. Effective weight management should be the cornerstone 
of treatment for obesity and T2DM, but this requires long term, consistent commitment from 
the individual and health practitioners. An increasing number of weight loss strategies are 
available for those patients who are moti vated to seek them out, but more resources are 
required from the National Health Service to implement adequate facilities nationwide. 
Alongside the weight loss remedies there need to be a shift in the paradigm of the medical 
profession towards preventative rather than curative medicine and holistic rather than 
condition focussed treatment. 
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Appendix A: Examples of Minimed analysis 
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Appendix B: Table for randomisation 
Number Sex Ethnicity Treat Number Sex Ethnicity Treat 
1 MC Male Caucasian Intervention 1 FC Female Caucasian Intervention 
2MC Male Caucasian Intervention ~FC Female Caucasian Intervention 
~MC Male Caucasian Control ~FC Female Caucasian Control 
~MC Male Caucasian Control 
5MC Male Caucasian Control 
6MC Male Caucasian Intervention 
~MC Male Caucasian Control 
~MC Male Caucasian Control 
SMC Male Caucasian Intervention 
~FC Female Caucasian Control 
~FC Female Caucasian Intervention 
~FC Female Caucasian Intervention 
lIFC Female Caucasian Intervention 
If! FC Female Caucasian Control 
~FC Female Caucasian Control 
10 MC Male Caucasian Intervention 10 FC Female Caucasian Control 
11 MC Male Caucasian Control 11 FC Female Caucasian Intervention 
12 MC Male Caucasian Intervention 12 FC Female Caucasian Control 
13 MC Male Caucasian Intervention 13 FC Female Caucasian Intervention 
14 MC Male Caucasian Control 14 FC Female Caucasian Control 
15 MC Male Caucasian Intervention 15 FC Female Caucasian Intervention 
16 MC Male Caucasian Intervention 16 FC Female Caucasian Intervention 
17 MC Male Caucasian Intervention 17 FC Female Caucasian Intervention 
18 MC Male Caucasian Control 18 FC Female Caucasian Control 
19 MC Male Caucasian Control 19 FC Female Caucasian Intervention 
~OMC Male Caucasian Intervention ~O FC Female Caucasian Control 
~1 MC Male Caucasian Control ~1 FC Female Caucasian Control 
22MC Male Caucasian Intervention 22 FC Female Caucasian Intervention 
23 MC Male Caucasian Control 23 FC Female Caucasian Intervention 
24MC Male Caucasian Intervention 24 FC Female Caucasian Control 
25MC Male Caucasian Intervention £5FC Female Caucasian Intervention 
1 MB Male Black Control 1 FB Female Black Intervention 
2MB Male Black Intervention £FB Female Black Control 
3MB Male Black Intervention ~FB Female Black Control 
4MB Male Black Control 4 FB Female Black Intervention 
5MB Male Black Intervention 5FB Female Black Control 
6MB Male Black Control 6 FB Female Black Intervention 
7MB Male Black Control 7 FB Female Black Intervention 
8MB Male Black Intervention 8 FB Female Black Control 
~MB Male Black Intervention ~ FB Female Black Intervention 
10 MB Male Black Control 10 FB Female Black Control 
11 MB Male Black Control 11 FB Female Black Intervention 
12 MB Male Black Intervention 12 FB Female Black Control 
13 MB Male Black Control 13 FB Female Black Intervention 
14 MB Male Black Control 14 FB Female Black Control 
15 MB Male Black Intervention 15 FB Female Black Control 
16 MB Male Black Intervention 16 FB Female Black Control 
17 MB Male Black Control 17 FB Female Black Intervention 
18 MB Male Black Control 18 FB Female Black Control 
19 MB Male Black Intervention 19 FB Female Black Control 
20MB Male Black Control 
121MB Male Black Control 
122 MB Male Black Control 
~O FB Female Black Intervention 
~1 FB Female Black Intervention 
~2 FB Female Black Control 
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~3 MB Male Black Intervention 123 FB Female Black Intervention 
124 MB Male Black Control ~4 FB Female Black Control 
125 MB Male Black Intervention [25 FB Female Black Control 
1 MA Male Asian Intervention 1 FA Female Asian Control 
12 MA Male Asian Control ~FA Female Asian Intervention 
3MA Male Asian Control ~FA Female Asian Control 
~MA Male Asian Intervention [iFA Female Asian Intervention 
5MA Male Asian Control 5 FA Female Asian Control 
6MA Male Asian Control [6 FA Female Asian Intervention 
7 MA Male Asian Intervention 7 FA Female Asian Control 
~MA Male Asian Control ~ FA Female Asian Control 
9 MA Male Asian Intervention 9 FA Female Asian Intervention 
10 MA Male Asian Intervention 10 FA Female Asian Control 
11 MA Male Asian Control 11 FA Female Asian Intervention 
12 MA Male Asian Intervention 12 FA Female Asian Intervention 
13 MA Male Asian Intervention 13 FA Female Asian Control 
14 MA Male Asian Control 14 FA Female Asian Control 
15 MA Male Asian Intervention 15 FA Female Asian Intervention 
16 MA Male Asian Intervention 16 FA Female Asian Control 
17 MA Male Asian Control 17 FA Female Asian Intervention 
18 MA Male Asian Intervention 18 FA Female Asian Intervention 
19 MA Male Asian Control 19 FA Female Asian Control 
20 MA Male Asian Intervention 120 FA Female Asian Intervention 
21 MA Male Asian Control 121 FA Female Asian Control 
22 MA Male Asian Intervention 122 FA Female Asian Intervention 
23 MA Male Asian Control 123 FA Female Asian Intervention 
24MA Male Asian Intervention 124 FA Female Asian Control 
25 MA Male Asian Control 125 FA Female Asian Control 
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Appendix C: A comparison of the Body Composition analysis 
methods used 
C.t Introduction 
Bioelectrical Impedance Analysis (BIA) measures the impedance of an electrical current 
through the body fluids. The analysis exploits the fact that impedance is low in lean tis,>ue. 
which consists primarily of intracellular fluid, but high in fat tissue which are hydrophilic. 
The BIA produces a small constant current and measures impedance as the drop in voltage 
between the electrodes. Predetermined prediction equations con\t~rt the impedance to 
estimated total body water. Lean body mass can be calculated from an assumed hydration 
fraction for lean tissue and fat mass calculated as the difference between total body weight 
and lean body mass. 
Different BIA were used in the randomised control trial investigating the impact of initiating 
insulin therapy in T2DM. The body fat analyser used was dependant upon the location from 
which the patient was recruited. Patients from the Hammersmith Hospital NHS trust were 
measured on the Biospace In Body 3.0 body composition ana/r:er (SMITECH Pic Lmt) 
whereas patients recruited from the Royal Surrey County Hospital were measured on the 
Bodystat® 1500MDD (Bodystat®). 
C.l.t Aim 
The aim of this study was to ascertain whether there were any significant difference in the 
two BIA machines used by comparing results obtained between the machines in percentage 
body fat. 
C.2 Method 
Five suhjects. were recruited separately from the main investigation. were measured uSing 
standard techniques on the Biospace and then the Bodystat machine. r-..lea,>urements took 
place under the same conditions and within 10 minutes of each other tt) minimise any 
difference in subject hydration status. 
C'.J Results 
Table AC - I shows the results of obtained from the two BIA from the individual subjl'(h. 
Table AC-1 Characteristics and estimated percentage body fat using two 
separate body fat analysers 
Percentage bod)' fat ( f( ) c 
Subject Weight Height BMI ( 
Biospace Bodystat Difference 
1 78,6 1.78 24.8 26.5 271 2.21 
2 67.2 1.62 25.6 334 33.9 1.47 
3 54.3 1.65 19.9 27.1 26.2 -, -+-+ 
4 81.3 1.68 28.8 32.1 31.8 -0.94 
5 72.5 1.74 24.0 24.9 26.0 4,23 
Mean 70.8 1.69 24.6 28.8 29.0 0.71 
SD 10.7 0.07 3.2 3.7 3.6 2.96 
The difference between the analysers was not greater than 5% for any subject and the mean 
difference between the body fat analysers was less than I Cj'(. There was no consistent 
direction of difference, which partly accounts for the small mean difference. If the direction 
of difference between the analysers was removed the mean difference between the analysers 
was 2.46 ± 1.36%. Correlation analysis was executed and the results showed that Pearsons 
correlation r=O. 977, p<0.005. 
C.4 Conclusion 
As the subject differences, and in particular the mean differences, between the results of the 
estimated percentage body fat using the two BrA were so small, no adjustments were needed 
to account for the different analysers. 
Appendix D: EuroQol quality of life questionnaire 
Your own health state today 
By placing a tick in one box in each group below, please indicate which statement 
best describes your own health state today. 
Do not tick more than one box in each group. 
Mobility 
I have no problems in walking about 
I have some problems in walking about 
I am confined to bed 
Self-care 
I have no problems with self-care 
I have some problems washing or dressing myself 
I am unable to wash or dress myself 
Usual activities (eg. Work, study, housework, family or leisure activities) 
I have no problems with performing my usual activities 
I have some problems with performing my usual activities 
I am unable to perform my usual activities 
Pain/Discomfort 
I have no pain or discomfort 
I have moderate pain or discomfort 
I have extreme pain or discomfort 
Anxiety/Depression 
I am not anxious or depressed 
I am moderately anxious or depressed 
I am extremely anxious or depressed 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
To help people ay how good or 
bad a health tate is, we have 
drawn a scale (rather like a 
thermometer) on which the best 
state you can imagine is marked 
100 and the worst state you can 
imagine is marked O. 
We would like you to indicate on 
thi scale how good or bad your own 
health is today, in your opinion. 
Please do this by drawing a line from 
the box below to whichever point on 
the scale indicates how good or bad 
your health state is . 
Your Iwalth 
statl' today 
Best 
imaginable 
health state 
100 
90 
8 
70 
60 
50 
40 
30 
~O 
1 
'vVorst 
i l1la~i nahll' , 
health statl' 
\. -
Appendix E: ED-SQ Tariff 
M S U P A Score M S U P A Score M S U P A Score M S U P A Score 1 1 1 1 1 1.00 1 3 2 2 1 0.28 2 2 3 3 1 0.00 3 2 2 1 0.20 
1 1 1 1 2 0.85 1 3 2 2 2 0.21 2 2 3 3 2 -0.07 3 2 2 2 O. \3 
1 1 1 1 3 0.41 1 3 2 2 3 0.04 2 2 3 3 3 -0.24 3 2 2 3 -0.04 
1 1 1 2 1 0.80 1 3 2 3 1 0.01 2 3 1 1 1 0.37 3 2 2 2 1 0.07 
1 1 1 2 2 0.73 1 3 2 3 2 -0.06 2 3 1 1 2 0.30 3 2 2 2 2 0.00 
1 1 1 2 3 0.29 1 3 2 3 3 -0.22 2 3 1 1 3 0.13 3 2 2 2 3 -0.16 
1 1 1 3 1 0.26 1 3 3 1 1 0.34 2 3 1 2 1 0.24 3 2 2 3 1 -0.19 
1 1 1 3 2 0.19 1 3 3 1 2 0.27 2 3 1 2 2 0.17 3 2 2 3 2 -0.26 
1 1 1 3 3 0.03 1 3 3 1 3 0.11 2 3 1 2 3 0.01 3 2 2 3 3 -0.43 
1 1 2 1 1 0.88 1 3 3 2 1 0.22 2 3 1 3 1 -0.02 3 2 3 1 1 0.14 
1 1 2 1 2 0.81 1 3 3 2 2 0.15 2 3 1 3 2 -0.09 3 2 3 1 2 0.07 
1 1 2 1 3 0.38 1 3 3 2 3 -0.02 2 3 1 3 3 -0.26 3 2 3 1 3 -0.10 
1 1 2 2 1 0.76 1 3 3 3 1 -0.04 2 3 2 1 1 0.33 3 2 3 2 1 0.02 
1 1 2 2 2 0.69 1 3 3 3 2 -0.12 2 3 2 1 2 0.26 3 2 3 2 2 -0.06 
1 1 2 2 3 0.26 1 3 3 3 3 -0.28 2 3 2 1 3 0.10 3 2 3 2 3 -0.22 
1 1 2 3 1 0.23 2 1 1 1 1 0.85 2 3 2 2 1 0.21 3 2 3 3 1 -0.25 
1 1 2 3 2 0.16 2 1 1 1 2 0.78 2 3 2 2 2 0.14 3 2 3 3 2 -0.32 
1 1 2 3 3 -0.01 2 1 1 1 3 0.35 2 3 2 2 3 -0.03 3 2 3 3 J -0.48 
1 1 3 1 1 0.56 2 1 1 2 1 0.73 2 3 2 3 1 -0.06 3 3 I 1 1 0.12 
1 1 3 1 2 0.49 2 I 1 2 2 0.66 2 3 2 3 2 -0.13 3 3 1 1 2 0.05 
1 1 3 1 3 0.32 2 1 1 2 3 0.22 2 3 2 3 3 -0.29 3 3 1 I 3 -0.11 
1 1 3 2 1 0.43 2 1 1 3 1 0.20 2 3 3 1 1 0.27 3 3 1 2 1 0.00 
1 1 3 2 2 0.36 2 1 1 3 2 0.12 2 3 3 1 2 0.20 3 3 1 2 2 -0.07 
1 1 3 2 3 0.20 2 1 1 3 3 -0.04 2 3 3 1 3 0.04 3 3 1 2 3 -0.24 
1 1 3 3 1 0.17 2 1 2 1 1 0.81 2 3 3 2 1 0.15 3 3 1 3 1 -0.26 
1 1 3 3 2 0.10 2 1 2 1 2 0.74 2 3 3 2 2 0.08 3 3 1 3 2 -0.34 
1 1 3 3 3 -0.07 2 1 2 1 3 0.31 2 3 3 2 3 -0.09 3 3 1 3 3 -0.50 
1 2 1 1 1 0.82 2 1 2 2 1 0.69 2 3 3 3 1 -0.11 3 3 2 1 1 0.09 
1 2 1 1 2 0.74 2 1 2 2 2 0.62 2 3 3 3 2 -0.18 3 3 2 1 2 0.02 
1 2 1 1 3 0.31 2 1 2 2 3 0.19 2 3 3 3 3 -0.35 3 3 2 1 3 -0.15 
1 2 1 2 1 0.69 2 1 2 3 1 0.16 3 1 1 1 1 0.34 3 3 2 2 I -0.04 
1 2 1 2 2 0.62 2 1 2 3 2 0.09 3 1 1 I 2 0.27 3 3 2 2 2 -0.11 
1 2 1 2 3 0.19 2 1 2 3 3 -0.08 3 1 1 1 3 0.10 3 3 2 2 3 -0.27 
1 2 1 3 1 0.16 2 I 3 I I 0.49 3 I I 2 1 0.21 3 3 2 3 1 -0.30 
1 2 I 3 2 0.09 2 1 3 I 2 0.42 3 1 1 2 2 0.14 3 3 2 3 2 -0.37 
1 2 1 3 3 -0.08 2 I 3 1 3 0.25 3 1 1 2 3 -0.02 3 3 2 3 3 -0.54 
1 2 2 1 1 0.78 2 1 3 2 1 0.36 3 1 1 3 1 -0.05 3 3 3 1 1 0.03 
1 2 2 1 2 0.71 2 1 3 2 2 0.29 3 1 3 2 -0.12 3 3 3 1 2 -0.04 
1 2 2 1 3 0.27 2 1 3 2 3 0.13 3 1 3 3 -0.29 3 3 3 1 3 -0.21 
1 2 2 2 1 0.66 2 1 3 3 1 0.10 3 2 1 1 0.30 3 3 3 2 1 -0.10 
1 2 2 2 2 0.59 2 1 3 3 2 0.03 3 2 1 2 0.23 3 3 3 2 2 -0.17 
1 2 2 2 3 0.15 2 1 3 3 3 -0.14 3 2 1 3 0.06 3 3 3 2 3 -0.33 
1 2 2 3 1 0.12 2 2 1 1 1 0.75 3 2 2 1 0.18 3 3 3 3 1 -0.36 
1 2 2 3 2 0.05 2 2 1 1 2 0.68 3 2 2 2 0.11 3 3 3 3 2 -0.43 
1 2 2 3 3 -0.11 2 2 I 1 3 0.24 3 2 2 3 -0.06 3 3 3 3 3 -0.59 
I 2 3 1 1 0.45 2 2 1 2 1 0.62 3 2 3 1 -0.09 unconscious 
-0.4 
1 2 3 1 2 0.38 2 2 1 2 2 0.55 3 1 2 3 2 -0.16 
1 2 3 1 3 0.22 2 2 1 2 3 0.12 3 1 2 3 3 -0.32 M - Mobility 
1 2 3 2 1 0.33 2 2 1 3 1 0.09 3 1 3 1 1 0.24 S - Self-care 
1 2 3 2 2 0.26 2 2 1 3 2 0.02 3 1 3 1 2 0.17 U - Usual activities 
1 2 3 2 3 0.09 2 2 1 3 3 -0.15 3 1 3 1 3 0.01 P - Pain/discomfort 
1 2 3 3 1 0.07 2 2 2 1 1 0.71 3 1 3 2 1 0.12 A - Anxiety/depression 
1 2 3 3 2 -0.01 2 2 2 1 2 0.64 3 1 3 2 2 0.05 
1 2 3 3 3 -0.17 2 2 2 1 3 0.21 3 1 3 2 3 -0.12 
1 3 1 1 1 0.44 2 2 2 2 1 0.59 3 1 3 3 1 -0.14 
1 3 1 1 2 0.37 2 2 2 2 2 0.52 3 1 3 3 2 -0.22 
1 3 1 1 3 0.20 2 2 2 2 3 0.08 3 1 3 3 3 -0.38 
1 3 1 2 1 0.31 2 2 2 3 1 0.06 3 2 1 1 1 0.23 
1 3 1 2 2 0.24 2 2 2 3 2 -0.02 3 2 1 2 0.16 
1 3 1 2 3 0.08 2 2 2 3 3 -0.18 3 2 1 3 0.00 
1 3 1 3 1 0.05 2 2 3 1 1 0.38 3 2 1 2 1 0.11 
1 3 1 3 2 -0.02 2 2 3 1 2 0.31 3 2 1 2 2 0.04 
1 3 1 3 3 -0.19 2 2 3 1 3 0.15 3 2 1 2 3 -0.13 
1 3 2 1 1 0.40 2 2 3 2 1 0.26 3 2 3 I -0.15 
1 3 2 1 2 0.33 2 2 3 2 2 0.19 3 2 3 2 -0.23 
1 3 2 1 3 0.16 2 2 3 2 3 0.02 3 2 .~ 3 -0.39 
186 
Appendix F: Estimated energy deficit requirements for weight 
loss 
AF - 1 Estimated energy requirements with energy deficit required for weight 
loss for female patients 
FEMALES 
Wt (k2) Wt (St Ib) Inactive Li2ht Moderate Hea\') 
60-70 96 Ib -II I Ib 1200 1500 1500 2000 
71-75 1121b-11121b 1500 1800 2000 2300 
'" 76-80 II 13 Ib - 129 Ib 1500 2000 2000 2,()O r.. 
:"l 81-85 12 10 Ib - 136 Ib 1500 2000 2000 25()O <:J ~. 
c= 86-90 137 Ib - 143 Ib 1500 2000 2300 25()O rt') 
I 91-100 1441b-15111b 1800 2300 2500 ::'5()O 
oe 101-114 15 12 Ib - 180 Ib 2000 2500 2500 2500 
-
115-125 18 I Ib - 19 10 Ib 2300 2500 2500 ::' 500 
>125 > 19 10 Ib 2500 2500 2500 2500 
60-70 96lb-Illlb 1200 1500 1500 1800 
71-75 II 2 Ib - II 12 Ib 1200 1500 1800 2000 
'" 
76-80 II 13 Ib - 12 9 Ib 1200 1800 1800 2oo0 ~ 81-95 12 10 Ib - 136 Ib 1500 1800 2000 ::' 300 ~ 
c= 96-114 15 I Ib - 18 0 Ib 1500 2000 2300 ::' 500 ~ 
I 115-130 18 1 Ib - 20 7 Ib 1800 2300 2500 ::' 500 
-rt') 131-150 20 8 Ib - 23 9 Ib 2000 2500 2500 ::' 500 
151-170 23 10 Ib -26 12 Ib 2300 2500 2500 ::' SOO 
>170 > 26 121b 2500 2500 2500 2'iOO 
60-65 961b-I051b 1200 1200 1500 1500 
66-75 10 61b - II 121b 1200 1500 1500 1800 
76-85 II 3 Ib - 136 Ib 1200 1500 1800 2000 ~ 
86-95 1371b 150lb 1500 1800 2000 2000 ~ 
~ 96-100 15 I Ib 15 II Ib 
-
1500 2000 '( )()() 2000 
~ 101-110 15 12 Ib 1751b 1500 2000 2()()( ) 2500 r.. 
aJ 111-120 1761b 1831b 1500 2000 ',()() 2500 > 0 121-135 18 --lIb 2141b 1800 2300 2500 2500 
136-165 2151b 26 lib 2000 2500 2500 2500 
>165 > 26 lib 2500 2500 2500 2500 
IS7 
AF - 2 Estimated energy requirements with energy deficit required for weight 
loss for male patients 
MALES 
Wt (kg) Wt(Stlb) Inactive Light Moderate Mean 
60-65 9 61b-1O 5 Ib 1500 1800 2300 2800 
66-70 10 6 Ib - II 1 Ib 1500 2000 i 25()() 3000 
'" 
71-75 1121b-11121b 1500 2000 2500 3000 
r.. 76-80 II 13 Ib - 12 9 Ib 1800 2300 2500 3000 ~ 
~ 
~. 81-85 12 10 Ib - 13 6 Ib 1800 2300 2800 3000 
Q 
~ 86-95 1371b-1501b 2000 2500 3000 3000 
I 96-110 151Ib-175Ib 2300 00 2800 3000 3000 
- 111-125 176 Ib - 19 10 Ib 2500 3000 3000 3000 
126-135 19 11 Ib - 21 4 Ib 2800 3000 3000 3000 
>135 > 21 41b 3000 3000 3000 3000 
60-65 96 Ib -10 5 Ib 1500 1800 2300 2800 
66-70 10 6 Ib - II 1 Ib 1500 2000 2300 2800 
71-75 II 2 Ib - II 12 Ib 1500 2000 2500 3000 
rIJ 76-80 11 13 Ib - 12 9 1b 1800 2000 2500 3000 ~ 81-85 12 10 Ib - 136 Ib 1800 2300 2500 3000 >. 
Q 86-90 13 7 Ib - 14 3 Ib 1800 2300 2800 3000 \Ci 
I 91-110 14 4 Ib - 17 5 Ib 2000 2500 2800 3000 
-~ 111-120 176Ib-1813Ib 2300 2800 3000 3000 
121-150 19 0 Ib - 23 9 Ib 2500 3000 3000 3000 
151-160 23 10 Ib - 25 2 Ib 2800 3000 3000 3000 
>160 > 25 21b 3000 3000 3000 3000 
60-65 96 Ib -10 5 Ib 1200 1500 1800 2()OO 
66-70 106 Ib - 11 1 Ib 1200 1500 1800 2~()() 
71-75 11 2 Ib - II 12 Ib 1200 1500 2000 2 )()() 
~ 76-80 11 13 Ib - 129 Ib 1500 1800 
2000 25()() 
~ 81-85 12 10 Ib - 13 6 Ib 1500 1800 2300 2X()O 
>. 86-95 137 Ib - 150 Ib 1500 2000 2300 2 X()O 
-\Ci 96-100 15 1 Ib - 15 11 Ib 1800 2000 2500 3000 r.. 3000 Q,I 101-110 15121b-1751b 1800 2300 2800 ~ 
0 111-125 176 Ib - 19 10 Ib 2000 2500 3000 3000 
126-135 19 11 Ib - 21 -+ Ib 2300 2800 3000 3000 
136-165 21 5 Ib - 26 I Ib 25()() 3000 3000 3000 
>165 > 26 lib 3000 3000 3000 3000 
AF - 3 Energy prescription with corresponding number of servings per food 
group and snack allowance 
f :J 
:J 
:J > 
'J 
.c ..c -- ,- - - -"'-
::5 "" -"'-
:0; ~ ~ u 
::J :-;l - u ::: I-. :; E ~~ 
.J I-. :; 2 -:.L. :'J) 2 3 :f: (/'; :; < > -< 
KcaUsening 80 60 15 140 90 36 - -
1200 5 ') 3 '1 
') 3 1133 67 
-
1500 7 3 3 ') 
') 3 1353 1.+7 
- -
c 1800 8 -+ .+ 
') ') 
.+ ISS() 220 
- 2000 8 .+ .+ 3 3 :'i 1810 IljO c. 
·c 
.+ ) 3 , 6 21()1 199 u 2300 II f 
::.. ) ) 3 3 6 22~ I 259 r.. 2500 12 :.. ~-
1.+ ) -~ 
, 7 2497 ,() -' 2800 () , 
16 6 ) 3 
, 7 21157 ,'.+' i 30m , 
Appendix G: Recipe for high fat milkshake and muffin used in the 
postprandial study 
Formulation for 1 high fat milkshake 
Ingredients 
Single cream 
Skimmed milk 
Polycal 
Nesquik 
Total volume 350m] 
Method 
100ml 
220ml 
30ml 
18g 
I. Add skimmed milk to the dry ingredients and mix with a electric hand mixer. add 
other ingredients and blend. 
2. Best made with chilled ingredients. 
3. Pour into waxed carboard cup. 
Formulation of high fat muffin 
Ingredients in g to make 10 muffins 
Dry ingredients 
Cornstarch 56g 
Pastry flour II0g 
Cocoa powder 56g 
Caster sugar 167g 
Baking powder 22g 
Dried paste uri sed egg white 22g 
Wet ingredients 
Skimmed milk 
High oleic sunflower oil 
Vanilla essence 
Wet weight per muffin 
Cooked weight 
Method 
220g 
330g 
))0 
--e 
90g 
8Sg 
I. Sift all the dry ingredients together twice, ensure thoroughly mixed. 
'1 Put all wet ingredients together into a mixing bowl, add the dry ingredients and ,,(ir 
gently for about 2 minutes to fully incorporate. 
3. Weigh batter into indi\'idual paper muffin case" and bake at -+00 T, 200 Cor Crll\ 6 ill 
a fan a""isted oven for 20 minutes. 
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Appendix H: Resource CD 
CD overleaf contains the Lifestyle booklets used for the randomised control trial and the 
SPSS databases of each study. 
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